nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,intervention_type,intervention_name,description,intervention_count,status,facility_name,city,state,zip,country,site_count
NCT04244591,"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-23,NA,NA,2020-04-14,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:53:30Z,2020-04-20T08:53:30Z,Drug|Other,methylprednisolone therapy|Standard care,Methylprednisolone 40 mg q12h for 5 days|Standard care,2,,"Medical ICU,Peking Union Medical College Hospital",Beijing,Beijing,010,China,1
NCT04252118,"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-27,NA,NA,2020-04-13,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"January 27, 2020",Actual,2020-01-27,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:53:22Z,2020-04-20T08:53:22Z,Biological,MSCs,"3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).",1,Recruiting,Beijing 302 Military Hospital of China,Beijing,,100039,China,1
NCT04251871,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-28,NA,NA,2020-01-30,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-30,2020-02-05,Actual,"January 22, 2020",Actual,2020-01-22,January 2020,2020-01-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:27:26Z,2020-04-01T09:27:26Z,Drug|Drug,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.",2,Recruiting,"The Fifth Medical Center, General Hospital of PLA",Beijing,Beijing,100039,China,1
NCT04252274,"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-29,NA,NA,2020-04-09,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"January 30, 2020",Actual,2020-01-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DC-COVID-19,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:53:21Z,2020-04-20T08:53:21Z,Drug,Darunavir and Cobicistat,"Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments",1,Recruiting|Recruiting,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04252885,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:27:18Z,2020-04-01T09:27:18Z,Drug|Drug,Lopinavir and Ritonavir Tablets|Arbidol,As indicated in arm/group descriptions|As indicated in arm/group descriptions,2,Recruiting,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong,510060,China,1
NCT04251767,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-30,NA,NA,2020-03-13,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"February 5, 2020",Anticipated,2020-02-05,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study",Withdrawn,NA,N/A,0,Actual,The Second Hospital of Nanjing Medical University,,2,NA,Follow new disciplines on disease control from government,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-01T09:27:26Z,2020-04-01T09:27:26Z,Other|Other,washed microbiota transplantation|placebo,"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.
Dose and frequency: 5u, once.|Placebo (edible suspension of the same color as the washed microbiota suspensionï¼Œ5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
Dose and frequency: 5u, once.",2,,"Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University",Nanjing,Jiangsu,210011,China,1
NCT04257656,"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-31,NA,NA,2020-04-13,2020-02-03,2020-02-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"April 10, 2020",Actual,2020-04-10,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,A Trial of Remdesivir in Adults With Severe COVID-19,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.",Terminated,NA,Phase 3,237,Actual,Capital Medical University,,2,NA,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:53:16Z,2020-04-20T08:53:16Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,,Bin Cao,Beijing,Beijing,100029,China,1
NCT04252664,"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-31,NA,NA,2020-04-13,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 12, 2020",Actual,2020-02-12,April 2020,2020-04-30,"April 27, 2020",Anticipated,2020-04-27,"April 10, 2020",Anticipated,2020-04-10,NA,Interventional,NA,,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.",Suspended,NA,Phase 3,308,Anticipated,Capital Medical University,,2,NA,"The epidemic of COVID-19 has been controlled well at present, no eligible patients can be
    recruitted.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:53:20Z,2020-04-20T08:53:20Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,,Jin Yin-tan hospital,Wuhan,Hubei,100013,China,1
NCT04263402,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:25:53Z,2020-04-01T09:25:53Z,Drug|Drug,Methylprednisolone|Methylprednisolone,"Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04255017,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:27:04Z,2020-04-01T09:27:04Z,Drug|Drug|Drug,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,"Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04254874,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:27:04Z,2020-04-01T09:27:04Z,Drug|Drug,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,"0.2g once, 3 times a day,two weeks|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-Î±-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04264533,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-04,NA,NA,2020-03-06,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Recruiting,NA,Phase 2,140,Anticipated,Zhongnan Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:25:41Z,2020-04-01T09:25:41Z,Drug|Drug,VC|Sterile Water for Injection,12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.,2,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04261270,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:26:11Z,2020-04-01T09:26:11Z,Drug|Drug|Drug,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,"ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|75mg ,once a day",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04331613,"ClinicalTrials.gov processed this data on April 10, 2020",2020-02-06,NA,NA,2020-03-31,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"January 27, 2020",Actual,2020-01-27,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-12T09:06:30Z,2020-04-12T09:06:30Z,Biological,CAStem,CAStem will be administered intravenously.,1,Recruiting,"Beijing YouAn Hospital, Capital Medical University",Beijing,"Beijing, China",100000,China,1
NCT04275245,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:15Z,2020-04-01T09:24:15Z,Drug,Meplazumab for Injection,humanized MAb against CD147,1,Recruiting,Tangdu Hospital,Xi'an,Shaanxi,710032,China,1
NCT04261907,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-10,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",Not yet recruiting,NA,N/A,160,Anticipated,First Affiliated Hospital of Zhejiang University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:26:07Z,2020-04-01T09:26:07Z,Drug|Drug,ASC09/ritonavir group|lopinavir/ritonavir group,"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04260594,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-07,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Not yet recruiting,NA,Phase 4,380,Anticipated,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:26:15Z,2020-04-01T09:26:15Z,Drug|Other,Arbidol|basic treatment,"Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days|basic treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04261517,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:53:10Z,2020-04-20T08:53:10Z,Drug,Hydroxychloroquine,"Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments",1,|,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04269525,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-07,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-17,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,10,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:25:03Z,2020-04-01T09:25:03Z,Biological,UC-MSCs,"After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.",1,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04268537,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-08,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"February 10, 2020",Anticipated,2020-02-10,February 2020,2020-02-29,"October 31, 2020",Anticipated,2020-10-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Immunoregulatory Therapy for 2019-nCoV,Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients,Not yet recruiting,NA,Phase 2,120,Anticipated,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:25:10Z,2020-04-01T09:25:10Z,Drug|Drug|Other,PD-1 blocking antibody+standard treatment|Thymosin+standard treatment|standard treatment,"After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Standard treatment is according to the protocol of treatment of 2019-nCoV infection",3,NA,NA,NA,NA,NA,NA,NA
NCT04264858,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-08,NA,NA,2020-03-13,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 17, 2020",Anticipated,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients,Not yet recruiting,NA,N/A,10,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:25:37Z,2020-04-01T09:25:37Z,Drug|Drug,Immunoglobulin of cured patients|Î³-Globulin,"0.2g/kg, ivdrip, once a day, for 3 days|0.2g/kg, ivdrip, once a day, for 3 days",2,,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430022,China,1
NCT04282902,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:17Z,2020-04-01T09:23:17Z,Drug,pirfenidone,"Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer",1,Recruiting,Tongji hospital affiliated to huazhong university of science and technology,Wuhan,Hubei,,China,1
NCT04276688,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:54Z,2020-04-20T08:52:54Z,Drug|Drug|Drug,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,400mg/100mg twice daily for 14 days|400mg twice daily for 14 days|0.25mg subcutaneous injection alternate day for 3 days,3,,"University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
NCT04280224,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-13,NA,NA,2020-04-11,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:50Z,2020-04-20T08:52:50Z,Biological,NK Cells,twice a week of NK cells (0.1-2*10E7 cells/kg body weight),1,Recruiting,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,453000,China,1
NCT04304313,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:20:35Z,2020-04-01T09:20:35Z,Drug,Sildenafil citrate tablets,0.1g/day for 14 days,1,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04273581,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 18, 2020",Anticipated,2020-02-18,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,40,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:28Z,2020-04-01T09:24:28Z,Drug|Drug,placebo|Thalidomide,100mg/dï¼Œqnï¼Œfor 14 days.|100mg/dï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04273529,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,100,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:28Z,2020-04-01T09:24:28Z,Drug|Drug,thalidomide|placebo,100mgï¼Œpoï¼Œqnï¼Œfor 14 days.|100mgï¼Œpoï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04275414,"ClinicalTrials.gov processed this data on April 10, 2020",2020-02-14,NA,NA,2020-04-01,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-13T09:02:44Z,2020-04-13T09:02:44Z,Drug,Bevacizumab Injection,"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip â‰¥90min",1,Recruiting|Recruiting|Recruiting,Renmin Hospital of Wuhan University|Qilu Hospital of Shandong University|Moriggia-Pelascini Gravedona Hospital,Wuhan|Jinan|Gravedona,Hubei|Shandong|,|250012|,China|China|Italy,3
NCT04273763,"ClinicalTrials.gov processed this data on April 01, 2020",2020-02-14,NA,NA,2020-03-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"February 16, 2020",Actual,2020-02-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Enrolling by invitation,NA,N/A,60,Anticipated,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:23:21Z,2020-04-02T09:23:21Z,Drug|Drug|Drug,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,Bromhexine Hydrochloride Tablets|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.,3,,The Second AffIliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China,1
NCT04273646,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-14,NA,NA,2020-04-10,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"February 15, 2022",Anticipated,2022-02-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Not yet recruiting,NA,N/A,48,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:57Z,2020-04-20T08:52:57Z,Biological|Drug,UC-MSCs|Placebo,"4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).",2,,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430000,China,1
NCT04293887,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-03-02,2020-03-02,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-02,2020-03-03,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon Î±1Î² in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Not yet recruiting,NA,Early Phase 1,328,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:21:54Z,2020-04-01T09:21:54Z,Drug,Recombinant human interferon Î±1Î²,Saline needle 2ml + recombinant human interferon Î±1Î²10ug bid nebulization inhalation,1,NA,NA,NA,NA,NA,NA,NA
NCT04279197,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu,"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV",Recruiting,NA,Phase 2,136,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:44Z,2020-04-01T09:23:44Z,Drug|Drug,N-acetylcysteine+ Fuzheng Huayu Tablet|N-acetylcysteine+Placebo,The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.|The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.,2,Recruiting,Shuguang Hospital,Shanghai,Shanghai,201203,China,1
NCT04273321,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-15,NA,NA,2020-04-16,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Suspended,NA,N/A,400,Anticipated,Beijing Chao Yang Hospital,,2,NA,The epidemic of COVID-19 in China has been coming to an end.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-20T08:52:57Z,2020-04-20T08:52:57Z,Drug,Methylprednisolone,Methylprednisolone 1mg/kg/day ivgtt for 7 days.,1,||||||,Hubei province hospital of integrated Chinese & Western Medicine|Yichang first people's Hospital|Beijing YouAn Hospital|Renmin Hospital of Wuhan University|Tianyou Hospital Affiliated to Wuhan University of science and technology|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology|the first peopel hospital of Xiangyang,Wuhan|Yichang|Beijing|Wuhan|Wuhan|Wuhan|Xiangyang,Hubei|Hubei|||||,||||||,China|China|China|China|China|China|China,7
NCT04276987,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-16,NA,NA,2020-02-21,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Not yet recruiting,NA,Phase 1,30,Anticipated,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-04-01T09:24:02Z,2020-04-01T09:24:02Z,Biological,MSCs-derived exosomes,"5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).",1,NA,NA,NA,NA,NA,NA,NA
NCT04276896,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:03Z,2020-04-01T09:24:03Z,Biological,Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,"Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.",1,Recruiting|Recruiting|Recruiting,Shenzhen Geno-immune Medical Institute|Shenzhen Second People's Hospital|Shenzhen Third People's Hospital,Shenzhen|Shenzhen|Shenzhen,Guangdong|Guangdong|Guangdong,518000|518000|518000,China|China|China,3
NCT04275388,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-17,NA,NA,2020-02-18,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-18,2020-02-19,Actual,"February 14, 2020",Anticipated,2020-02-14,February 2020,2020-02-29,"December 14, 2021",Anticipated,2021-12-14,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,NA,,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia",Not yet recruiting,NA,N/A,348,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:13Z,2020-04-01T09:24:13Z,Drug|Drug,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization","Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04285190,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-02-24,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-02-24,2020-02-26,Actual,"February 26, 2020",Anticipated,2020-02-26,February 2020,2020-02-29,"September 15, 2020",Anticipated,2020-09-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,NA,,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,120,Anticipated,"Tasly Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share,2020-04-01T09:23:00Z,2020-04-01T09:23:00Z,Drug,T89,"The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.",1,NA,NA,NA,NA,NA,NA,NA
NCT04278963,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-03-15,2020-02-19,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 27, 2020",Actual,2020-02-27,March 2020,2020-03-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,China Academy of Chinese Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:46Z,2020-04-01T09:23:46Z,Drug|Drug|Other|Other,YinHu QingWen Decoction|YinHu QingWen Decoction(low dose)|Chinese medicine treatment|standard western medicine treatment,"YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.",4,||,Jingzhou Hospital of Traditional Chinese Medicine|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University|Xiangyang Hospital of Traditional Chinese Medicine,Jingzhou|Wuhan|Xiangyang,Hubei|Hubei|Hubei,434000|430200|441000,China|China|China,3
NCT04281693,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-21,2020-02-21,2020-02-24,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-24,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,A New Screening Strategy for 2019 Novel Coronavirus Infection,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,NA,N/A,230,Anticipated,Affiliated Hospital to Academy of Military Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:25Z,2020-04-01T09:23:25Z,Diagnostic Test|Diagnostic Test,Standard screening strategy|New screening strategy,The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.,2,,the Fifth Medical Center of Chinese PLA General Hospital,Beijing,Beijing,100071,China,1
NCT04280588,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-01T09:23:33Z,2020-04-01T09:23:33Z,Drug,Fingolimod 0.5 mg,"Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days",1,Recruiting,Wan-Jin Chen,Fuzhou,,,China,1
NCT04280705,"ClinicalTrials.gov processed this data on April 15, 2020",2020-02-20,NA,NA,2020-04-02,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"February 21, 2020",Actual,2020-02-21,"March 20, 2020",2020-03-20,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,440,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-16T09:18:35Z,2020-04-16T09:18:35Z,Other|Drug,Placebo|Remdesivir,"The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease|University of California San Diego Health - Jacobs Medical Center|University of California Los Angeles Medical Center - Westwood Clinic|University of California Irvine Medical Center - Infectious Disease|VA Palo Alto Health Care System - Infectious Diseases|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases|University of California Davis Medical Center - Internal Medicine - Infectious Disease|Naval Medical Center San Diego - Infectious Disease Clinic|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine|Cedars Sinai Medical Center|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases|Denver Health Division of Hospital Medicine - Main Campus|University of Florida Health Sciences Center, College of Public Health- Epidemiology|Emory Vaccine Center - The Hope Clinic|Northwestern Hospital - Infectious Disease|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore|Johns Hopkins Hospital - Medicine - Infectious Diseases|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section|Walter Reed Army Institute of Research - Clinical Trials Center|Massachusetts General Hospital - Infectious Diseases|University of Massachusetts Medical School - Infectious Diseases and Immunology|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine|Saint Louis University - Center for Vaccine Development|University of Nebraska Medical Center - Infectious Diseases|Montefiore Medical Center - Infectious Diseases|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology|University of Rochester Medical Center - Vaccine Research Unit|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases|Hospital of the University of Pennsylvania - Infectious Diseases|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology|Vanderbilt University Medical Center - Infectious Diseases|Brooke Army Medical Center|University of Texas Medical Branch - Division of Infectious Disease|Baylor College of Medicine - Molecular Virology and Microbiology|University of Texas Health Science Center at San Antonio - Infectious Diseases|University of Virginia - Acute Care Surgery|Naval Medical Center Portsmouth - Infectious Disease Division|EvergreenHealth Infectious Disease Service|The University of Washington - Virology Research Clinic|Providence Sacred Heart Medical Center|Madigan Army Medical Center - Infectious Disease Clinic|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik|UniversitÃ¤tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center|Seoul National University Bundang Hospital - Division of Infectious Diseases|Seoul National University Hospital|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael CosÃ­o Villegas|National Centre for Infectious Diseases (NCID)|Saint Thomas' Hospital - Directorate of Infection|Royal Victoria Infirmary - Department of Infectious Diseases","Birmingham|La Jolla|Los Angeles|Orange|Palo Alto|Palo Alto|Sacramento|San Diego|San Francisco|West Hollywood|Aurora|Denver|Gainesville|Decatur|Chicago|Chicago|New Orleans|Annapolis|Baltimore|Bethesda|Silver Spring|Boston|Worcester|Minneapolis|Saint Louis|Omaha|Bronx|New York|Rochester|Durham|Hershey|Philadelphia|Philadelphia|Nashville|Fort Sam Houston|Galveston|Houston|San Antonio|Charlottesville|Portsmouth|Kirkland|Seattle|Spokane|Tacoma|Copenhagen|Bonn|Frankfurt|Tokyo|Bundang-gu Seongnam-si|Seoul|Mexico City|Singapore|London|Level 6, Ward 19","Alabama|California|California|California|California|California|California|California|California|California|Colorado|Colorado|Florida|Georgia|Illinois|Illinois|Louisiana|Maryland|Maryland|Maryland|Maryland|Massachusetts|Massachusetts|Minnesota|Missouri|Nebraska|New York|New York|New York|North Carolina|Pennsylvania|Pennsylvania|Pennsylvania|Tennessee|Texas|Texas|Texas|Texas|Virginia|Virginia|Washington|Washington|Washington|Washington||Nordrhein-Westfalen|||Gyeonggi-do|Jongno-gu|||London, City Of|Newcastle Upon Tyne",35233|29037|90095|92868-3298|94304-1207|94304-1503|95817-1460|92314|94110-2859|90048-1804|80045|80204|32610-3003|30030-1705|60611-2908|60612|70119|21401-1527|21287-0005|20892-1504|20910-7500|02114-2621|01655-0002|55455-0341|63104-1015|68198-5400|10467-2401|10016-6402|14642-0001|27704|17033|19104-4238|19104-4863|37232-0011|78234|77555-0435|77030-3411|78229-3901|22908-0816|23708|98034|98104-2433|99204|98431|2100|53127|60590|162-8655|13620|03080|14080|308442|SE1 7EH|NE1 4LP,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Denmark|Germany|Germany|Japan|Korea, Republic of|Korea, Republic of|Mexico|Singapore|United Kingdom|United Kingdom",54
NCT04343794,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-20,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,NA,N/A,200,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:48:43Z,2020-04-20T08:48:43Z,Device,BIOVITALS,"Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period",1,Recruiting,"The University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
NCT04287686,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-21,NA,NA,2020-03-15,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,February 2020,Anticipated,2020-02-29,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19",Withdrawn,NA,N/A,0,Actual,The First Affiliated Hospital of Guangzhou Medical University,,2,NA,Without CDE Approval,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:38Z,2020-04-01T09:22:38Z,Drug,Recombinant human angiotensin-converting enzyme 2 (rhACE2),"In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.",1,,GCP Office of The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,510120,China,1
NCT04283461,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-21,NA,NA,2020-04-09,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 3, 2020",Actual,2020-03-03,"February 20, 2020",2020-02-20,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,45,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:52:48Z,2020-04-20T08:52:48Z,Biological,mRNA-1273,"Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.",1,Recruiting|Not yet recruiting|Recruiting,Emory Vaccine Center - The Hope Clinic|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Decatur|Bethesda|Seattle,Georgia|Maryland|Washington,30030-1705|20892|98101-1466,United States|United States|United States,3
NCT04283838,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Healthcare Workers in Coronavirus Disease 2019,The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,1,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:10Z,2020-04-01T09:23:10Z,Behavioral,Humanistic Care,Psychological and physical rehabilitation based humanistic care regimen,1,NA,NA,NA,NA,NA,NA,NA
NCT04283825,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Patients With Coronavirus Disease 2019,The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,2,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:10Z,2020-04-01T09:23:10Z,Behavioral,Psychological and physical rehabilitation based humanistic care,"This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.",1,NA,NA,NA,NA,NA,NA,NA
NCT04293692,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-24,NA,NA,2020-03-15,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus,Withdrawn,NA,N/A,0,Actual,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,"Patients were transferred to designated hospitals for treatment as needed, the clinical trials
    cannot be conducted.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:55Z,2020-04-01T09:21:55Z,Biological|Other,UC-MSCs|Placebo,"0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7",2,,Puren Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei,430081,China,1
NCT04288102,"ClinicalTrials.gov processed this data on April 16, 2020",2020-02-24,NA,NA,2020-04-05,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence",Recruiting,NA,Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:15:55Z,2020-04-17T09:15:55Z,Biological|Biological,MSCs|Saline containing 1% Human serum albuminï¼ˆsolution of MSCï¼‰,"3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.|3 times of placeboï¼ˆintravenously at Day 0, Day 3, Day 6ï¼‰",2,Recruiting|Recruiting,Maternal and Child Hospital of Hubei Province|Wuhan Huoshenshan Hospital,Wuhan|Wuhan,Hubei|Hubei,430000|430000,China|China,2
NCT04303299,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-24,NA,NA,2020-04-08,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,THDMS-COVID-19,,"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Not yet recruiting,NA,Phase 3,320,Anticipated,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:52:18Z,2020-04-20T08:52:18Z,Drug,Oral,Anti virus treatment,1,,Assistant Professor Subsai Kongsaengdao,Bangkok,,10400,Thailand,1
NCT04286503,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-25,NA,NA,2020-02-25,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-27,Actual,"February 23, 2020",Anticipated,2020-02-23,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study",Not yet recruiting,NA,Phase 4,520,Anticipated,Beijing YouAn Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:50Z,2020-04-01T09:22:50Z,Drug|Drug|Drug,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,3,NA,NA,NA,NA,NA,NA,NA
NCT04302519,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-27,NA,NA,2020-03-09,2020-03-09,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-10,Actual,"March 5, 2020",Anticipated,2020-03-05,February 2020,2020-02-29,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Not yet recruiting,NA,Early Phase 1,24,Anticipated,"CAR-T (Shanghai) Biotechnology Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:50Z,2020-04-01T09:20:50Z,Biological,Dental pulp mesenchymal stem cells,"On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.",1,NA,NA,NA,NA,NA,NA,NA
NCT04291053,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-27,NA,NA,2020-03-14,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,550,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:15Z,2020-04-01T09:22:15Z,Drug,Huaier Granule,standard treatment + Huaier Granule 20g po tid for 2weeks,1,NA,NA,NA,NA,NA,NA,NA
NCT04290871,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,A new coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:21:51Z,2020-04-03T09:21:51Z,Drug,Nitric Oxide Gas,"Inspired NO will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment. After that, NO levels will be decreased to 40 ppm until severe hypoxia resolves. Weaning from NO will start when patients improves the level of oxygenation to a PaO2/FiO2 > 300 mmHg or SpO2 > 93% for more than 24 hours consecutively. Physician will follow their own institutional weaning protocols. In the absence of institutional protocols, NO will be reduced every 4 hours in step-wise fashion starting from 40 ppm to 20, 10, 5, 3, 2 and 1 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04290858,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"February 1, 2022",Anticipated,2022-02-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,New coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:21:51Z,2020-04-03T09:21:51Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.",1,NA,NA,NA,NA,NA,NA,NA
NCT04291729,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:52:33Z,2020-04-20T08:52:33Z,Drug,Ganovo+ritonavir+/-Interferon nebulization,"Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50Î¼g / time for adults, twice a day up to 14 days.",1,,The Ninth Hospital of Nanchang,Nanchang,Jiangxi,330000,China,1
NCT04299152,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-28,NA,NA,2020-04-13,2020-03-05,2020-03-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"May 10, 2020",Anticipated,2020-05-10,April 2020,2020-04-30,"November 10, 2020",Anticipated,2020-11-10,"October 9, 2020",Anticipated,2020-10-09,NA,Interventional,NA,,Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19,Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Not yet recruiting,NA,Phase 2,20,Anticipated,Tianhe Stem Cell Biotechnologies Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:24Z,2020-04-20T08:52:24Z,Combination Product,Stem Cell Educator-Treated Mononuclear Cells Apheresis,"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the ""educated"" autologous immune cells to the patient's circulation.",1,NA,NA,NA,NA,NA,NA,NA
NCT04292899,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-28,NA,NA,2020-04-16,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Recruiting,NA,Phase 3,6000,Anticipated,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:31Z,2020-04-20T08:52:31Z,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of Care Treatment for COVID-19 Infection,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave|St Joseph Hospital Eureka|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.|Kaiser Permanente Los Angeles Medical Center|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue|Mission Hospital Regional Medical Center|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue|El Camino Hospital|Hoag Memorial Hospital Presbyterian|Kaiser Permanente Oakland Medical Center|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street|Sutter Medical Center Sacramento, One Medical Plaza|Sutter Medical Center Sacramento|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue|California Pacific Medical Center-Infectious Disease Associates Medical Group|Kaiser Permanente-Oakland, 2425 Geary Blvd|Providence St. Johns Medical Center|Sutter Santa Rosa Regional Hospital|Stanford Hospital|University of Colorado Denver, University of Colorado Hospital|SCL Health St. Joseph Hospital, 1375 East 19th Ave|SCL Health St. Joseph Hospital|Rose Medical Center|SCL Health St. Joseph Hospital, 200 Exempla Circle.|Yale-New Haven Hospital|John H. Stroger Jr. Hospital of Cook County|Rush University Medical Center|University of Chicago|IU Health Methodist Hospital|University of Iowa Hospitals & Clinics|Tulane University|Maine Medical Center|Holy Cross Hospital|Tufts Medical Center|Brigham & Women's Hospital and Harvard Medical School|Beth Israel Deaconess Medical Center|The University of Michigan Hospitals and Health Systems|Henry Ford Health System|Hennepin Healthcare|Mayo Clinic|Providence St Patrick Hospital and International Heart Institute of MT Foundation|Darmouth-Hitchhock Medical Center|Hackensack University Medical Center|Robert Wood Johnson University Hospital Somerset|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue|St. Joseph's University Medical Center|Jacobi Medical Center|James J. Peters Veterans Administration Medical Center|Jamaica Hospital Medical Center|Danbury Hospital|North Shore University Hospital, 270-05 76th Ave|North Shore University Hospital|Icahn School of Medicine at Mount Sinai, 350 East 17th Street|Icahn School of Medicine at Mount Sinai, 440 West 114th St.|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue|Icahn School of Medicine at Mount Sinai|Columbia University Medical Center-New York Presbyterian Hospital|New York Presbyterian Hospital/Weill Cornell Medical Center|Duke University Medical Center|University Hospitals Cleveland Medical Center|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave|Providence Portland Medical Center|Providence St. Vincent Medical Center|Kaiser Sunnyside Medical Center|Hospital of the University of Pennsylvania, 51 N. 31st Street|Hospital of the University of Pennsylvania|Temple University Hospital|The Miriam Hospital|Prisma Health Richland Hospital|The Liver Institute of Methodist Dallas Medical Center|UT Southwestern Medical Center Amelia Court, HIV Research Clinic|Baylor University Medical Center|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd.|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd|Baylor University Medical Center, 1400 8th Ave|Houston Methodist Hospital|Baylor University Medical Center, 2401 S. 31st St.|University of Utah Health|Virginia Hospital Center|Inova Fairfax Medical Campus|VCU Health Medical Center|Providence Regional Medical Center Everett|Kadlec Regional Medical Center|Providence St. Peter Hospital|Virginia Mason Medical Center|Swedish Center for Comprehensive Care|MultiCare Deaconess Hospital|MultiCare Tacoma General Hospital|St Joseph Medical Center|CHU de BORDEAUX|Chu Montpellier|CHU de Nantes|Saint Louis hospital|Hopital Saint Antoine|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie|Universitatsklinikum Hamburg-Eppendorf|UniversitÃ¤tsklinikum Schleswig-Holstein Campus Kiel|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2|Klinik fÃ¼r HÃ¤matologie, Onkologie, Immunologie|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP)|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia|ASST degli Spedali Civili di Brescia|ASST di Cremona - Azienda Socio Sanitaria Territor|UOC Malattie Infettive, IRCCS Ospedale San Raffaele|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova|Azienda Ospedaliero Universitaria di Parma|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo|Ospedale Guglielmo da Saliceto AUSL di Piacenza|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia|Yokohama Municipal Citizen's Hospital|Nagoya City Easter Medical Center|Tokyo Metropolitan Bokutoh Hospital|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|Amsterdam University Medical Centre - Location AMC|Leiden University Medical Center|Erasmus Medical Centre|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Principe de Asturias|Hospital Universitari Vall d'Hebron|Hospital Clinic de Barcelona|Hospital Universitario Cruces|Hospital Universitario RamÃ³n y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Regional Universitario de MÃ¡laga|Sahlgrenska University Hospital, Ostra|SUS (Skanes University Hospital)|Karolinska University Hospital|Hopitaux Universitaires de GenÃ¨ve|Ospedale Regionale di Locarno La CaritÃ |UniversitÃ¤tsspital ZÃ¼rich|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital|Royal Infirmary of Edinburgh|Queen Elizabeth University Hospital|Hull University Teaching Hospitals NHS Trust|Royal Lancaster Hospital|Liverpool University Hospital|Northwick Park Hospital|Royal Free London NHS Foundation Trust|King's College Hospital NHS Trust|Imperial College Healthcare NHS Trust|University College London|Manchester Royal|Manchester University NHS Foundation Trust|Pennine Acute Hospitals NHS Trust|Derriford Hospital|Sheffield Teaching Hospitals",Anaheim|Downey|Fontana|Fortuna|Harbor City|Los Angeles|Los Angeles|Los Angeles|Los Angeles|Mission Viejo|Moreno Valley|Mountain View|Newport Beach|Oakland|Ontario|Orange|Panorama City|Roseville|Sacramento|San Diego|San Diego|San Francisco|San Francisco|Santa Monica|Santa Rosa|Stanford|Aurora|Denver|Denver|Denver|Lafayette|New Haven|Chicago|Chicago|Chicago|Indianapolis|Iowa City|New Orleans|Portland|Silver Spring|Boston|Boston|Boston|Ann Arbor|Detroit|Minneapolis|Rochester|Missoula|Lebanon|Hackensack|Hillsborough|New Brunswick|Newark|Paterson|Bronx|Bronx|Jamaica|Lagrangeville|Manhasset|Manhasset|New York|New York|New York|New York|New York|New York|Durham|Cleveland|Hillsboro|Portland|Portland|Portland|Philadelphia|Philadelphia|Philadelphia|Providence|Columbia|Dallas|Dallas|Dallas|Dallas|Dallas|Fort Worth|Houston|Temple|Salt Lake City|Arlington|Falls Church|Richmond|Everett|Kennewick|Olympia|Seattle|Seattle|Spokane|Tacoma|Tacoma|Bordeaux|Montpelier Cedex 5|Nantes|Paris|Paris|DÃ¼sseldorf|Berlin|Hamburg|Kiel|Leipzig|Munich|MÃ¼nchen|Stuttgart|Hong Kong|Hong Kong|Hong Kong|Bergamo|Brescia|Cremona|Milano|Milano|Milan|Padova PD|Parma|Pavia|Piacenza|Roma|Torino|Kanagawa|Nagoya|Tokyo|Daegu|Seoul|Seoul|Amsterdam|Leiden|Rotterdam|Singapore|Singapore|Singapore|AlcalÃ¡ De Henares|Barcelona|Barcelona|Bizkaia|Madrid|Madrid|Madrid|MÃ¡laga|Gothenburg|Malmo|Stockholm|GenÃ¨ve 14|Lugano|ZÃ¼rich|Kaohsiung|Taichung|Taipei City|Edinburgh|Glasgow|Hull|Lancaster|Liverpool|London|London|London|London|London|Manchester|Manchester|Manchester|Plymouth|Sheffield,California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|Colorado|Colorado|Colorado|Colorado|Colorado|Connecticut|Illinois|Illinois|Illinois|Indiana|Iowa|Louisiana|Maine|Maryland|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Minnesota|Minnesota|Montana|New Hampshire|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|North Carolina|Ohio|Oregon|Oregon|Oregon|Oregon|Pennsylvania|Pennsylvania|Pennsylvania|Rhode Island|South Carolina|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Utah|Virginia|Virginia|Virginia|Washington|Washington|Washington|Washington|Washington|Washington|Washington|Washington||||||WA|||||||||||||||||||||||||||||||||||Madrid|||||||||||||||||||||||||||||||,92806|90241|92335|95540|90710|90027|90034|91365|92505|92691|92555|94040|92658|94611|91761|92868|91402|95661|95815|18038|92120-2507|94109|94115|90404|95403|94305|80045|80208|80218|80220|80026|06510|60612|60612|60637|46077|52242|70112|04102|20910|02111|02115|02215|48109-5378|48202|55415|55905|59802|03756|07601|08844|08901|07112|07503|10461|10468|11418|12540|11030|11030|10003|10025|10029|10029|10032|10065|27710|44106|97124|97213|97225|97227|19104|19104|19140|02906|29203|75203|75235|75246|75390|75390|76104|77030|76508|84132|22205|22042|23298|98201|99336|98506|98101|98104|99204|98405|98405|33076|34295|44035|75010|75012|40225|13353|20246|24105|4129|81675|80804|70376||||24127|25123|26100|20127|20157|20122|35121|43126|27100||00149|10149|240-8555|464-8547|130-8575|41944|02053|04564|1105 AZ|2300 RC|3015 GD|119228|169856|308442|28805|08035|8036|48903|28034|28041|28046|29010|41685|20502|SE-141 86|1211|CH- 6900|8091|81362|40447|10002|EH4 2XU|G51 4TF|HU16 5JQ|LA1 4RP|L7 8XP|HA1 3UJ|NW3 2QG|SE5 9RS|W2 1NY|WC1E 6JF|M13 9WL|M23 9LT|M8 5RB|PL6 8BG|S10 2JF,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Netherlands|Netherlands|Netherlands|Singapore|Singapore|Singapore|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Switzerland|Switzerland|Switzerland|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",169
NCT04292730,"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-28,NA,NA,2020-04-14,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Recruiting,NA,Phase 3,1600,Anticipated,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:32Z,2020-04-20T08:52:32Z,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of Care Treatment for COVID-19 Infection,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave|St Joseph Hospital Eureka|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.|Kaiser Permanente Los Angeles Medical Center|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue|Mission Hospital Regional Medical Center|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue|El Camino Hospital|Hoag Memorial Hospital Presbyterian|Kaiser Permanente-Oakland/San Francisco|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street|Sutter Medical Center Sacramento, One Medical Plaza|Sutter Medical Center Sacramento|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue|California Pacific Medical Center-Infectious Disease Associates Medical Group|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd|Providence St. Johns Medical Center|Sutter Santa Rosa Regional Hospital|Stanford Hospital|University of Colorado Denver, University of Colorado Hospital|SCL Health St. Joseph Hospital, 1375 East 19th Ave|SCL Health St. Joseph Hospital|Rose Medical Center|SCL Health St. Joseph Hospital, 200 Exempla Circle.|Yale University|Cook County General Hospital|Rush University Medical Center|University of Chicago|IU Health Methodist Hospital|University of Iowa Hospitals & Clinics|Tulane University|Maine Medical Center|Holy Cross Hospital|Tufts Medical Center|Brigham & Women's Hospital and Harvard Medical School|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center|The University of Michigan Hospitals and Health Systems|Henry Ford Health System|Hennepin Healthcare|Mayo Clinic|Providence St Patrick Hospital and International Heart Institute of MT Foundation|Darmouth-Hitchhock Medical Center|Hackensack Medical Center|Robert Wood Johnson University Hospital Somerset|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue|St. Joseph's University Medical Center|Jacobi Medical Center|James J. Peters Veterans Administration Medical Center|Jamaica Hospital Medical Center|Danbury Hospital|North Shore University Hospital|North Shore University Hospital, 270-05 76th Ave|Icahn School of Medicine at Mount Sinai, 350 East 17th Street|Icahn School of Medicine at Mount Sinai, 440 West 114th St.|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue|Icahn School of Medicine at Mount Sinai|Columbia University Irving Medical Center|Weill Cornell Medical College/NYU Presbyterian Hospital|Duke University Medical Center|University Hospitals Cleveland Medical Center|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave|Providence Portland Medical Center|Providence St. Vincent Medical Center|Kaiser Sunnyside Medical Center|Hospital of the University of Pennsylvania, 51 N. 31st Street|Hospital of the University of Pennsylvania|Temple University Hospital|The Miriam Hospital|Prisma Health Richland Hospital|The Liver Institute of Methodist Dallas Medical Center|UTSW Medical Center|Baylor University Medical Center|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd.|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd|Baylor University Medical Center, 1400 8th Ave|Houston Methodist Hospital|Baylor University Medical Center, 2401 S. 31st St.|University of Utah Health|Virginia Hospital Center|Inova Fairfax Hospital|VCU Health Medical Center|Providence Medical Research Center|Kadlec Regional Medical Center|Providence St. Peter Hospital|Virginia Mason Medical Center|Swedish Center for Comprehensive Care|MultiCare Deaconess Hospital|MultiCare Tacoma General Hospital|St Joseph Medical Center|The First Affiliated Hospital of Guangzhou Medical University|CHU de BORDEAUX|Chu Montpellier|CHU de Nantes|Saint Louis hospital|Hopital Saint Antoine|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie|Universitatsklinikum Hamburg-Eppendorf|UniversitÃ¤tsklinikum Schleswig-Holstein Campus Kiel|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2|Klinik fÃ¼r HÃ¤matologie, Onkologie, Immunologie|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP)|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia|ASST degli Spedali Civili di Brescia|ASST di Cremona - Azienda Socio Sanitaria Territor|UOC Malattie Infettive, IRCCS Ospedale San Raffaele|ASST Fatebenefratelli Sacco|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova|Azienda Ospedaliero Universitaria di Parma|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo|Ospedale Guglielmo da Saliceto AUSL di Piacenza|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia|Yokohama Municipal Citizen's Hospital|Nagoya City Easter Medical Center|Tokyo Metropolitan Bokutoh Hospital|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|Amsterdam University Medical Centre - Location AMC|Leiden University Medical Center|Erasmus Medical Centre|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Principe de Asturias|Hospital Clinic de Barcelona|Hospital Universitario Cruces|Hospital Universitario RamÃ³n y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Regional Universitario de MÃ¡laga|Sahlgrenska University Hospital, Ostra|SUS (Skanes University Hospital)|Karolinska University Hospital|Hopitaux Universitaires de GenÃ¨ve|Ospedale Regionale di Locarno La CaritÃ |UniversitÃ¤tsspital ZÃ¼rich|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital|Imperial College NHS Trust|Manchester Royal|Royal infirmary edinburgh|Queen Elizabeth University Hospital|Hull University Teaching Hospitals NHS Trust|Royal Lancaster Hospital|Liverpool University Hospital|Northwick Park Hospital|Royal Free London NHS Foundation Trust|King's College Hospital NHS Trust|University College London|Manchester University NHS Foundation Trust|Pennine Acute Hospitals NHS Trust|Derriford Hospital|Sheffield Teaching Hospitals",Anaheim|Downey|Fontana|Fortuna|Harbor City|Los Angeles|Los Angeles|Los Angeles|Los Angeles|Mission Viejo|Moreno Valley|Mountain View|Newport Beach|Oakland|Ontario|Orange|Panorama City|Roseville|Sacramento|San Diego|San Diego|San Francisco|San Francisco|Santa Monica|Santa Rosa|Stanford|Aurora|Denver|Denver|Denver|Lafayette|New Haven|Chicago|Chicago|Chicago|Indianapolis|Iowa City|New Orleans|Portland|Silver Spring|Boston|Boston|Boston|Ann Arbor|Detroit|Minneapolis|Rochester|Missoula|Lebanon|Hackensack|Hillsborough|New Brunswick|Newark|Paterson|Bronx|Bronx|Jamaica|Lagrangeville|Manhasset|New Hyde Park|New York|New York|New York|New York|New York|New York|Durham|Cleveland|Hillsboro|Portland|Portland|Portland|Philadelphia|Philadelphia|Philadelphia|Providence|Columbia|Dallas|Dallas|Dallas|Dallas|Dallas|Fort Worth|Houston|Temple|Salt Lake City|Arlington|Falls Church|Richmond|Everett|Kennewick|Olympia|Seattle|Seattle|Spokane|Tacoma|Tacoma|Guangzhou|Bordeaux|Montpelier Cedex 5|Nantes|Paris|Paris|Berlin|DÃ¼sseldorf|Hamburg|Kiel|Leipzig|Munich|MÃ¼nchen|Stuttgart|Hong Kong|Hong Kong|Hong Kong|Bergamo|Brescia|Cremona|Milano|Milano|Milan|Padova PD|Parma|Pavia|Piacenza|Roma|Torino|Kanagawa|Nagoya|Tokyo|Daegu|Seoul|Seoul|Amsterdam|Leiden|Rotterdam|Singapore|Singapore|Singapore|AlcalÃ¡ De Henares|Barcelona|Bizkaia|Madrid|Madrid|Madrid|MÃ¡laga|Gothenburg|Malmo|Stockholm|GenÃ¨ve 14|Lugano|ZÃ¼rich|Kaohsiung|Taichung|Taipei City|London|Manchester|Edinburgh|Glasgow|Hull|Lancaster|Liverpool|London|London|London|London|Manchester|Manchester|Plymouth|Sheffield,California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|Colorado|Colorado|Colorado|Colorado|Colorado|Connecticut|Illinois|Illinois|Illinois|Indiana|Iowa|Louisiana|Maine|Maryland|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Minnesota|Minnesota|Montana|New Hampshire|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|North Carolina|Ohio|Oregon|Oregon|Oregon|Oregon|Pennsylvania|Pennsylvania|Pennsylvania|Rhode Island|South Carolina|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Utah|Virginia|Virginia|Virginia|Washington|Washington|Washington|Washington|Washington|Washington|Washington|Washington||||||||||||||||||||||||||||||||||||||||||Madrid||||||||||||||||Greater London|M13 9wl|||||||||||||,92806|90241|92335|95540|90710|90027|90034|91365|92505|92691|92555|94040|92658|94611|91761|92868|91402|95661|95815|18038|92120-2507|94109|94115|90404|95403|94305|80045|80208|80218|80220|80026|06510|60612|60612|60637|46077|52242|70112|04102|20910|02111|02115|02215|48109-5378|48202|55415|55905|59802|03756|07601|08844|08901|07112|07503|10461|10468|11418|12540|11303|11040|10003|10025|10029|10029|10032|10065|27710|44106|97124|97213|97225|97227|19104|19104|19140|02906|29203|75203|75235|75246|75390|75390|76104|77030|76508|84132|22205|22042|23298|98201|99336|98506|98101|98104|99204|98405|98405||33076|34295|44035|75010|75012|13353|40225|20246|24105|4129|81675|80804|70376||||24127|25123|26100|20127|20157|20122|35121|43126|27100||00149|10149|240-8555|464-8547|130-8575|41944|02053|04564|1105 AZ|2300 RC|3015 GD|119228|169856|308442|28805|8036|48903|28034|28041|28046|29010|41685|20502|SE-141 86|1211|CH- 6900|8091|81362|40447|10002|W2 1NY|M13 9WL|EH4 2XU|G51 4TF|HU16 5JQ|LA1 4RP|L7 8XP|HA1 3UJ|NW3 2QG|SE5 9RS|WC1E 6JF|M23 9LT|M8 5RB|PL6 8BG|S10 2JF,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|China|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Germany|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Japan|Japan|Japan|Korea, Republic of|Korea, Republic of|Korea, Republic of|Netherlands|Netherlands|Netherlands|Singapore|Singapore|Singapore|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Sweden|Sweden|Sweden|Switzerland|Switzerland|Switzerland|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",169
NCT04296643,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-05,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Not yet recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:31Z,2020-04-01T09:21:31Z,Device|Device,Medical Mask|N95 respirator,Medical Mask (known also as Surgical Mask)|N95 respirator,2,NA,NA,NA,NA,NA,NA,NA
NCT04295551,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-04,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"April 14, 2021",Anticipated,2021-04-14,"July 14, 2020",Anticipated,2020-07-14,NA,Interventional,NA,,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,NA,N/A,80,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:39Z,2020-04-01T09:21:39Z,Drug|Drug,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04308317,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:05Z,2020-04-01T09:20:05Z,Drug,Tetrandrine,Tetrandrine 60mg QD for 1week,1,,Tetrandrine Tablets,Jinhua,Zhejiang,321000,China,1
NCT04299724,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:21:09Z,2020-04-01T09:21:09Z,Biological,Pathogen-specific aAPC,The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.,1,Recruiting,Shenzhen Geno-immune Medical Institute,Shenzhen,Guangdong,518000,China,1
NCT04304053,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-05,NA,NA,2020-04-14,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"June 15, 2020",Anticipated,2020-06-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Recruiting,NA,Phase 3,3040,Anticipated,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2020-04-20T08:52:17Z,2020-04-20T08:52:17Z,Drug|Other,Treatment and prophylaxis|Standard Public Health measures,"hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4, 5, 6 and 7
Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.|Isolation of patient and contact tracing as per national guidelines.",2,Recruiting,Departament de Salut,Barcelona,,,Spain,1
NCT04303507,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-06,NA,NA,2020-03-25,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Not yet recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-04-06T08:56:55Z,2020-04-06T08:56:55Z,Drug|Drug,Chloroquine or Hydroxychloroquine|Placebo,A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months|Placebo,2,NA,NA,NA,NA,NA,NA,NA
NCT04323332,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-08,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,Traditional Chinese Medicine for Severe COVID-19,A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19,Not yet recruiting,NA,Phase 3,50,Anticipated,Xiyuan Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-05T09:04:37Z,2020-04-05T09:04:37Z,Drug,Traditional Chinese Medicine Prescription,Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.,1,,Hao Li,Beijing,Beijing,100091,China,1
NCT04306055,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,N/A,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:12Z,2020-04-20T08:52:12Z,Other|Other,Questionnaire with precaution information|Experimental: Questionnaire without precaution information,Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.|Ever blood donors in this group would receive a questionnaire which dose not include the information above.,2,,Guangzhou Blood Center,Guangzhou,Guangdong,510095,China,1
NCT04305106,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,N/A,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-05T09:06:32Z,2020-04-05T09:06:32Z,Drug,Bevacizumab,"Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
NCT04305457,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-09,NA,NA,2020-04-07,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"March 21, 2020",Actual,2020-03-21,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-19T09:04:36Z,2020-04-19T09:04:36Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114-2621,United States,1
NCT04310228,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-09,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"March 8, 2020",Actual,2020-03-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:52:07Z,2020-04-20T08:52:07Z,Drug|Drug|Drug,Favipiravir Combined With Tocilizumab|Favipiravir|Tocilizumab,"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",3,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Guiqiang Wang|Peking University First Hospital|Ezhou Central Hospital|Huoshenshan Hospital of Wuhan|Jinyintan Hospital of Wuhan|Wuhan Pulmonary Hospital,Beijing|Beijing|Wuhan|Wuhan|Wuhan|Wuhan,Beijing|Beijing|Hubei|Hubei|Hubei|Hubei,100034|100034|430000|430000|430000|430000,China|China|China|China|China|China,6
NCT04304690,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-09,NA,NA,2020-04-10,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:15Z,2020-04-20T08:52:15Z,Other,blood sample,2 blood samples at T0 and 3 months,1,Recruiting,Hopital PitiÃ© SalpetriÃ¨re,Paris,,75013,France,1
NCT04307693,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-10,NA,NA,2020-03-12,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-12,2020-03-13,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,Asan Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:10Z,2020-04-01T09:20:10Z,Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate,Lopinavir / Ritonavir tablet|Hydroxychloroquine sulfate tablet,2,Recruiting,"Asan Medical Center, University of Ulsan College of Medicine",Seoul,,138-736,"Korea, Republic of",1
NCT04306393,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-10,NA,NA,2020-04-04,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-04,2020-04-07,Actual,"March 21, 2020",Actual,2020-03-21,April 2020,2020-04-30,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-17T09:15:14Z,2020-04-17T09:15:14Z,Drug,Nitric Oxide Gas,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.
Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.",1,Recruiting|Recruiting|Recruiting,University of Alabama|Louisiana State University Health Shreveport|Massachusetts General Hospital,Birmingham|Shreveport|Boston,Alabama|Louisiana|Massachusetts,35294|71103|02114,United States|United States|United States,3
NCT04308668,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-11,NA,NA,2020-04-06,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 17, 2020",Actual,2020-03-17,April 2020,2020-04-30,"May 12, 2020",Anticipated,2020-05-12,"April 21, 2020",Anticipated,2020-04-21,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3000,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:12:54Z,2020-04-18T09:12:54Z,Drug|Other,Hydroxychloroquine|Placebo,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota|Internet|University of Alberta|University of Manitoba|Research Institute of the McGill University Heath Centre",Minneapolis|Minneapolis|New York|Edmonton|Winnipeg|MontrÃ©al,Minnesota|Minnesota|New York|Alberta|Manitoba|Quebec,55455|55455|10001|||,United States|United States|United States|Canada|Canada|Canada,6
NCT04316377,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-13,NA,NA,2020-03-30,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-03,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"March 3, 2025",Anticipated,2025-03-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 4,202,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-13T09:01:21Z,2020-04-13T09:01:21Z,Drug,Hydroxychloroquine Sulfate,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,1,Recruiting,Akershus University Hospital,LÃ¸renskog,,1478,Norway,1
NCT04315948,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-13,NA,NA,2020-03-23,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-04T09:18:48Z,2020-04-04T09:18:48Z,Drug|Drug|Drug|Drug|Other,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine|Standard of care,"The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.|The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the ""a"" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).|IFN-ÃŸ-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 Âµg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).|Standard of care.",5,Recruiting|Recruiting|Recruiting,CHRU Lille|CHU Nantes|APHP - Bichat Claude Bernard,Lille|Nantes|Paris,||,59000|44000|75018,France|France|France,3
NCT04312009,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-13,NA,NA,2020-04-15,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:04Z,2020-04-20T08:52:04Z,Drug|Other,Losartan|Placebo,"Losartan; 50 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,Not yet recruiting|Recruiting|Recruiting,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
NCT04311177,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-13,NA,NA,2020-04-09,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Recruiting,NA,Phase 2,580,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:05Z,2020-04-20T08:52:05Z,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,Not yet recruiting|Recruiting|Recruiting|Not yet recruiting,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota|Mayo Clinic Health System,Minneapolis|Minneapolis|Minneapolis|Rochester,Minnesota|Minnesota|Minnesota|Minnesota,55415|55455|55455|55415,United States|United States|United States|United States,4
NCT04316728,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-14,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19,Not yet recruiting,NA,N/A,200,Anticipated,"Centro Studi Internazionali, Italy",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months,Still under development,NA,Yes,Still under development,2020-04-01T09:19:01Z,2020-04-01T09:19:01Z,Device,VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test,"VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma",1,,"UnitÃ ' Complesse di cure primarie (UCCP), ASP Catanzaro",Catanzaro,,88100,Italy,1
NCT04315480,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-14,NA,NA,2020-04-09,2020-03-18,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 12, 2020",Actual,2020-03-12,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,"April 9, 2020",Anticipated,2020-04-09,NA,Interventional,NA,,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia,"Active, not recruiting",NA,Phase 2,38,Actual,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:58Z,2020-04-20T08:51:58Z,Drug,Tocilizumab,single intravenous administration 8mg/Kg,1,,UniversitÃ  Politecnica delle Marche,Ancona,AN,60020,Italy,1
NCT04311697,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-14,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Not yet recruiting,NA,Phase 2,120,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-20T08:52:05Z,2020-04-20T08:52:05Z,Drug|Drug,Aviptadil by intravenous infusion + maximal intensive care|Normal Saline Infusion + Maximal intensive care,Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.|Maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.,2,|||,Miller School of Medicine / University of Miami Medical Center|Robert I Grossman School of Medicine / NYU Langone Medical Center|Thomas Jefferson University Hospital|Rambam Health Care Campus,Miami|New York|Philadelphia|Haifa,Florida|New York|Pennsylvania|,33136|10016|19107|3109601,United States|United States|United States|Israel,4
NCT04313322,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:25Z,2020-04-01T09:19:25Z,Biological,WJ-MSCs,"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.",1,Recruiting,Stem Cells Arabia,Amman,,11953,Jordan,1
NCT04310865,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"June 30, 2021",Anticipated,2021-06-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",Not yet recruiting,NA,Phase 2/Phase 3,116,Anticipated,China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:45Z,2020-04-01T09:19:45Z,Drug|Drug|Other,Yinhu Qingwen Granula|Yin Hu Qing Wen Granula(low does)|standard medical treatment,"Yinhu Qingwen Granula is a kind of herbal granula made from ""Yinhu Qingwen Decoction"", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.",3,|||,Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University,Wuhan|Wuhan|Wuhan|Wuhan,Hubei|Hubei|Hubei|Hubei,430071|430071|430071|430200,China|China|China|China,4
NCT04312243,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-15,NA,NA,2020-04-01,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 2, 2020",Anticipated,2020-04-02,April 2020,2020-04-30,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Not yet recruiting,NA,Phase 2,470,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-13T09:01:32Z,2020-04-13T09:01:32Z,Drug,Inhaled nitric oxide gas,"Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04315298,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-15,NA,NA,2020-04-02,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"March 9, 2021",Anticipated,2021-03-09,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://errs.regeneron.com/external,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-04-16T09:17:12Z,2020-04-16T09:17:12Z,Drug|Drug,Sarilumab|Placebo,Single intravenous (IV) dose of sarilumab|Single intravenous (IV) dose of placebo to match sarilumab administration,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site 1|Regeneron Study Site 2|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Facility 2|Regeneron Study Site 1|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site 1|Regeneron Study Site 2|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site,Los Angeles|Sacramento|Santa Monica|Aurora|Denver|New Haven|Washington|Coral Gables|Gainesville|Orlando|Atlanta|Decatur|Marietta|Chicago|Chicago|New Orleans|Baltimore|Boston|Boston|Boston|Boston|Ann Arbor|Detroit|Rochester|Edison|Hackensack|Livingston|Morristown|Neptune|Newark|Teaneck|Bronx|Bronx|Bronx|Bronx|Brooklyn|Elmhurst|Manhasset|Manhasset|New York|New York|New York|New York|New York|New York|New York|New York|New York|Stony Brook|Valhalla|Tulsa|Portland|Portland|Danville|Philadelphia|Scranton|Wilkes-Barre|Dallas|Dallas|Murray|Falls Church|Everett|Renton,California|California|California|Colorado|Colorado|Connecticut|District of Columbia|Florida|Florida|Florida|Georgia|Georgia|Georgia|Illinois|Illinois|Louisiana|Maryland|Massachusetts|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Minnesota|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|Oklahoma|Oregon|Oregon|Pennsylvania|Pennsylvania|Pennsylvania|Pennsylvania|Texas|Texas|Utah|Virginia|Washington|Washington,90095|95817|90404|80045|80206|06520|20010|33146|32610|32803|30322|30033|30060|60611|60612|70112|21205|02111|02114|02115|02215|48109|48236|55905|08820|07601|07039|07960|07753|07112|07666|10451|10461|10461|10467|11219|11373|11030|11030|10003|10016|10025|10025|10029|10032|10037|10065|10075|11794|10595|74104|97213|97239|17822|19140|18510|18711|75246|75390|84107|22042|98201|98055,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,63
NCT04313127,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-15,NA,NA,2020-04-10,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:01Z,2020-04-20T08:52:01Z,Biological,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Intramuscular other name:Ad5-nCoV,1,,Hubei Provincial Center for Disease Control and Prevention,Wuhan,Hubei,,China,1
NCT04313023,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-16,NA,NA,2020-04-12,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Not yet recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:02Z,2020-04-20T08:52:02Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) PUL-042 Inhalation Solution|Sterile saline for inhalation,2,NA,NA,NA,NA,NA,NA,NA
NCT04312997,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-16,NA,NA,2020-04-12,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:52:02Z,2020-04-20T08:52:02Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042)|Sterile saline for inhalation,2,NA,NA,NA,NA,NA,NA,NA
NCT04321174,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-18,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 30, 2020",Anticipated,2020-03-30,March 2020,2020-03-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Not yet recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-04-04T09:17:44Z,2020-04-04T09:17:44Z,Drug,Lopinavir/ritonavir,"The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.",1,||,Sunnybrook Hospital|St. Michael's Hospital|Toronto General Hospital,Toronto|Toronto|Toronto,Ontario|Ontario|Ontario,M4N 3M5|M5B 1W8|M5G 2N2,Canada|Canada|Canada,3
NCT04323514,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,N/A,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-05T09:04:31Z,2020-04-05T09:04:31Z,Dietary Supplement,Vitamin C,10 gr of vitamin C intravenously in addition to conventional therapy.,1,Recruiting,A.R.N.A.S. Civico - Di Cristina - Benfratelli,Palermo,,90127,Italy,1
NCT04315987,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-18,NA,NA,2020-04-14,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,HOPE,,NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Exploratory Clinical Study to Assess the Efficacy of NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,NA,Phase 1,66,Anticipated,Azidus Brasil,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-20T08:51:57Z,2020-04-20T08:51:57Z,Biological,NestCellÂ®,"A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3 and 5 in all subjects. If necessary, subjects will receive and extra dose on day 7",1,,Hospital Vera Cruz,Campina Grande,SÃ£o Paulo,,Brazil,1
NCT04315896,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-18,NA,NA,2020-04-15,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-04-20T08:51:57Z,2020-04-20T08:51:57Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,hydroxychloroquine 400mg day for 10 days|Placebo oral tablet,2,Recruiting,"Instituto Nacional de Enfermedades Respiratorias, ""Ismael CosÃ­o Villegas""","Mexico, City",,14080,Mexico,1
NCT04323592,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,MP-C19,,Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Recruiting,NA,Phase 2/Phase 3,104,Anticipated,University of Trieste,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2020-04-06T08:55:46Z,2020-04-06T08:55:46Z,Drug|Other,Methylprednisolone|standard care,"Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description|usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins",2,Recruiting,Marco Confalonieri,Trieste,TS,34149,Italy,1
NCT04320056,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-19,NA,NA,2020-03-26,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia,Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Not yet recruiting,NA,N/A,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2020-04-06T08:56:16Z,2020-04-06T08:56:16Z,Other|Device,Standard administration of oxygen flow|Automated oxygen administration - FreeO2,"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.
In this group the SpO2 was recorded any time with FreeO2 device - recording mode|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)",2,NA,NA,NA,NA,NA,NA,NA
NCT04317092,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-19,NA,NA,2020-04-03,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,400,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:14:48Z,2020-04-17T09:14:48Z,Drug,Tocilizumab Injection,"Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia)|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive)|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza)|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O.|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive)|ASST OVEST MILANESE presidi Legnano - Magenta|Azienda Ospedaliero-Universitaria di Modena|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I)|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II)|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive)|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia)|National Cancer Institute|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva)|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio)|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza)|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione)|Grande Ospedale Metropolitano, Reggio Calabria|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive)|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche)|ASST Sette Laghi (Dipartimento di Medicina Interna)|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze)|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale)|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali)|A.O.U. Integrata di Verona (Dip. Malattie Infettive)|Ospedale Magalini (U.O. Malattie Infettive)",Alessandria|Busto Arsizio|Catania|Catania|Cosenza|Magenta|Modena|Modena|Modena|Modena|Modena|Naples|Naples|Naples|Naples|Pesaro|Pozzuoli|Ravenna|Reggio Calabria|Rimini|Rome|Varese|Varese|Varese|Varese|Verona|Villafranca Di Verona,||||||||||||||||||||||||||,||||||42100|||||80131|80131||||||||||||||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,27
NCT04323527,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-19,NA,NA,2020-04-13,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Recruiting,NA,Phase 2,440,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-04-20T08:51:41Z,2020-04-20T08:51:41Z,Drug,Chloroquine diphosphate,150mg chloroquine diphosphate tablets.,1,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
NCT04318015,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-19,NA,NA,2020-04-15,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:51:53Z,2020-04-20T08:51:53Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,All treatment will be administered orally.|All placebo will be administered orally,2,Recruiting,"Instituto Nacional de Enfermedades Respiratorias, ""Ismael CosÃ­o Villegas""","Mexico, City",,14080,Mexico,1
NCT04317040,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-19,NA,NA,2020-04-08,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:55Z,2020-04-20T08:51:55Z,Drug|Drug,CD24Fc|Placebo,CD24Fc is given on Day 1.|Placebo is given on Day 1.,2,Recruiting,"Institute of Human Virology, University of Maryland Baltimore",Baltimore,Maryland,21201,United States,1
NCT04320277,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,BARI-COVID,,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study",Recruiting,NA,Phase 3,60,Anticipated,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:19:18Z,2020-04-03T09:19:18Z,Drug,Baricitinib,Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.,1,Recruiting,Fabrizio Cantini,Prato,Tuscany,59100,Italy,1
NCT04319900,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:19:32Z,2020-04-03T09:19:32Z,Drug|Drug|Drug,favipiravir tablets+chloroquine phosphatetablets tablets|Favipiravir tablets|Placebo,"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).
Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.",3,Recruiting,Beijing Chaoyang hospital,Beijing,Beijing,100020,China,1
NCT04318444,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-20,NA,NA,2020-03-24,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Not yet recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-04-04T09:18:34Z,2020-04-04T09:18:34Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.",2,,Columbia University Irving Medical Center,New York,New York,10032,United States,1
NCT04321928,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-20,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Not yet recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-06T08:56:05Z,2020-04-06T08:56:05Z,Behavioral|Behavioral,Personalized health education|General health education,"Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.",2,NA,NA,NA,NA,NA,NA,NA
NCT04319445,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-20,NA,NA,2020-04-06,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Recruiting,NA,N/A,200,Anticipated,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:12:27Z,2020-04-18T09:12:27Z,Behavioral,Mindfulness session(s),"The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).",1,Recruiting,Wake Forest Health Sciences,Winston-Salem,North Carolina,27157,United States,1
NCT04324606,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-20,NA,NA,2020-04-14,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,510,Anticipated,University of Oxford,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:37Z,2020-04-20T08:51:37Z,Biological|Biological,ChAdOx1 nCoV-19|MenACWY Placebo,5x10^10vp of ChAdOx1 nCoV-19|Standard single dose of MenACWY vaccine delivered intramuscularly,2,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust|Imperial College Healthcare NHS Trust|CCVTM, University of Oxford, Churchill Hospital|John Radcliffe Hospital",Southampton|London|Oxford|Oxford,Hampshire|||,SO16 6YD|W2 1NY|OX3 7LE|OX3 9DU,United Kingdom|United Kingdom|United Kingdom|United Kingdom,4
NCT04320953,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:47Z,2020-04-20T08:51:47Z,Device,Non-contact MCE system,"After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.",1,,Changhai Hospital,Shanghai,,200433,China,1
NCT04320238,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:16:56Z,2020-04-10T09:16:56Z,Drug|Drug,recombinant human interferon Alpha-1b|thymosin alpha 1,"recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.|thymosin alpha 1 subcutaneous injection 1 time per week.",2,Recruiting,Taihe Hospital,Shiyan,Hubei,,China,1
NCT04325867,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,eCardioCovid19,,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,N/A,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2020-04-11T09:14:01Z,2020-04-11T09:14:01Z,Other,Tele-medicine platform,"Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).",1,Recruiting|Recruiting,Medical Sciences Academy|University of Medicine and Pharmacy Gr T Popa,Bucharest|Iasi,|,|700503,Romania|Romania,2
NCT04319731,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-22,NA,NA,2020-04-15,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 20, 2021",Anticipated,2021-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NA,,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,NA,Early Phase 1,10,Anticipated,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:50Z,2020-04-20T08:51:50Z,Biological,Human Amniotic Fluid,Administration of amniotic fluid in SARS-CoV-2 positive patients,1,Recruiting,University of Utah Health,Salt Lake City,Utah,84132,United States,1
NCT04321421,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,"Active, not recruiting",NA,N/A,49,Anticipated,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2020-04-04T09:17:36Z,2020-04-04T09:17:36Z,Other,hyperimmune plasma,administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5,1,,Catherine Klersy,Pavia,PV,27100,Italy,1
NCT04321096,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-23,NA,NA,2020-04-02,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,180,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-04-16T09:16:53Z,2020-04-16T09:16:53Z,Drug|Drug,Camostat Mesilate|Placebo oral tablet,Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2|Placebo,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Department of Infectious Diseases|Department for Infectious Diseases, Aarhus University Hospital|Herning Regional Hospital|Northzealands hospital - HillerÃ¸d|Horsens Regional Hospital|Bispebjerg hospital|Dept. of Infectious Diseases, Odense University Hospital|Randers Regional Hospital|Silkeborg Hospital",Aalborg|Aarhus N|Herning|HillerÃ¸d|Horsens|KÃ¸benhavn|Odense|Randers|Silkeborg,||||||||,|8200|7400|3400|8700|2400|5000|8900|8600,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,9
NCT04323345,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"May 10, 2020",Anticipated,2020-05-10,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Not yet recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-05T09:04:37Z,2020-04-05T09:04:37Z,Dietary Supplement|Other,Natural Honey|Standard Care,Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.,2,,Mahmoud Tantawy,Cairo,,,Egypt,1
NCT04322344,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-06T08:55:58Z,2020-04-06T08:55:58Z,Drug|Drug,Escin|standard therapy,treatment with escin or escinate sodium|antiviral drugs,2,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
NCT04320615,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-06,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 3,330,Anticipated,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).
Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2020-04-18T09:12:24Z,2020-04-18T09:12:24Z,Drug|Drug,Tocilizumab (TCZ)|Placebo,Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.,2,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,"University of California San Diego|eStudySite|David Geffen School of Medicine UCLA|Denver Health Medical Center|University of Chicago|Ochsner Clinic Foundation|Baystate Health System|Mayo Clinic - PPDS|Hackensack University Medical Center|James J Peters Veterans Administration Medical Center - NAVREF|New York University Langone Medical Center|Duke University Medical Center|Baylor University Medical Center; Valdez/ Rhone|Swedish Hospital Medical Center|McMaster University Medical Centre|University Health Network|Clinical Research Institute of Montreal|Rigshospitalet Copenhagen University Hospital|Hvidovre Hospital|Odense Universitetshospital|SjÃ¦llands Universitetshospital, Roskilde|Centre Hospitalier Departemental de Vendee|Centre Hospitalier et Universitaire de Limoges|HÃ´pital de La Croix Rousse|Hotel Dieu - Nantes|Hopital de la Pitie Salpetriere|CHRU de Tours, Pharmacie|Universitatsklinikum Dusseldorf|Medizinische Hochschule Hannover|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin|Uniklinik KÃ¶ln|LMU Klinikum der Universitat Munchen|Azienda Ospedaliera Dei Colli|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria|Amphia Ziekenhuis|St. Antonius Ziekenhuis Nieuwegein|Erasmus MC|Universitair Medisch Centrum Utrecht|Hospital Universitario de Bellvitge|Hospital Universitari Vall d'Hebron|Hospital Clinic de Barcelona|Hospital Universitario La Paz|Hospital Universitario Ramon y Cajal|Hospital General Universitario Gregorio Maranon|Leeds Teaching Hospitals NHS Trust|Royal Free Hospital|Imperial College London|North Manchester General Hospital|Salford Royal Hospital",La Jolla|La Mesa|Los Angeles|Denver|Chicago|Baton Rouge|Springfield|Rochester|Hackensack|Bronx|New York|Durham|Dallas|Seattle|Hamilton|Toronto|Montreal|Copenhagen|Hvidovre|Odense C|Roskilde|La Roche Sur Yon|Limoges|Lyon|Nantes|Paris|Tours|Dusseldorf|Hannover|Kiel|KÃ¶ln|Munchen|Napoli|Roma|Bergamo|Milano|Pavia|Breda|Nieuwegein|Rotterdam|Utrecht|Hospitalet de Llobregat|Barcelona|Barcelona|Madrid|Madrid|Madrid|Leeds|London|London|Manchester|Salford,California|California|California|Colorado|Illinois|Louisiana|Massachusetts|Minnesota|New Jersey|New York|New York|North Carolina|Texas|Washington|Ontario|Ontario|Quebec||||||||||||||||Campania|Lazio|Lombardia|Lombardia|Lombardia|||||Barcelona||||||||||,92093|91942|90095|80204|60637|70809|01107|55905|07601|10468|10016|27710|75246|98104|L8N 3Z5|M5G2M9|H2W 1R7|DK-2100|DK-2650|5000|4000|85925|87042|69004|44093|75013|37044|40225|30625|24105|50931|80337|80131|00149|24127|20157|27100|4819 EV|3430 EM|3015 GD|3584 CX|08907|08035|08036|28034|28034|28040|LS9 7AU|NW3 2QS|W6 8RF|M8 5RB|M6 8HD,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Canada|Canada|Canada|Denmark|Denmark|Denmark|Denmark|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Germany|Italy|Italy|Italy|Italy|Italy|Netherlands|Netherlands|Netherlands|Netherlands|Spain|Spain|Spain|Spain|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,52
NCT04322682,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-07,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-19T09:03:56Z,2020-04-19T09:03:56Z,Drug|Drug,Colchicine|Placebo oral tablet,"Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.",2,Recruiting|Recruiting,New York University School of Medecine|Montreal Heart Institute,New York|Montreal,New York|Quebec,10010|H1T 1C8,United States|Canada,2
NCT04346368,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19),Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial,Not yet recruiting,NA,Phase 1/Phase 2,20,Anticipated,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:09Z,2020-04-20T08:47:09Z,Biological|Biological,BM-MSCs|Placebo,Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).|Placebo,2,,"Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University",Guangzhou,Guangdong,510120,China,1
NCT04330690,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-16,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"May 18, 2022",Anticipated,2022-05-18,"March 18, 2022",Anticipated,2022-03-18,NA,Interventional,CATCO,,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,440,Anticipated,Sunnybrook Health Sciences Centre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.
Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2020-04-20T08:51:18Z,2020-04-20T08:51:18Z,Drug,Lopinavir/ritonavir,"Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"University of Alberta Hopsital|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia|St Paul's Hospital|The Ottawa Hospital - General Campus|The Ottawa Hospital - Civic Campus|Sunnybrook Health Sciences Centre|Toronto Western Hospital|McGill University Health Centre-Glen Site Royal Victoria Hospital|CHU de QuÃ©bec - UniversitÃ© Laval|Institut Universitaire de Cardiologie et de Pneumologie de QuÃ©bec- UniversitÃ© Laval|Centre IntÃ©grÃ© Universitaire de SantÃ© et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke",Edmonton|Vancouver|Vancouver|Ottawa|Ottawa|Toronto|Toronto|MontrÃ©al|QuÃ©bec|QuÃ©bec|Sherbrooke,Alberty|British Columbia|British Columbia|Ontario|Ontario|Ontario|Ontario|Quebec|Quebec|Quebec|Quebec,T6G 2B7|V5Z1M9|V6Z 1Y6|K1H 8L6|K1Y 4E9|M4N3M5|M5T2S8|H4A 3J1|G1J 1Z4|G1V 4G5|J1H 5N4,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,11
NCT04328129,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-15,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in French Guiana,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana,Recruiting,NA,N/A,450,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:28Z,2020-04-20T08:51:28Z,Procedure,Human biological samples,"Blood sample
Nasopharyngeal swab.",1,Enrolling by invitation|Recruiting,Centre Hospitalier AndrÃ©e Rosemon|Institut Pasteur de la Guyane,Cayenne|Cayenne,|,|,French Guiana|French Guiana,2
NCT04323228,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-13,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,ONSCOVID19,,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Not yet recruiting,NA,Phase 4,30,Anticipated,King Saud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2020-04-20T08:51:42Z,2020-04-20T08:51:42Z,Dietary Supplement|Dietary Supplement,"oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|isocaloric/isonutrigenous ONS","the intervention group will receive a commercially available anti-inflammatory/antioxidant ONS, which will be given to patients with COVID-19 in the morning 3 hours after breakfast.|The placebo group will receive an isocaloric/isonutrigenous ONS at the same time in the same shape/size/color of the cans.",2,NA,NA,NA,NA,NA,NA,NA
NCT04322396,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,ProPAC-COVID,,Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19,"Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Recruiting,NA,Phase 2,226,Anticipated,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:44Z,2020-04-20T08:51:44Z,Drug|Drug|Drug|Drug,Azithromycin|Hydroxychloroquine|Placebo oral tablet|Placebo oral tablet,Azithromycin|Hydroxychloroquine|Placebo Azithromycin|Placebo Hydroxychloroquine,4,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Aalborg Sygehus|Bispebjerg Hospital|Herlev-Gentofte Hospital|Hvidovre Hospital|NordsjÃ¦llands Hospital|Odense Universitetshospital|Roskilde Sygehus|Slagelse Sygehus,Aalborg|Copenhagen|Copenhagen|Copenhagen|HillerÃ¸d|Odense|Roskilde|Slagelse,|||||||,|||||||,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,8
NCT04321616,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-04-20T08:51:45Z,2020-04-20T08:51:45Z,Drug|Drug|Other,Hydroxychloroquine|Remdesivir|(Standard of Care) SoC,Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.|The standard of care will be supplied to all patients not receiving a drug intervention.,3,Recruiting,Andreas Barratt-Due,Oslo,,0756,Norway,1
NCT04328961,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-23,NA,NA,2020-03-29,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-29,2020-04-01,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 PEP,"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Not yet recruiting,NA,Phase 1,2000,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-04-11T09:13:22Z,2020-04-11T09:13:22Z,Drug|Drug,Hydroxychloroquine Sulfate|Ascorbic Acid,Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.,2,||,"NYU Langone Health|University of Washington, Coordinating Center|UW Virology Research Clinic",New York|Seattle|Seattle,New York|Washington|Washington,10016|98104|98104,United States|United States|United States,3
NCT04321278,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-23,NA,NA,2020-03-30,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients,Recruiting,NA,Phase 3,440,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-11T09:14:23Z,2020-04-11T09:14:23Z,Drug|Drug,Hydroxychloroquine + azithromycin|Hydroxychloroquine,"Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.",2,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting,"Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Hospital UniversitÃ¡rio Onofre Lopes|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Hospital Israelita Albert Einstein|AMICO Saude LTDA|Associacao Beneficente Siria|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Serv Social da Industria do papel, papelÃ£o e cortiÃ§a do estado de SP|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo",BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Distrito Federal|Espirito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|||||||||||,|||||||||||05652-900||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,22
NCT04326920,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-24,NA,NA,2020-03-31,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"March 24, 2020",Actual,2020-03-24,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,SARPAC,,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Recruiting,NA,Phase 4,80,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-12T09:07:40Z,2020-04-12T09:07:40Z,Drug|Other,Sargramostim|Control,Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration|Standard of care,2,Recruiting|Recruiting,AZ Sint Jan Brugge|University Hospital Ghent,Brugge|Gent,|,8000|9000,Belgium|Belgium,2
NCT04322773,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-24,NA,NA,2020-04-05,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Recruiting,NA,Phase 2,200,Anticipated,Frederiksberg University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-04-17T09:14:28Z,2020-04-17T09:14:28Z,Drug|Drug|Drug|Other,RoActemra iv|RoActemra sc|Kevzara sc|Standard medical care,single dose treatment with tocilizumab 400 mg intravenously|single dose treatment with tocilizumab 2 x 162 mg subcutaneously|single dose treatment with sarilumab 1 x 200 mg subcutaneously|management as usual,4,Recruiting|Recruiting,Bispebjerg-Frederiksberg Hospital|HillerÃ¸d Hospital,Copenhagen|HillerÃ¸d,|,2000|,Denmark|Denmark,2
NCT04321993,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-24,NA,NA,2020-04-04,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-04,2020-04-07,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Not yet recruiting,NA,Phase 2,1000,Anticipated,Nova Scotia Health Authority,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:14:33Z,2020-04-17T09:14:33Z,Drug|Drug|Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate|Baricitinib (janus kinase inhibitor)|Sarilumab (anti-IL-6 receptor),"Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth, every 12 hours for 10 days|Hydroxychloroquine sulfate sulfate tablet 200 mg 2 tablets by mouth, every 12 hours for 10 days|Baricitinib 2 mg po daily for 10 days|Sarilumab 200mg subcutaneous injection once",4,,Nova Scotia Health Authority,Halifax,Nova Scotia,B3H 1V7,Canada,1
NCT04323800,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-24,NA,NA,2020-04-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",Not yet recruiting,NA,Phase 2,150,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2020-04-18T09:12:11Z,2020-04-18T09:12:11Z,Biological|Biological,Anti- SARS-CoV-2 Plasma|SARS-CoV-2 non-immune Plasma,SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody >1:64)|Standard plasma collected prior to December 2019,2,NA,NA,NA,NA,NA,NA,NA
NCT04322565,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-24,NA,NA,2020-04-14,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 20, 2020",Anticipated,2020-07-20,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,ColCOVID-19,,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA,Not yet recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-04-20T08:51:42Z,2020-04-20T08:51:42Z,Drug,Colchicine,Cochicine 1mg/day,1,NA,NA,NA,NA,NA,NA,NA
NCT04322123,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-24,NA,NA,2020-04-09,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients",Recruiting,NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:45Z,2020-04-20T08:51:45Z,Drug|Drug,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,Hydroxychloroquine 400 mg BID|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day,2,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Hospital Geral ClÃ©riston Andrade|Hospital Ana Nery - HAN/SESAB|HHospital SAMUR|Hospital Geral de VitÃ³ria da Conquista|Hospital de BrasÃ­lia|Instituto de Cardiologia do Distrito Federal|Hospital Maternidade SÃ£o JosÃ© - UNESC - FundaÃ§Ã£o Social Rural de Colatina|Hospital Vila da Serra|Santa Casa de MisericÃ³rdia de SÃ£o JoÃ£o Del Rei|AssociaÃ§Ã£o EvangÃ©lica Beneficente de Londrina - Hospital EvangÃ©lico de Londrina|Instituto Estadual do CÃ©rebro Paulo Niemeyer|Hospital Geral de Caxias do Sul|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o Francisco - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o JosÃ©|Hospital BaÃ­a Sul - BaÃ­a Sul Medical Center|Hospital Nereu Ramos|Centro Hospitalar Unimed|Hospital de Amor - Unidade Barretos (FundaÃ§Ã£o PIO XII)|Casa de SaÃºde Santa Marcelina|Hospital Albert Einstein|Hospital BeneficÃªncia Portuguesa - Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia|Hospital BP Mirante - Real e BenemÃ©rita|Hospital das ClÃ­nicas da FMUSP|Hospital do Servidor PÃºblico Estadual - HSPE - IAMSPE|Hospital SÃ£o Paulo - UNIFESP|Hospital SÃ­rio-LibanÃªs|Hospital SEPACO,Feira De Santana|Salvador|VitÃ³ria Da Conquista|VitÃ³ria Da Conquista|Brasilia|BrasÃ­lia|Colatina|Nova Lima|SÃ£o JoÃ£o Del Rei|Londrina|Rio De Janeiro|Caxias do Sul|Porto Alegre|Porto Alegre|Criciuma|FlorianÃ³polis|FlorianÃ³polis|Joinville|Barretos|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,BA|BA|BA|BA|DF|DF|ES|MG|MG|PR|RJ|RS|RS|RS|SC|SC|Sc|SC|SP|SP|SP|SP|SP|SP|SP|SP|SP|S,|||||||||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,28
NCT04327349,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:15:52Z,2020-04-10T09:15:52Z,Biological,Convalescent Plasma,Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU,1,,"Imam Khomeini Hospital, Mazandaran University of Medical Sciences",Sari,Mazandaran,4816633131,"Iran, Islamic Republic of",1
NCT04328272,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"June 28, 2020",Anticipated,2020-06-28,"May 28, 2020",Anticipated,2020-05-28,NA,Interventional,Covid,,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study,Not yet recruiting,NA,Phase 3,75,Anticipated,"Ayub Medical College, Abbottabad",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,as each individual will have his/her own coded file. the required data from each will be extracted and will be made available in soft copies,2020-04-12T09:07:28Z,2020-04-12T09:07:28Z,Drug|Drug|Dietary Supplement,Hydroxychloroquine 200 Mg Oral Tablet|Azithromycin 500Mg Oral Tablet|Glucose tablets,Hydroxychloroquine administered orally with water|Azithromycin administered orally with water|administered orally with water,3,,Ayub Teaching Institution,AbbottÄbÄd,K.p.k,00532,Pakistan,1
NCT04324489,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"March 6, 2020",Actual,2020-03-06,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Recruiting,NA,N/A,4,Anticipated,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-12T09:07:53Z,2020-04-12T09:07:53Z,Drug,DAS181,"Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.",1,Recruiting,Renmin Hospital of Wuhan University,Wuhan,Hubei,,China,1
NCT04323631,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Not yet recruiting,NA,Early Phase 1,1116,Anticipated,Rambam Health Care Campus,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-05T09:04:26Z,2020-04-05T09:04:26Z,Drug|Other,Hydroxychloroquine|The control group will not receive hydroxychloroquine,Oral|The control group will not receive hydroxychloroquine,2,NA,NA,NA,NA,NA,NA,NA
NCT04324996,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-06T08:55:03Z,2020-04-06T08:55:03Z,Biological,"NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.,1,Recruiting,Chongqing Public Health Medical Center,Chongqing,,,China,1
NCT04324463,"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACT COVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Not yet recruiting,NA,Phase 3,1500,Anticipated,Population Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-06T08:55:21Z,2020-04-06T08:55:21Z,Drug|Drug,Azithromycin|Chloroquine,oral medication|oral medication,2,,Hamilton Health Sciences,Hamilton,Ontario,L8L2X2,Canada,1
NCT04336462,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-25,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"February 15, 2020",Actual,2020-02-15,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"February 21, 2020",Actual,2020-02-21,NA,Interventional,COVID-19,,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19",Recruiting,NA,N/A,100,Anticipated,Shanghai Asclepius Meditec Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:12:39Z,2020-04-17T09:12:39Z,Device|Device,oxyhydrogen|Oxygen,"Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.|oxygen inhaled,3 L/min . 6 hour a day.",2,Recruiting,First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,510000,China,1
NCT04327206,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-25,NA,NA,2020-04-06,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 30, 2022",Anticipated,2022-03-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial,Recruiting,NA,Phase 3,4170,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2020-04-17T09:14:10Z,2020-04-17T09:14:10Z,Drug,BCG Vaccine,"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection",1,Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Epworth Victoria Parade|Royal Children's Hospital|Epworth Richmond|Epworth Eastern|Monash Health- Monash Medical Centre|Fiona Stanley Hospital|Perth Children's Hospital|Sir Charles Gairdner Hospital,Melbourne|Melbourne|Melbourne|Melbourne|Melbourne|Murdoch|Perth|Perth,Victoria|Victoria|Victoria|Victoria|Victoria|Western Australia|Western Australia|Western Australia,3002|3052|3121|3128|3168|6150|6009|6009,Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia,8
NCT04325893,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-07,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,HYCOVID,,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Recruiting,NA,Phase 3,1300,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-18T09:12:01Z,2020-04-18T09:12:01Z,Drug|Drug,Hydroxychloroquine|Placebo,"First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.|The first dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.",2,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,CH Agen|CHU Amiens|CHU Angers|APHP Avicenne|CHU Brest|CHU Caen|CH Cherbroug|CH Cholet|CH Colmar|APHP Henri Mondor|CHU Dijon|CHD VendÃ©e|CH Laval|CH Le Mans|CHU Limoges|CH Lorient|CH Melun|CHU Nantes|HÃ´pital PrivÃ© du Confluent|CH Niort|CHR OrlÃ©ans|APHP Saint-Antoine|La PitiÃ©-SalpÃ©triÃ¨re|CHU Poitiers|CH Pointoise|CH Quimper|CH Saint-Brieuc|CH Saint-Nazaire|CHU Saint-Etienne|CHU Toulouse|CH Tourcoing|CHU Tours|CH Valenciennes|Clinique Tessier Valenciennes|CH Vannes|CH Versailles|CH Princesse Grace,Agen|Amiens|Angers|Bobigny|Brest|Caen|Cherbourg|Cholet|Colmar|CrÃ©teil|Dijon|La Roche-sur-Yon|Laval|Le Mans|Limoges|Lorient|Melun|Nantes|Nantes|Niort|OrlÃ©ans|Paris|Paris|Poitiers|Pontoise|Quimper|Saint-Brieuc|Saint-Nazaire|Saint-Ã‰tienne|Toulouse|Tourcoing|Tours|Valenciennes|Valenciennes|Vannes|Versailles|Monaco,||||||||||||||||||||||||||||||||||||,||||||||||||||||||||||||||||||||||||,France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Monaco,37
NCT04324021,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-08,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Recruiting,NA,Phase 2/Phase 3,54,Anticipated,Swedish Orphan Biovitrum,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-19T09:03:53Z,2020-04-19T09:03:53Z,Biological|Biological,Emapalumab|Anakinra,I.v infusion every third day|Daily i.v infusion,2,Recruiting|Recruiting|Recruiting|Recruiting,"ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta IntensitÃ  di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani",Brescia|Milano|Parma|Roma,|||,|||,Italy|Italy|Italy|Italy,4
NCT04328285,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-15,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVIDAXIS,,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,Recruiting,NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:28Z,2020-04-20T08:51:28Z,Drug|Drug|Drug|Drug,Hydroxychloroquine|Placebo of Hydroxychloroquine|Lopinavir and ritonavir|Placebo of LPV/r Tablets,Hydroxychloroquine Oral Tablets|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets|LPV/r Oral Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets,4,Not yet recruiting|Not yet recruiting|Recruiting,CHU d'Angers|AP-HP - HÃ´pital Bichat|CHU de Saint-Etienne,Angers|Paris|Saint-Ã‰tienne,||,||,France|France|France,3
NCT04325061,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-15,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,DEXA-COVID19,,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Recruiting,NA,Phase 4,200,Anticipated,Dr. Negrin University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:35Z,2020-04-20T08:51:35Z,Drug,Dexamethasone,"Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization",1,"Recruiting|Active, not recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting","ICU, Hospital Universitari Mutua Terrassa|Hospital Universitario Dr. Negrin|Department of Anesthesia, Hospital Universitario de Cruces|Intensive Care Unit, Hospital Universitario de Cruces|AVI, Hospital Clinic|Cardiac ICU, Hospital Clinic|Department of Anesthesia, Hospital Clinic|Hepatic ICU, Hospital ClÃ­nic|UVIR, Hospital Clinic|Intensive Care Unit, Hospital General de Ciudad Real|Department of Anesthesia, Hospital Universitario La Princesa|Intensive Care Unit, Hospital Universitario La Princesa|Intensive Care Unit, Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az|Department of Anesthesia, Hospital Universitario La Paz|Intensive Care Unit, Hospital Universitario La Paz|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca|Department of Anesthesia, Hospital Unversitario Montecelo|Anesthesia, Hospital General Universitario de Valencia|Department of Anesthesia, Hospital Clinico Universitario|Intensive Care Unit, Hospital Clinico Universitario|Department of Anesthesia, Hospital ClÃ­nico Universitario|Anesthesia, Hospital Universitario RÃ­o Hortega|Intensive Care Unit, Hospital Universitario RÃ­o Hortega",Terrassa|Las Palmas de Gran Canaria|Barakaldo|Barakaldo|Barcelona|Barcelona|Barcelona|Barcelona|Barcelona|Ciudad Real|Madrid|Madrid|Madrid|Madrid|Madrid|Murcia|Murcia|Pontevedra|Valencia|Valencia|Valencia|Valladolid|Valladolid|Valladolid,Barcelona|Las Palmas|Vizcaya|Vizcaya||||||||||||||||||||,08221|35019|48903|48903|08036|08036|08036|08036|08036|13005|28006|28006|28040|28046|28046|30120|30120|36071|46010|46010|46010|47003|47012|47012,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,24
NCT04324073,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-20T08:51:39Z,2020-04-20T08:51:39Z,Drug,Sarilumab,(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1,1,|||,Kremlin Bicetre hospital APHP|Cochin Aphp|HEGP|NECKER Hospital,Le Kremlin-BicÃªtre|Paris|Paris|Paris,Ile De France|Ile De France|Ile De France|,|||75005,France|France|France|France,4
NCT04327505,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"April 25, 2020",Anticipated,2020-04-25,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,COVID-19-HBO,,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial",Not yet recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-10T09:15:47Z,2020-04-10T09:15:47Z,Drug,Hyperbaric oxygen,"2.4 Bar (2.4 ATA), 30 min (excluding compression/recompression)",1,NA,NA,NA,NA,NA,NA,NA
NCT04324528,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-10T09:16:23Z,2020-04-10T09:16:23Z,Device|Device,vv-ECMO + cytokine adsorption (Cytosorb adsorber)|vv-ECMO only (no cytokine adsorption),in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)|COVID-19-diseased treated with vv-ECMO,2,Recruiting,University Clinic Freiburg,Freiburg,,79108,Germany,1
NCT04326452,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-25,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 1, 2020",Anticipated,2020-06-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,15,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-11T09:13:55Z,2020-04-11T09:13:55Z,Device,bidirectional oxygenation mouthpiece,Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.,1,Recruiting|Recruiting|Recruiting,TMC HealthCare|Stanford University|Emory Saint Joseph's Hospital,Tucson|Stanford|Atlanta,Arizona|California|Georgia,85712|94305|30342,United States|United States|United States,3
NCT04326790,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-26,NA,NA,2020-03-31,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,GRECCO-19,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Not yet recruiting,NA,Phase 2,180,Anticipated,National and Kapodistrian University of Athens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-12T09:07:41Z,2020-04-12T09:07:41Z,Drug|Drug,Colchicine|Standard treatment,"Low-dose colchicine treatment, 0.5 mg bid|Standard treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04325906,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-26,NA,NA,2020-04-01,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Not yet recruiting,NA,N/A,346,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-13T09:00:49Z,2020-04-13T09:00:49Z,Device|Procedure,high flow nasal cannula (HFNC)|Prone positioning (PP),"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (â‰¤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.",2,|,Rush University Medical Center|Medical College of Wisconsin,Chicago|Wauwatosa,Illinois|Wisconsin,60612|53226,United States|United States,2
NCT04326426,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-26,NA,NA,2020-04-02,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Not yet recruiting,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-16T09:16:30Z,2020-04-16T09:16:30Z,Drug|Drug,Tradipitant|Placebo,Neurokinin-1 antagonist|Matching placebo,2,NA,NA,NA,NA,NA,NA,NA
NCT04325672,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Convalescent Plasma to Limit Coronavirus Associated Complications,"Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19",Withdrawn,NA,Phase 2,0,Actual,Mayo Clinic,,1,NA,Study stopped due to opening Expanded Access Protocol.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:12:02Z,2020-04-18T09:12:02Z,Biological,Convalescent Plasma,Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.,1,NA,NA,NA,NA,NA,NA,NA
NCT04326114,"ClinicalTrials.gov processed this data on April 08, 2020",2020-03-26,NA,NA,2020-03-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,"April 26, 2020",Anticipated,2020-04-26,March 2020,2020-03-31,"October 12, 2020",Anticipated,2020-10-12,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,NA,,Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19,Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial,Not yet recruiting,NA,N/A,240,Anticipated,Universidad Complutense de Madrid,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-09T09:14:34Z,2020-04-09T09:14:34Z,Device|Device,Inspiratory training device|Expiratory training device,Inspiratory training by a Power-breath device|Expiratory training a Winner-flow device,2,NA,NA,NA,NA,NA,NA,NA
NCT04329533,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-09,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Not yet recruiting,NA,N/A,150,Anticipated,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:25Z,2020-04-20T08:51:25Z,Other,"""Calm"" is a mindfulness meditation mobile app","Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the ""Calm"" app, can be used to help manage stress, especially during this uncertain time.",1,NA,NA,NA,NA,NA,NA,NA
NCT04327401,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-13,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CoDEX,,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)",Recruiting,NA,Phase 3,290,Anticipated,Hospital Sirio-Libanes,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:30Z,2020-04-20T08:51:30Z,Drug,Dexamethasone,Dexamethasone administration for 10 consecutive days after randomization.,1,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting,Hospital Ana Nery|Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Eurolatino Natal Pesquisas MÃ©dicas Ltda|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Associacao Beneficente Siria|Hospital das ClÃ­nicas da Faculdade de Medicina de RibeirÃ£o Preto da USP - HCFMRP|Hospital Israelita Albert Einstein|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo,Salvador|BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Bahia|Distrito Federal|EsoÃ­rito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|||||||||,||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,21
NCT04327388,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-16,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-04-20T08:51:31Z,2020-04-20T08:51:31Z,Drug|Drug,Sarilumab SAR153191|Placebo,Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion|Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Investigational Site Number 1240001|Investigational Site Number 1240002|Investigational Site Number 1240003|Investigational Site Number 2500001|Investigational Site Number 2500002|Investigational Site Number 2500005|Investigational Site Number 2500003|Investigational Site Number 2500004|Investigational Site Number 2760004|Investigational Site Number 2760001|Investigational Site Number 3800005|Investigational Site Number 3800001|Investigational Site Number 3800004|Investigational Site Number 3920002|Investigational Site Number 7240003|Investigational Site Number 7240004|Investigational Site Number 7240002|Investigational Site Number 7240005|Investigational Site Number 7240001,Montreal|Toronto|Vancouver|Bordeaux Cedex|Nantes|Paris Cedex 18|Strasbourg|Suresnes|KÃ¶ln|MÃ¼nster|Milano|Milano|Parma|Fuchu-Shi|Barcelona|Barcelona|Madrid|Madrid|Madrid,||||||||||||||||||,H2X3E4|M5G 2N2|V5Z 1M9|33076|44093|75877|67098|92151|50937|48149|20122|20132|43100||08035|08036|28007|28034|28046,Canada|Canada|Canada|France|France|France|France|France|Germany|Germany|Italy|Italy|Italy|Japan|Spain|Spain|Spain|Spain|Spain,19
NCT04325633,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-12,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"July 13, 2021",Anticipated,2021-07-13,"May 13, 2021",Anticipated,2021-05-13,NA,Interventional,ENACOVID,,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Not yet recruiting,NA,Phase 3,584,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:33Z,2020-04-20T08:51:33Z,Drug|Drug,1: Naproxen|2: Standard of care,Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)|Standard of care,2,NA,NA,NA,NA,NA,NA,NA
NCT04324190,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-11,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DISPOSE,,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Recruiting,NA,N/A,600,Anticipated,International Psychoanalytic University Berlin,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:38Z,2020-04-20T08:51:38Z,Behavioral|Behavioral,Guided online support program|WHO recommendations (waiting condition),"Guided online support program consisting of several modules; Module ""General information ..."" is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)|During the waiting period, a german translation of the WHO recommendations ""Coping with stress during the 2019-nCoV outbreak"" is provided",2,Recruiting,Selfapy GmbH,Berlin,,10435,Germany,1
NCT04326075,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-26,NA,NA,2020-03-28,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-28,2020-03-31,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"October 5, 2020",Anticipated,2020-10-05,NA,Interventional,EC-COVID-RCT,,Early CPAP in COVID Patients With Respiratory Failure.,EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial,Not yet recruiting,NA,N/A,900,Anticipated,Mario Negri Institute for Pharmacological Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:16:10Z,2020-04-10T09:16:10Z,Device,CPAP treatment,"CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.",1,NA,NA,NA,NA,NA,NA,NA
NCT04326036,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Healeon Medical Inc,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2020-04-10T09:16:11Z,2020-04-10T09:16:11Z,Device|Procedure|Procedure|Drug|Drug,Centricyte 1000|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Liberase Enzyme (Roche)|Sterile Normal Saline for Intravenous Use,"Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration|Sterile Collagenase Blend to separate cSVF from the AD-SVF|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter",5,,"Robert W. Alexander, MD, FICS, LLC",Stevensville,Montana,59870,United States,1
NCT04331899,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-27,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"April 15, 2020",Anticipated,2020-04-15,March 2020,2020-03-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COVID-Lambda,,Mild COVID-19 Peginterferon Lambda,"A Phase 2 Randomized, Open Label Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19",Not yet recruiting,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No current plan to share the data.,2020-04-12T09:06:18Z,2020-04-12T09:06:18Z,Drug|Other,Peginterferon Lambda-1a|Standard of Care Treatment,Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose|Standard of Care Treatment for COVID-19 Infection,2,NA,NA,NA,NA,NA,NA,NA
NCT04328441,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-27,NA,NA,2020-03-31,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-03,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 25, 2020",Anticipated,2020-12-25,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,BCG-CORONA,,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in SARS-CoV-2 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.",Recruiting,NA,Phase 3,1500,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,The results of this study will be disclosed unreservedly at the end of the study.,2020-04-13T09:00:31Z,2020-04-13T09:00:31Z,Drug|Drug,BCG Vaccine|Placebo,"Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis|Intracutaneously 0.1ml NaCl 0,9%",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Jeroen Bosch ziekenhuis|Canisius Wilhelmina Ziekenhuis|Radboud UMC|Sint Maartenskliniek|Noordwest Ziekenhuisgroep locatie Alkmaar|Hagaziekenhuis|Leiden University Medical Center|Erasmus Medical Center|University Medical Center Utrecht,Den Bosch|Nijmegen|Nijmegen|Nijmegen|Alkmaar|Den Haag|Leiden|Rotterdam|Utrecht,Brabant|Gelderland|Gelderland|Gelderland|Noord Holland|Zuid-Holland|Zuid-Holland|Zuid-Holland|,||||||||,Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands,9
NCT04333251,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-27,NA,NA,2020-04-02,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Study Testing Convalescent Plasma vs Best Supportive Care,Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19,Not yet recruiting,NA,Phase 1,115,Anticipated,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-16T09:15:45Z,2020-04-16T09:15:45Z,Biological|Other,high-titer anti-Sars-CoV-2 plasma|oxygen therapy,Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer >1:64 vs best supportive care|oxygen therapy,2,NA,NA,NA,NA,NA,NA,NA
NCT04332666,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-27,NA,NA,2020-04-02,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"June 15, 2020",Anticipated,2020-06-15,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ATCO,,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",Not yet recruiting,NA,Phase 2/Phase 3,60,Anticipated,Erasme University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-16T09:15:53Z,2020-04-16T09:15:53Z,Drug|Drug,Angiotensin 1-7|Placebos,endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%|infusion of NaCl 0.9% without diluted peptide in it,2,NA,NA,NA,NA,NA,NA,NA
NCT04328012,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-27,NA,NA,2020-04-06,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,COVIDMED,,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Bassett Healthcare,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-18T09:11:54Z,2020-04-18T09:11:54Z,Drug|Drug|Drug|Drug,lopinavir/ritonavir|Hydroxychloroquine Sulfate|Losartan|Placebos,"administered for minimum of 5 days, up to 14 days if supply available|administered for minimum of 5 days, up to 14 days if supply available|administered for minimum of 5 days, up to 14 days if supply available|administered 14 days",4,Recruiting,Bassett Medical Center,Cooperstown,New York,13326,United States,1
NCT04344379,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-27,NA,NA,2020-04-16,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,PREP-COVID,,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Recruiting,NA,Phase 3,900,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:20Z,2020-04-20T08:48:20Z,Drug|Drug|Drug,hydroxychloroquine|azithromycin|hydroxychloroquine placebo,200 mg BID per day|250 mg per day|200 mg BID per day,3,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,HÃ´pital GHU Paris Saclay|HÃ´pital Saint Antoine|HÃ´pital Broca|HÃ´pital La PitiÃ©-SalpÃ©triÃ¨re|HÃ´pital Cochin|HÃ´pital europÃ©en Georges Pompidou|HÃ´pital Necker,Boulogne-Billancourt|Paris|Paris|Paris|Paris|Paris|Paris,||||||,92100|75012|75013|75013|75014|75015|75015,France|France|France|France|France|France|France,7
NCT04328467,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-27,NA,NA,2020-04-08,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3500,Anticipated,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:51:27Z,2020-04-20T08:51:27Z,Drug|Other,Hydroxychloroquine|Placebo,Hydroxychloroquine; 200mg tablet; oral|Placebo; tablet; oral,2,Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota",Minneapolis|Minneapolis,Minnesota|Minnesota,55455|55455,United States|United States,2
NCT04328493,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,VICO,,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Not yet recruiting,NA,Phase 2,250,Anticipated,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-10T09:15:12Z,2020-04-10T09:15:12Z,Drug,Chloroquine phosphate,"Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.
A loading dose of 1200mg chloroquine phosphate base, administered with food where possible, is given on the first 24 hours after randomization. Following, patients will receive a dose of chloroquine phosphate base of 300mg once daily for 9 days (unless they are <60Kg, when the dose will be reduced following its pharmacokinetic properties).
The total duration of treatment with Chloroquine will be 10 days",1,||||,National Hospital for Tropical Diseases|Can Gio COVID Hospital|Cho Ray Hospital|Cu Chi COVID Hospital|Hospital for Tropical Diseases,Hanoi|Ho Chi Minh City|Ho Chi Minh City|Ho Chi Minh City|Ho Chi Minh City,||||,||||,Vietnam|Vietnam|Vietnam|Vietnam|Vietnam,5
NCT04332042,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-28,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 10, 2020",Anticipated,2020-07-10,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,NA,,TOFAcitinib in SARS-CoV2 Pneumonia,TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia,Not yet recruiting,NA,Phase 2,50,Anticipated,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-12T09:06:13Z,2020-04-12T09:06:13Z,Drug,Tofacitinib,Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days,1,,Ospedali Riuniti di Ancona,Ancona,Marche,60126,Italy,1
NCT04336254,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-28,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19ï¼ša Single-center, Prospective, Randomised Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Renmin Hospital of Wuhan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:12:46Z,2020-04-17T09:12:46Z,Biological|Other,allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous saline injection (Placebo),"Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19",2,Recruiting,Renmin Hospital of Wuhan University (East Campus),Wuhan,Hubei,,China,1
NCT04329195,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-28,NA,NA,2020-04-12,2020-03-28,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"May 9, 2020",Anticipated,2020-05-09,"May 9, 2020",Anticipated,2020-05-09,NA,Interventional,ACORES-2,,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study,Recruiting,NA,Phase 3,554,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:25Z,2020-04-20T08:51:25Z,Drug|Drug,1: discontinuation of RAS blocker therapy|2: continuation of RAS blocker therapy,discontinuation of RAS blocker therapy|continuation of RAS blocker therapy,2,Recruiting,"Cardiologie, Groupe Hospitalier PitiÃ©-SalpÃªtriÃ¨re",Paris,,75013,France,1
NCT04333368,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-29,NA,NA,2020-04-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"May 31, 2021",Anticipated,2021-05-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,STROMA-CoV2,,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Not yet recruiting,NA,Phase 1/Phase 2,60,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-13T08:59:27Z,2020-04-13T08:59:27Z,Biological|Other,Umbilical cord Wharton's jelly-derived human|NaCl 0.9%,"Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 30-45 minutes, using tubing with a 200-Î¼m filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5",2,|,HÃ´pital PitiÃ©-SalpÃªtriÃ¨re - APHP|HÃ´pital EuropÃ©en Georges Pompidou - APHP,Paris|Paris,|,75013|75015,France|France,2
NCT04334005,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-29,NA,NA,2020-04-03,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,COVITD-19,,Vitamin D on Prevention and Treatment of COVID-19,Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19,Not yet recruiting,NA,N/A,200,Anticipated,Universidad de Granada,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-17T09:13:20Z,2020-04-17T09:13:20Z,Dietary Supplement,Vitamin D,"The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.",1,|,Universidad de Granada|Medicine Faculty,Granada|Granada,Andalucia|,18071|18001,Spain|Spain,2
NCT04331054,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-29,NA,NA,2020-04-16,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"July 13, 2020",Anticipated,2020-07-13,"July 13, 2020",Anticipated,2020-07-13,NA,Interventional,INHASCO,,Protective Role of Inhaled Steroids for Covid-19 Infection,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,NA,Phase 3,436,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:17Z,2020-04-20T08:51:17Z,Drug|Other,2: Usual practice + SYMBICORT RAPIHALER|1: Usual practice,2 puffs bid during 30 days by inhalation|Usual practice,2,Recruiting,HÃ´pital Bichat - Service de Pneumologie,Paris,,75010,France,1
NCT04329611,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-29,NA,NA,2020-04-13,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.",Recruiting,NA,Phase 3,1660,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,24 months after study close out.,pending.,NA,Yes,NA,2020-04-20T08:51:23Z,2020-04-20T08:51:23Z,Drug,Hydroxychloroquine,COVID19,1,Recruiting|Recruiting,University of Calgary/Foothills Medical Centre|University of Alberta,Calgary|Edmonton,Alberta|Alberta,T2N 2T9|,Canada|Canada,2
NCT04329572,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-29,NA,NA,2020-04-15,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 23, 2020",Anticipated,2020-04-23,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,"Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus",Not yet recruiting,NA,Early Phase 1,400,Anticipated,Azidus Brasil,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-20T08:51:24Z,2020-04-20T08:51:24Z,Drug|Drug,Hydroxychloroquine Sulfate|Azithromycin Tablets,All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.|All patients included in the study will receive AZT 500 mg per day for 5 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04332380,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Not yet recruiting,NA,Phase 2,10,Anticipated,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-12T09:05:59Z,2020-04-12T09:05:59Z,Drug,Plasma,"Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.",1,,Universidad del Rosario,Bogota,Cundinamarca,11100,Colombia,1
NCT04331600,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,QUARANTINE2020,,ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications",Not yet recruiting,NA,Phase 4,400,Anticipated,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-12T09:06:30Z,2020-04-12T09:06:30Z,Drug|Other,Chloroquine phosphate|Telemedicine,Oral chloroquine phosphate for 14 days|Telemedical supervision for 42 days,2,NA,NA,NA,NA,NA,NA,NA
NCT04332107,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-06,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"July 30, 2021",Anticipated,2021-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,ACTION,,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Not yet recruiting,NA,Phase 3,2271,Anticipated,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-04-18T09:11:32Z,2020-04-18T09:11:32Z,Drug|Drug,Azithromycin|Placebos,Participants will be shipped a single 1 g dose of oral azithromycin|Participants will be shipped a dose of matching placebo,2,,University of California San Francisco,San Francisco,California,94143,United States,1
NCT04332081,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-07,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Recruiting,NA,N/A,40,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2020-04-19T09:03:18Z,2020-04-19T09:03:18Z,Device,hyperbaric oxygen therapy (HBOT),The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.,1,Recruiting,NYU Winthrop Hospital,Mineola,New York,11501,United States,1
NCT04329832,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-07,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HAHPS,,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,Recruiting,NA,Phase 2,300,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-04-19T09:03:30Z,2020-04-19T09:03:30Z,Drug|Drug,Hydroxychloroquine|Azithromycin,"Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5-day total.",2,Recruiting|Not yet recruiting,Intermountain Medical Center|University of Utah,Murray|Salt Lake City,Utah|Utah,84107|84112,United States|United States,2
NCT04348370,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,BCG Vaccine for Health Care Workers as Defense Against SARS-COV2,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,Not yet recruiting,NA,Phase 4,700,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2020-04-20T08:45:57Z,2020-04-20T08:45:57Z,Biological|Biological,BCG Vaccine|Placebo Vaccine,BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.,2,||||,Harvard T.H. Chan School of Public Health|Baylor College of Medicine|Baylor St. Luke's Medical Center|Harris Health System - Ben Taub Hospital|MD Anderson Cancer Center,Boston|Houston|Houston|Houston|Houston,Massachusetts|Texas|Texas|Texas|Texas,02115|77030|77030|77030|77030,United States|United States|United States|United States|United States,5
NCT04341285,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-14,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"June 1, 2020",Anticipated,2020-06-01,April 2020,2020-04-30,"December 1, 2025",Anticipated,2025-12-01,"June 1, 2024",Anticipated,2024-06-01,NA,Interventional,ECMO-VID,,Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID),Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID),Not yet recruiting,NA,N/A,200,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:50:09Z,2020-04-20T08:50:09Z,Procedure,ECMO Implantation,Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.,1,,University Hospital Tuebingen,Tuebingen,,72076,Germany,1
NCT04331470,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,NA,,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2020-04-20T08:51:15Z,2020-04-20T08:51:15Z,Drug|Drug,Levamisole Pill + Budesonide+Formoterol inhaler|Lopinavir/Ritonavir + hydoxychloroquine,Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours,2,Recruiting,Vali-Asr Hospital,Fasa,Fars,,"Iran, Islamic Republic of",1
NCT04330300,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CORONACION,,Coronavirus (COVID-19) ACEi/ARB Investigation,The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial,Recruiting,NA,Phase 4,2414,Anticipated,"National University of Ireland, Galway, Ireland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,12-24 months,To be determined,NA,Yes,NA,2020-04-20T08:51:20Z,2020-04-20T08:51:20Z,Drug|Drug|Drug|Drug,Thiazide or Thiazide-like diuretics|Calcium Channel Blockers|ACE inhibitor|Angiotensin receptor blocker,Anti-hypertensive (Active Arm)|Anti-hypertensive (Active Arm)|Anti-hypertensive (Control Arm)|Anti-hypertensive (Control Arm),4,Recruiting,University Hospital Galway,Galway,,H91 YR71,Ireland,1
NCT04329923,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"December 1, 2021",Anticipated,2021-12-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,PATCH,,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Recruiting,NA,Phase 2,400,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2020-04-20T08:51:22Z,2020-04-20T08:51:22Z,Drug|Drug|Drug|Drug,Hydroxychloroquine Sulfate 400 mg twice a day|Hydroxychloroquine Sulfate 600 mg twice a day|Hydroxychloroquine Sulfate 600 mg once a day|Placebo oral tablet,Antimalarial compound|Antimalarial compound|Antimalarial compound|Placebo,4,Recruiting,University of Pennsylvania,Philadelphia,Pennsylvania,19104,United States,1
NCT04328480,"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-30,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,COLCOVID,,The ECLA PHRI COLCOVID Trial,The ECLA PHRI COLCOVID Trial,Not yet recruiting,NA,Phase 3,2500,Anticipated,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-10T09:15:13Z,2020-04-10T09:15:13Z,Drug|Other,Colchicine|Local standard of care,"The colchicine dosage schedule will vary according to the following scenarios:
In patients not receiving Lopinavir/Ritonavir
Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)
The next day 0.5 mg bid for 14 days or until discharge.
In patients receiving Lopinavir/Ritonavir
Loading dose of 0.5 mg (day 1)
After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.
Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir
Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.
Continue with 0.5 mg every 72 hours for 14 days or until discharge.
Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.|Local standard of care for COVID-19 SARS moderate /high-risk patients",2,NA,NA,NA,NA,NA,NA,NA
NCT04330144,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-30,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),Not yet recruiting,NA,Phase 3,2486,Anticipated,Gangnam Severance Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-11T09:12:43Z,2020-04-11T09:12:43Z,Drug|Other,Hydroxychloroquine as post exposure prophylaxis|Others(No intervention),1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po|No treatment. Close monitoring and quarantine.,2,NA,NA,NA,NA,NA,NA,NA
NCT04333355,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-31,NA,NA,2020-04-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,NA,,Safety in Convalescent Plasma Transfusion to COVID-19,Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 1,20,Anticipated,Hospital San Jose Tec de Monterrey,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-13T08:59:28Z,2020-04-13T08:59:28Z,Biological,Convalescent Plasma,"Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.",1,,Hospital San JosÃ©,Monterrey,Nuevo Leon,64718,Mexico,1
NCT04332835,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-31,NA,NA,2020-04-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,80,Anticipated,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-13T08:59:50Z,2020-04-13T08:59:50Z,Drug|Drug|Drug,Plasma|Hydroxychloroquine|Azithromycin,"Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.|400 milligrams each 12 hours for 10 days|500 milligrams daily for 10 days",3,,Universidad del Rosario,Bogota,Cundinamarca,11100,Colombia,1
NCT04329520,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Estimate,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarato/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,"Active, not recruiting",NA,Phase 3,4000,Anticipated,Effice Servicios Para la Investigacion S.L.,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:13:28Z,2020-04-02T09:13:28Z,Drug|Drug|Drug|Drug,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil|Placebo: Hydroxychloroquine,"Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.|Placebo. Tablets similar in appearance to Emtricitabine/tenofovir disoproxil|Placebo. Tablets similar in appearance to Hydroxychloroquine",4,,Hospital Universitario RamÃ³n y Cajal,Madrid,,28034,Spain,1
NCT04335201,"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-31,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,DEFI-VID19,,Defibrotide in COVID-19 Pneumonia,Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia,Not yet recruiting,NA,Phase 2,50,Anticipated,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-16T09:14:53Z,2020-04-16T09:14:53Z,Drug,Defibrotide Injection,"Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days",1,NA,NA,NA,NA,NA,NA,NA
NCT04332991,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-31,NA,NA,2020-04-03,2020-03-31,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Recruiting,NA,Phase 3,510,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:13:31Z,2020-04-17T09:13:31Z,Drug|Drug,Hydroxychloroquine|Placebo,"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.
For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.",2,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,University of Arizona|UCSF Fresno|Cedars-Sinai Medical Center|Ronald Reagan UCLA Medical Center|UC Davis Medical Center|UCSF Medical Center|Stanford University|Medical Center of Aurora|University of Colorado Hospital|Denver Health Medical Center|St. Joseph Hospital|University of Florida|University of Kentucky|University Medical Center|Maine Medical Center|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Baystate Medical Center|St. Vincent's Hospital|University of Michigan Medical Center|Henry Ford Medical Center|Hennepin County Medical Center|University of Mississippi Medical Center|Montefiore Medical Center-Weiler|Montefiore Medical Center-Moses|Mt. Sinai Hospital|University of North Carolina at Chapel Hill|Wake Forest Baptist Medical Center|University of Cincinnati Medical Center|Cleveland Clinic Foundation|Ohio State University Wexner Medical Center|Oregon Health and Science University|Penn State Hershey Medical Center|Temple University Hospital|UPMC Presbyterian/Mercy/Shadyside|Medical University of South Carolina|Vanderbilt University Medical Center|University of Texas Health Science Center|Intermountain Medical Center|University of Utah Hospital|University of Virginia Health System|VCU Medical Center|Harborview Medical Center|Swedish Hospital First Hill,Tucson|Fresno|Los Angeles|Los Angeles|Sacramento|San Francisco|Stanford|Aurora|Aurora|Denver|Denver|Gainesville|Lexington|New Orleans|Portland|Boston|Boston|Springfield|Worcester|Ann Arbor|Detroit|Minneapolis|Jackson|Bronx|Bronx|New York|Chapel Hill|Winston-Salem|Cincinnati|Cleveland|Columbus|Portland|Hershey|Philadelphia|Pittsburgh|Charleston|Nashville|Houston|Murray|Salt Lake City|Charlottesville|Richmond|Seattle|Seattle,Arizona|California|California|California|California|California|California|Colorado|Colorado|Colorado|Colorado|Florida|Kentucky|Louisiana|Maine|Massachusetts|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Minnesota|Mississippi|New York|New York|New York|North Carolina|North Carolina|Ohio|Ohio|Ohio|Oregon|Pennsylvania|Pennsylvania|Pennsylvania|South Carolina|Tennessee|Texas|Utah|Utah|Virginia|Virginia|Washington|Washington,85721|93701|90048|90095|95817|94143|94305|80045|80045|80204|80218|32608|40506|70112|04102|02114|02115|01199|01608|48109|48025|55415|39216|10461|10467|10029|27514|27157|45219|44195|43210|97239|17033|19140|15261|29425|37221|77030|84107|84132|22903|23298|98104|98122,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,44
NCT04332094,"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-31,NA,NA,2020-04-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,TOCOVID,,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:13:39Z,2020-04-17T09:13:39Z,Drug|Drug|Drug,Tocilizumab|Hydroxychloroquine|Azithromycin,162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)|500 mg / day v.o. for 3 days,3,Recruiting,Hospital de la Santa Creu i Sant Pau,Barcelona,,,Spain,1
NCT04331808,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-06,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),Not yet recruiting,NA,Phase 2,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-18T09:11:35Z,2020-04-18T09:11:35Z,Drug,Tocilizumab,Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.,1,NA,NA,NA,NA,NA,NA,NA
NCT04330638,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-07,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,COV-AID,,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Recruiting,NA,Phase 3,342,Anticipated,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-18T09:11:40Z,2020-04-18T09:11:40Z,Other|Drug|Drug|Drug,Usual Care|Anakinra|Siltuximab|Tocilizumab,"Usual Care|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection",4,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting,AZ Sint-Jan Brugge|University Hospital Saint-Pierre|Erasmus University Hospital|University Hospital Saint-Luc|University Hospital Antwerp|Ziekenhuis Oost-Limurg|University Hospital Ghent|University Hospital Brussels|University Hospital LiÃ¨ge,Brugge|Brussels|Brussels|Brussels|Edegem|Genk|Gent|Jette|LiÃ¨ge,||||||||,8000|1000|1070|1200|2650|3600|9000|1090|4000,Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium,9
NCT04347174,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-15,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Not yet recruiting,NA,N/A,40,Anticipated,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:39Z,2020-04-20T08:46:39Z,Drug|Drug,Suspension of heat killed (autoclaved) Mycobacterium w|Standard therapy of COVID-19,Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician,2,,Postgraduate Institute of Medical Education and Research,Chandigarh,,160012,India,1
NCT04343651,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"April 4, 2021",Anticipated,2021-04-04,"December 4, 2020",Anticipated,2020-12-04,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,75,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:48:47Z,2020-04-20T08:48:47Z,Drug|Drug,Placebos|Leronlimab (700mg),"Placebo|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)",2,Recruiting,Montefiore Medical Center,Bronx,New York,10467,United States,1
NCT04342182,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-15,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,ConCoVid-19,,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19,Recruiting,NA,Phase 2/Phase 3,426,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:37Z,2020-04-20T08:49:37Z,Biological,Convalescent plasma,"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.
Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products",1,Recruiting|Not yet recruiting,Erasmus Medical Center|Maasstad Ziekenhuis,Rotterdam|Rotterdam,Zuid-Holland|,3000 CA|,Netherlands|Netherlands,2
NCT04336332,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-09,2020-04-02,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,NA,Phase 2,160,Anticipated,"Rutgers, The State University of New Jersey",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:50:57Z,2020-04-20T08:50:57Z,Combination Product|Drug,Hydroxychloroquine Sulfate + Azithromycin|Hydroxychloroquine Sulfate,Given PO|Given PO,2,Recruiting|Recruiting|Recruiting,Robert Wood Johnson University Hopsital|Rutgers Cancer Institute of New Jersey|The University Hospital,New Brunswick|New Brunswick|Newark,New Jersey|New Jersey|New Jersey,08901|08903|07103,United States|United States|United States,3
NCT04335305,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-14,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 14, 2020",Anticipated,2020-04-14,March 2020,2020-03-31,"May 15, 2020",Anticipated,2020-05-15,"May 15, 2020",Anticipated,2020-05-15,NA,Interventional,COPERNICO,,Checkpoint Blockade in COVID-19 Pandemic,"A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy",Recruiting,NA,Phase 2,24,Anticipated,MedSIR,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:02Z,2020-04-20T08:51:02Z,Drug|Biological,Tocilizumab|Pembrolizumab (MK-3475),"IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose|IV infusion over 30 minutes, 200 mg; single dose",2,Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting,Hospital QuirÃ³nsalud Barcelona|Hospital de la Santa Creu i Sant Pau|Hospital Ruber Juan Bravo|Hospital Ruber Internacional|Hospital Arnau de Vilanova-Lliria|Hospital Universitario Doctor Peset,Barcelona|Barcelona|Madrid|Madrid|Valencia|Valencia,|||||,08023|08025|28006|28036|46015|46017,Spain|Spain|Spain|Spain|Spain|Spain,6
NCT04335123,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-10,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Recruiting,NA,Phase 1,50,Anticipated,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:02Z,2020-04-20T08:51:02Z,Drug,Losartan,25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion,1,Recruiting,University of Kansas Medical Center,Kansas City,Kansas,66160,United States,1
NCT04334980,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-08,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults",Not yet recruiting,NA,Phase 1,84,Anticipated,Symvivo Corporation,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:51:04Z,2020-04-20T08:51:04Z,Biological|Other,bacTRL-Spike|Placebo,"Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.|Placebo consists of bacterial medium without bacteria.",2,|,"Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia.|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre",Vancouver|Halifax,British Columbia|Nova Scotia,V5Z 4H4|B3K 6R8,Canada|Canada,2
NCT04333732,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-12,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,CROWN CORONA,,CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION,"An International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers",Not yet recruiting,NA,Phase 3,55000,Anticipated,Washington University School of Medicine,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:08Z,2020-04-20T08:51:08Z,Drug|Drug|Drug|Drug,Low-dose chloroquine/hydroxychloroquine|Mid dose chloroquine or hydroxychloroquine|High does chloroquine or hydroxychloroquine|Placebo,"chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate or 400mg hydroxychloroquine sulphate) weekly
In all treatment arms, an induction dose of 1200mg chloroquine or hydroxychloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.|chloroquine base 300mg (equivalent to 500 mg chloroquine phosphate or 400mg chloroquine sulphate or 400mg hydroxychloroquine sulphate) twice weekly
In all treatment arms, an induction dose of 1200mg chloroquine or hydroxychloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.|chloroquine base 150mg (equivalent to 250mg chloroquine phosphate or 200mg chloroquine sulphate or 200mg hydroxychloroquine sulphate) daily
In all treatment arms, an induction dose of 1200mg chloroquine or hydroxychloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.|The placebo equivalent of low, medium and high arm. Low- once weekly Medium - twice weekly High - daily
In all treatment arms, an induction dose of 1200mg chloroquine or hydroxychloroquine base (or equivalent number of placebo tablets) will be taken in 4 divided daily doses (that is 300mg chloroquine or hydroxychloroquine base per day for four days) before starting the low, medium, or high dose regimen.",4,|||||||||||,"Washington University School of Medicine|Melbourne Medical School|Population Health Resarch Institute|University of Toronto|St James's Hospital|Universitas Academic Hospital|Wits RHI, University of the Witwatersrand|Steve Biko Academic Hospital|Tygerberg Hospital|Groote Schuur Hospital|University College London|Centre for Infectious Disease Research in Zambia [CIDRZ]",Saint Louis|Melbourne|Hamilton|Toronto|Dublin|Bloemfontein|Johannesburg|Pretoria|Cape Town|Cape Town|London|Lusaka,Missouri|Victoria|Ontario|Ontario|Leinster|Free State|Gauteng|Gauteng|Western Cape|Western Cape||,63110|VIC 3010|L8L 2X2|M5G 1E2|Dublin 8|9301|2001|0001|7505|7925||H8R9+9V,United States|Australia|Canada|Canada|Ireland|South Africa|South Africa|South Africa|South Africa|South Africa|United Kingdom|Zambia,12
NCT04331366,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-10,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Recruiting,NA,N/A,5,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:16Z,2020-04-20T08:51:16Z,Device,GO2 PEEP MOUTHPIECE,"The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.",1,Recruiting|Recruiting,Emory University Hospital|Emory St. Joseph's Hospital,Atlanta|Atlanta,Georgia|Georgia,30322|30342,United States|United States,2
NCT04330495,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-09,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"November 6, 2020",Anticipated,2020-11-06,"November 6, 2020",Anticipated,2020-11-06,NA,Interventional,NA,,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",Not yet recruiting,NA,Phase 4,800,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:51:18Z,2020-04-20T08:51:18Z,Drug|Drug,Hidroxicloroquina|Control group,Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months,2,NA,NA,NA,NA,NA,NA,NA
NCT04329650,"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-16,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Recruiting,NA,Phase 2,200,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:23Z,2020-04-20T08:51:23Z,Drug|Drug,Siltuximab|Methylprednisolone,"A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.|A dose of 250mg/24 hours of methylprednisolone during 3 days followed by 30mg/24 hours during 3 days will be administered by intravenous infusion.
If the patient is taken lopinavir/ritonavir, the dose will be 125 mg/ 24 hours during 3 days followed by 15mg/24 hours during 3 days.",2,Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting,Hospital Germans Trias i Pujol|Hospital ClÃ­nic de Barcelona|Hospital Universitario de Salamanca|Hospital Universitari MÃºtua de Terrassa,Badalona|Barcelona|Salamanca|Terrassa,|||,|08036||,Spain|Spain|Spain|Spain,4
NCT04330586,"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,A Trial of Ciclesonide in Adults With Mild COVID-19,A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19,Not yet recruiting,NA,Phase 2,141,Anticipated,Korea University Guro Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-11T09:12:27Z,2020-04-11T09:12:27Z,Drug|Drug,Ciclesonide Metered Dose Inhaler [Alvesco]|Hydroxychloroquine,Ciclesonide 320ug oral inhalation q12h for 14 days|Hydroxychloroquine 400mg QD for 10 days,2,NA,NA,NA,NA,NA,NA,NA
NCT04333472,"ClinicalTrials.gov processed this data on April 10, 2020",2020-04-01,NA,NA,2020-04-02,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-03,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"July 6, 2020",Anticipated,2020-07-06,"June 6, 2020",Anticipated,2020-06-06,NA,Interventional,NA,,Piclidenoson for Treatment of COVID-19,Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial,Not yet recruiting,NA,Phase 2,40,Anticipated,Can-Fite BioPharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"January 2021, indefinitely",To be determined,NA,Yes,To be determined,2020-04-13T08:59:23Z,2020-04-13T08:59:23Z,Drug,Piclidenoson,Piclidenoson 2 mg orally every 12 hours for up to 21 days,1,,Rabin Medical Center,Petah tikva,,,Israel,1
NCT04335279,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-01,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"June 3, 2020",Anticipated,2020-06-03,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SPIN-CHAT,,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Not yet recruiting,NA,N/A,162,Anticipated,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2020-04-16T09:14:50Z,2020-04-16T09:14:50Z,Other,SPIN-CHAT Program,"Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.",1,NA,NA,NA,NA,NA,NA,NA
NCT04335136,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-01,NA,NA,2020-04-03,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-06,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,APN01-COVID-19,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Not yet recruiting,NA,Phase 2,200,Anticipated,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-16T09:14:55Z,2020-04-16T09:14:55Z,Drug|Drug,RhACE2 APN01|Physiological saline solution,Patients will be treated with APN01 intravenously twice daily (BID).|Patients will be treated with placebo intravenously twice daily (BID).,2,||||||||,"Medizinische UniversitÃ¤t Innsbruck|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin|Medizinische UniversitÃ¤t Wien|The National University Hospital, Rigshospitalet|Herlev Gentofte Hospital|NordsjÃ¦llands Hospital|Hvidovre Hospital|UniversitÃ¤tsklinikum Hamburg-Eppendorf|Klinikum rechts der Isar, Technische UniversitÃ¤t MÃ¼nchen",Innsbruck|Wien|Wien|Copenhagen|Herlev|HillerÃ¸d|Hvidovre|Hamburg|MÃ¼nchen,||||||||,||||2730|3400|2650||,Austria|Austria|Austria|Denmark|Denmark|Denmark|Denmark|Germany|Germany,9
NCT04334265,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-01,NA,NA,2020-04-03,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-06,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Not yet recruiting,NA,N/A,750,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-16T09:15:26Z,2020-04-16T09:15:26Z,Drug,Anluohuaxian,"6g each time, twice a day",1,||||||||,The Second People's Hospital of Fuyang|Ezhou Central Hospital|Huoshenshan Hospital of Wuhan|Jinyintan Hospital of Wuhan|Tongji Hospital of Huazhong University of Science and Technology|West Hospital Union Hospital Huazhong University of Science and Technology|Wuhan Pulmonary Hospital|Zhongnan Hospital of Wuhan University|Wenzhou Medical University Affiliated First Hospital,Fuyang|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wenzhou,Anhui|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Zhejiang,230022|430000|430000|430000|430000|430000|430000|430000|325000,China|China|China|China|China|China|China|China|China,9
NCT04333550,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-01,NA,NA,2020-04-02,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Application of Desferal to Treat COVID-19,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-16T09:15:43Z,2020-04-16T09:15:43Z,Drug,Deferoxamine,Intravenous infusion of Deferoxamine,1,Recruiting,"Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran",Kermanshah,,083,"Iran, Islamic Republic of",1
NCT04331834,"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-01,NA,NA,2020-04-03,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 3, 2020",Anticipated,2020-10-03,NA,Interventional,PrEP_COVID,,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial",Recruiting,NA,Phase 3,440,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-17T09:13:40Z,2020-04-17T09:13:40Z,Drug|Drug,Hydroxychloroquine|Placebos,"Hydroxychloroquine with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months|Placebo with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months",2,Recruiting,ISGlobal,Barcelona,,08036,Spain,1
NCT04338802,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-07,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"April 2, 2020",Anticipated,2020-04-02,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"May 4, 2020",Anticipated,2020-05-04,NA,Interventional,NA,,Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19,"Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study",Not yet recruiting,NA,Phase 2,96,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:11Z,2020-04-18T09:10:11Z,Drug|Other,Nintedanib 150 MG|Placebo,"Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.",2,NA,NA,NA,NA,NA,NA,NA
NCT04338009,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-07,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"March 31, 2020",Anticipated,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Not yet recruiting,NA,N/A,152,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2020-04-18T09:10:40Z,2020-04-18T09:10:40Z,Other|Other,Discontinuation of ARB/ACEI|Continuation of ARB/ACEI,"The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).",2,NA,NA,NA,NA,NA,NA,NA
NCT04337996,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-03,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,July 2020,Anticipated,2020-07-31,NA,Interventional,TRODVID-19,,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Not yet recruiting,NA,N/A,176,Anticipated,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:41Z,2020-04-18T09:10:41Z,Diagnostic Test,COVID-19 diagnostic test,comparing 3 COVID-19 diagnostic tests performed at day 1 and day 5. And according to the start date of the symtpomes (more than 7 days less than 7 days),1,NA,NA,NA,NA,NA,NA,NA
NCT04333407,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,C-19-ACS,,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,NA,N/A,3170,Anticipated,Imperial College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be shared with other researchers or organisations. Anonymised data might be shared with other research organisations,2020-04-19T09:03:13Z,2020-04-19T09:03:13Z,Drug|Drug|Drug|Drug|Drug,Aspirin 75mg|Clopidogrel 75mg|Rivaroxaban 2.5 MG|Atorvastatin 40mg|Omeprazole 20mg,"â€¢ If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.|â€¢ If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated|If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated
If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated|â€¢ If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated|â€¢ If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.",5,Recruiting,Charing Cross Hospital,London,,W6 8RF,United Kingdom,1
NCT04331795,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Recruiting,NA,Phase 2,50,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-19T09:03:20Z,2020-04-19T09:03:20Z,Drug|Drug,Tocilizumab|Tocilizumab,"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.
Second dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.|Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.
Second dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.",2,Recruiting,University of Chicago Medicine,Chicago,Illinois,60637,United States,1
NCT04339712,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-14,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Recruiting,NA,Phase 2,20,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:42Z,2020-04-20T08:50:42Z,Drug|Drug,Anakinra|Tocilizumab,In case of diagnosis of MAS treatment with anakinra|In case of diagnosis of immune dysregulation treatment with tocilizumab,2,Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,"2nd Department of Critical Care Medicine, ATTIKON University Hospital|Intensive Care Unit, Ioannina University Hospital|Department of Internal Medicine, Patras University Hospital|Department of Internal Medicine, I PAMMAKARISTOS Hospital|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.|1st Department of Pulmonary Medicine and Intensive Care Unit|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO|4th Department of Internal Medicine, Attikon University Hospital|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital|Department of Internal Medicine, Larissa University Hospital|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA",Athens|IoÃ¡nnina|Patras|Athens|Athens|Athens|Athens|Athens|Athens|ElefsÃ­na|Larissa|Larissa|Thessaloniki|Thessaloniki|Thessaloniki|Thessaloniki|Thessaloniki,Haidari|Ioannina|Rion||||||||||||||,12462|45500|26504|11144|11526|11527|11527|12462|16673|19600|41221|41334|54 634|546 35|546 39|546 42|54636,Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece,17
NCT04337216,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Not yet recruiting,NA,Phase 2,10,Anticipated,Virginia Commonwealth University,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:54Z,2020-04-20T08:50:54Z,Drug,Mavrilimumab,single IV dose of mavrilimumab,1,,Virginia Commonwealth University,Richmond,Virginia,23298,United States,1
NCT04335097,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-14,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 7, 2020",Anticipated,2020-04-07,April 2020,2020-04-30,"December 20, 2025",Anticipated,2025-12-20,"April 8, 2021",Anticipated,2021-04-08,NA,Interventional,HSC19,,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study",Not yet recruiting,NA,N/A,214,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:03Z,2020-04-20T08:51:03Z,Device,Biosensors,Sensor that detect vital signs,1,NA,NA,NA,NA,NA,NA,NA
NCT04335032,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-09,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 13, 2020",Anticipated,2020-07-13,NA,Interventional,NA,,EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2),A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2,Not yet recruiting,NA,Phase 3,240,Anticipated,S.L.A. Pharma AG,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:03Z,2020-04-20T08:51:03Z,Drug,Eicosapentaenoic acid gastro-resistant capsules,same as in arm/group description,1,NA,NA,NA,NA,NA,NA,NA
NCT04334044,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:07Z,2020-04-20T08:51:07Z,Drug,Ruxolitinib Oral Tablet,Ruxolitinib 5 mg twice a day,1,Recruiting,Grupo Cooperativo de HemopatÃ­as Malignas,Huixquilucan,Estado De MÃ©xico,52763,Mexico,1
NCT04333914,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,IMMUNONCOVID,,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,"A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection",Recruiting,NA,Phase 2,273,Anticipated,Centre Leon Berard,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:08Z,2020-04-20T08:51:08Z,Drug|Drug|Drug|Other,Chloroquine analog (GNS651)|Nivolumab|Tocilizumab|Standard of care,"Cohort 1 (arm B): 200mg bid loading dose for 2 days then, 200 qd orally for 14 consecutive days.
Cohorte 2 (arm E): 200mg bid loading dose for 2 days then, 200 qd/day orally, per os, for 14 consecutive days.
If for any reason a treatment is not given within the allowed treatment window (Â± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.|Cohorte 1 (arm C): 0.3mg/Kg, intravenously, single infusion at Day 1.|Cohorte 2 (arm F): 400mg flat dose, intravenously, single infusion at Day 1.|In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.
Additional care and medications should be administered in the patient's best interest.",4,Recruiting|Recruiting|Recruiting|Recruiting,Centre LÃ©on BÃ©rard|AP-HP HÃ´pital Saint Antoine|AP-HP La PitiÃ© SalpÃ©triÃ¨re|AP-HP HÃ´pital Bichat Claude Bernard,Lyon|Paris|Paris|Paris,RhÃ´ne|||,69373|75012|75013|75877,France|France|France|France,4
NCT04333654,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-10,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Hydroxychloroquine in Outpatient Adults With COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19",Recruiting,NA,Phase 1,210,Anticipated,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-04-20T08:51:09Z,2020-04-20T08:51:09Z,Drug|Drug,Hydroxychloroquine SAR321068|Placebo,Pharmaceutical form:Tablet Route of administration: Oral|Pharmaceutical form:Tablet Route of administration: Oral,2,Recruiting|Recruiting,Investigational Site Number 8400001|Investigational Site Number 2501001,Boston|Bordeaux Cedex,Massachusetts|,02115|33076,United States|France,2
NCT04333628,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-12,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,"Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial",Not yet recruiting,NA,Phase 2/Phase 3,210,Anticipated,"HaEmek Medical Center, Israel",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:10Z,2020-04-20T08:51:10Z,Drug|Other,chloroquine|standard care,"oral treatment of chloroquine|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.",2,NA,NA,NA,NA,NA,NA,NA
NCT04333589,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"September 15, 2020",Anticipated,2020-09-15,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Not yet recruiting,NA,N/A,210,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:10Z,2020-04-20T08:51:10Z,Drug,Favipiravir,"On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.",1,|||||||,The Second People's Hospital of Fuyang|Ezhou Hospital of Traditional Chinese Medicine|Ezhou Central Hospital|Huoshenshan Hospital of Wuhan|Jinyintan Hospital of Wuhan|Wuhan Pulmonary Hospital|Zhongnan Hospital of Wuhan University|Wenzhou Medical University Affiliated First Hospital,Fuyang|Ezhou|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wenzhou,Anhui|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Zhejiang,230022|436000|430000|430000|430000|430000|430000|325000,China|China|China|China|China|China|China|China,8
NCT04333420,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-15,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,PANAMO,,"Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2/Phase 3,130,Anticipated,InflaRx GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:11Z,2020-04-20T08:51:11Z,Drug|Drug,Best supportive Care (BSC) + IFX-1|Best supportive care only,Best supportive care [BSC] + IFX-1|Best supportive care only,2,Recruiting|Recruiting|Recruiting,University Amsterdam|University Amsterdam|University Maastricht,Amsterdam|Amsterdam|Maastricht,||,1105||,Netherlands|Netherlands|Netherlands,3
NCT04333225,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 3, 2020",Anticipated,2020-04-03,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Enrolling by invitation,NA,Phase 2,360,Anticipated,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:11Z,2020-04-20T08:51:11Z,Drug,Hydroxychloroquine,Weekly treatment in individuals at high risk,1,,Baylor University Medical Center,Dallas,Texas,75226,United States,1
NCT04331665,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-09,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"January 31, 2021",Anticipated,2021-01-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia,Not yet recruiting,NA,N/A,64,Anticipated,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:15Z,2020-04-20T08:51:15Z,Drug,Ruxolitinib,"Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.",1,,Princess Margaret Cancer Centre,Toronto,Ontario,M5G 2M9,Canada,1
NCT04335851,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-03,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-06,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,NA,,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Not yet recruiting,NA,N/A,30,Anticipated,Biruni University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-16T09:14:31Z,2020-04-16T09:14:31Z,Other,Video based aerobic exercise,"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videos""walk at home"" which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes.",1,|,Biruni University|Istanbul University Cerrahpasa,Istanbul|Istanbul,|,|,Turkey|Turkey,2
NCT04335084,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,HELPCOVID-19,,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","An Open Label Phase II Pilot Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Not yet recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-16T09:14:58Z,2020-04-16T09:14:58Z,Drug|Dietary Supplement|Dietary Supplement|Dietary Supplement,Hydroxychloroquine|Vitamin C|Vitamin D|Zinc,Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19,4,,ProgenaBiome,Ventura,California,93003,United States,1
NCT04334967,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment,Enrolling by invitation,NA,Phase 4,1250,Anticipated,Providence Health & Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-16T09:15:03Z,2020-04-16T09:15:03Z,Drug|Dietary Supplement,Hydroxychloroquine|Vitamin C,"Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.",2,,Portland Providence Medical Center,Portland,Oregon,97213,United States,1
NCT04334850,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,MultiCov,,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Not yet recruiting,NA,N/A,194,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-16T09:15:07Z,2020-04-16T09:15:07Z,Procedure|Other,Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Usual antibiotic treatment,"The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.",2,,Intensive care department-Hospital Tenon,Paris,,75020,France,1
NCT04334629,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"November 5, 2020",Anticipated,2020-11-05,"August 5, 2020",Anticipated,2020-08-05,NA,Interventional,LIBA,,LIBA Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Not yet recruiting,NA,Phase 4,230,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-16T09:15:14Z,2020-04-16T09:15:14Z,Drug,Ibuprofen,Lipid ibuprofen 200 mg,1,NA,NA,NA,NA,NA,NA,NA
NCT04334460,"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-03,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-06,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment",Not yet recruiting,NA,Phase 2,120,Anticipated,Blade Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-16T09:15:20Z,2020-04-16T09:15:20Z,Drug,BLD-2660,"BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.",1,NA,NA,NA,NA,NA,NA,NA
NCT04337541,"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Recruiting,NA,N/A,6000,Anticipated,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:12:00Z,2020-04-17T09:12:00Z,Other,Surgical facial mask,"Participants will follow normal Authority recommendations AND wear mask outside their homes, or when receiving visits in their home.",1,Recruiting,Rigshospitalet,Copenhagen,,2100,Denmark,1
NCT04335071,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-06,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,CORON-ACT,,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",Not yet recruiting,NA,Phase 2,100,Anticipated,"University Hospital Inselspital, Berne",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:11:14Z,2020-04-18T09:11:14Z,Drug|Drug,Tocilizumab (TCZ)|Placebo,"Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) ActemraÂ® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.",2,||,University Hospital Bern (Inselspital)|Centre Hospitalier Universitaire Vaudois (CHUV)|University Hospital Zurich,Bern|Lausanne|Zurich,||,3010|1011|8091,Switzerland|Switzerland|Switzerland,3
NCT04340349,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-08,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 10, 2020",Anticipated,2020-07-10,"June 9, 2020",Anticipated,2020-06-09,NA,Interventional,HCQINRLGII,,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Not yet recruiting,NA,Early Phase 1,100,Anticipated,Instituto Nacional de Rehabilitacion,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"Under Mexican Law, we are not able to provide IPD",2020-04-19T09:01:44Z,2020-04-19T09:01:44Z,Drug|Drug,Hydroxychloroquine Sulfate|Bromhexine 8 MG,A daily low dose of Hydroxychloroquine Sulfate|TMPRSS2 blocker,2,,National Institute of Rehabilitation,Mexico City,Cdmx,14389,Mexico,1
NCT04339660,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-09,Actual,"February 1, 2020",Actual,2020-02-01,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-19T09:02:11Z,2020-04-19T09:02:11Z,Biological|Other,UC-MSCs|Placebo,1*10E6 UC-MSCs /kg body weight suspended in 100mL saline|100mL saline intravenously,2,Recruiting,Puren Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei,430081,China,1
NCT04334928,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-07,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,"Active, not recruiting",NA,Phase 3,4000,Anticipated,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-19T09:03:04Z,2020-04-19T09:03:04Z,Drug|Drug|Drug|Drug,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Hydroxychloroquine,"Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil|Placebo: Tablets similar in appearance to Hydroxychloroquine",4,,Hospital Universitario RamÃ³n y Cajal,Madrid,,28034,Spain,1
NCT04334382,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-07,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HyAzOUT,,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial,Recruiting,NA,Phase 3,1550,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-04-19T09:03:06Z,2020-04-19T09:03:06Z,Drug|Drug,Hydroxychloroquine|Azithromycin,"Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.",2,Recruiting|Not yet recruiting,Intermountain Medical Center|University of Utah,Murray|Salt Lake City,Utah|Utah,84107|84112,United States|United States,2
NCT04347226,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Cancer Patients With Severe COVID-19,Not yet recruiting,NA,Phase 2,138,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:37Z,2020-04-20T08:46:37Z,Drug,BMS-986253,BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).,1,,Columbia University Irving Medical Center,New York,New York,10032,United States,1
NCT04345523,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,ConPlas-19,,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,278,Anticipated,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:38Z,2020-04-20T08:47:38Z,Other|Drug,Blood and derivatives.|Standard of Care,Administration of fresh plasma from donor immunized against COVID-19|Standard of care for the treatment of COVID-19 in hospitalized patients,2,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Hospital ClÃ­nico Universitario Lozano Blesa|Hospital Universitario Severo Ochoa|Hospital Universitario Puerta de Hierro Majadahonda|Hospital Universitario PrÃ­ncipe de Asturias|Hospital Universitario La Princesa|Hospital General Universitario Gregorio MaraÃ±Ã³n|Hospital Universitario RamÃ³n y Cajal|Hospital ClÃ­nico San Carlos|Hospital Universitario 12 de Octubre,Zaragoza|LeganÃ©s|Majadahonda|Meco|Madrid|Madrid|Madrid|Madrid|Madrid,AragÃ³n|Madrid|Madrid|Madrid|||||,50009|28911|28222|28805|28006|28009|28034|28040|28041,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,9
NCT04335786,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-15,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2021,Anticipated,2021-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,"PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease",Recruiting,NA,Phase 4,651,Anticipated,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:00Z,2020-04-20T08:51:00Z,Drug|Drug,Valsartan (Diovan)|Placebo oral tablet,"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d.|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.",2,Recruiting,Jeroen Bosch Ziekenhuis,'s-Hertogenbosch,,,Netherlands,1
NCT04334512,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-09,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,HAZDpaC,,A Study of Quintuple Therapy to Treat COVID-19 Infection,A Phase II Pilot Study of Quintuple Therapy to Treat COVID-19 Infection,Not yet recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:06Z,2020-04-20T08:51:06Z,Drug|Drug|Dietary Supplement|Dietary Supplement|Dietary Supplement,Hydroxychloroquine|Azithromycin|vitamin C|Vitamin D|Zinc,treatment with hydroxychloroquine|Treatment with azithromycin|Treatment with vitamin c|Treatment with vitamin D|Treatment with Zinc,5,,ProgenaBiome,Ventura,California,93003,United States,1
NCT04334434,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Not yet recruiting,NA,N/A,30,Anticipated,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:06Z,2020-04-20T08:51:06Z,Other,Telerehabilitation,15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist,1,,Istanbul university Cerrahpasa,Istanbul,,,Turkey,1
NCT04337008,"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-03,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,,Renin Angiotesnin System - CoronaVirus,Renin Angiotesnin System - CoronaVirus,Recruiting,NA,N/A,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:12:19Z,2020-04-17T09:12:19Z,Other,blood draw,20 mL blood draw will be performed at J1 et J7,1,Recruiting,ASSISTANCE PUBLIQUE HÃ–PITAUX de MARSEILLE,Marseille,,13005,France,1
NCT04336774,"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-03,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,"November 9, 2020",Anticipated,2020-11-09,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,CAPTION AI,,CAPTION AI to Minimize Risk of COVID Exposure,Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19,Not yet recruiting,NA,N/A,500,Anticipated,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-17T09:12:28Z,2020-04-17T09:12:28Z,Device,Caption AI,Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.,1,,Duke University Medical Center,Durham,North Carolina,27710,United States,1
NCT04338906,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-06,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"June 1, 2020",Anticipated,2020-06-01,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,CLOCC,,Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19,Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection,Not yet recruiting,NA,Phase 4,334,Anticipated,"Heinrich-Heine University, Duesseldorf",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,3 Months after publication,Open,NA,Yes,NA,2020-04-18T09:10:07Z,2020-04-18T09:10:07Z,Drug|Drug|Drug,Camostat Mesilate|Placebo|Hydroxychloroquine,"400 mg tid, d1-d7|Instead of Camostat Mesilate, tid, d1-d7|400 mg bid on day 1, 200 mg bid d2-d7",3,NA,NA,NA,NA,NA,NA,NA
NCT04337788,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,COVIDeHPAD,,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease,Not yet recruiting,NA,N/A,200,Anticipated,"University Hospital, Limoges",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:48Z,2020-04-18T09:10:48Z,Other,telehealth applications,telehealth applications during 30 days/patient,1,NA,NA,NA,NA,NA,NA,NA
NCT04336904,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Active, not recruiting",NA,Phase 3,100,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-18T09:10:57Z,2020-04-18T09:10:57Z,Drug|Other,Favipiravir|Placebo,"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
Where the subject has experienced an adverse event related to liver injury of gradeâ‰¥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of gradeâ‰¥3 after dose reduction|Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
Where the subject has experienced an adverse event related to liver injury of gradeâ‰¥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of gradeâ‰¥3 after dose reduction",2,,Asst Fatebenefratelli Sacco,Milano,,20157,Italy,1
NCT04340544,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-08,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"September 30, 2022",Anticipated,2022-09-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,COMIHY,,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Not yet recruiting,NA,Phase 3,2700,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-19T09:01:35Z,2020-04-19T09:01:35Z,Drug|Drug,Hydroxychloroquine|Placebo,"Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.|Placebo capsules",2,,Institute for Tropical Medicine,TÃ¼bingen,,72074,Germany,1
NCT04340232,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Safety and Efficacy of Baricitinib for COVID-19,Safety and Efficacy of Baricitinib for COVID-19,Not yet recruiting,NA,Phase 2/Phase 3,80,Anticipated,"University of Colorado, Denver",,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,Data will be made available upon publication in a peer-reviewed journal.,Data access requests will be reviewed by the sponsor-investigator and collaborators.,NA,Yes,De-identified individual participant data will be made available for all primary outcome measures.,2020-04-19T09:01:49Z,2020-04-19T09:01:49Z,Drug,Baricitinib,Subjects will receive a 2 mg oral dose of baricitinib.,1,,"University of Colorado, Denver",Aurora,Colorado,80045,United States,1
NCT04336410,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1,40,Anticipated,Inovio Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-04-19T09:02:52Z,2020-04-19T09:02:52Z,Drug|Device,INO-4800|CELLECTRAÂ® 2000,INO-4800 will be administered ID on Day 0 and Week 4.|EP using the CELLECTRAÂ® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Week 4.,2,Recruiting|Recruiting,Center for Pharmaceutical Research|University of Pennsylvania,Kansas City|Philadelphia,Missouri|Pennsylvania,64114|19104,United States|United States,2
NCT04348409,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,"April 12, 2020",Anticipated,2020-04-12,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",Not yet recruiting,NA,N/A,50,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-20T08:45:56Z,2020-04-20T08:45:56Z,Drug|Drug,Nitazoxanide Tablets|Placebo,Patients will receive nitazoxanide 600 mg BID for 7 days|Patients will receive placebo BID for 7 days,2,|,Centro de Genomas|Hospital EmÃ­lio Ribas,SÃ£o Paulo|SÃ£o Paulo,|,|,Brazil|Brazil,2
NCT04343053,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-08,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-13,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,ATTAC-Co,,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection",Recruiting,NA,N/A,60,Anticipated,University Hospital of Ferrara,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,After specific request to study PIs,2020-04-20T08:49:06Z,2020-04-20T08:49:06Z,Other,SARS-Cov-2 infection,blood sample withdrawal,1,Recruiting,Azienda Ospedaliera Universitaria di Ferrara,Ferrara,,,Italy,1
NCT04335552,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-09,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Not yet recruiting,NA,Phase 2,500,Anticipated,Duke University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:51:01Z,2020-04-20T08:51:01Z,Other|Drug|Drug,Standard of care|Hydroxychloroquine|Azithromycin,"Standard of care|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5",3,|||,Duke Regional Hospital|Duke University Hospital|Durham VA Medical Center|Duke Raleigh Hospital,Durham|Durham|Durham|Raleigh,North Carolina|North Carolina|North Carolina|North Carolina,27704|27710|27710|27609,United States|United States|United States|United States,4
NCT04336748,"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-04,NA,NA,2020-04-04,2020-04-04,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-04,2020-04-07,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers,"Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial",Not yet recruiting,NA,Phase 3,440,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:12:29Z,2020-04-17T09:12:29Z,Drug,Hydroxychloroquine,low dose (200mg) Hydroxychloroquine once daily for 4 weeks,1,NA,NA,NA,NA,NA,NA,NA
NCT04342650,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-04,NA,NA,2020-04-10,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Recruiting,NA,Phase 2,210,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2020-04-20T08:49:21Z,2020-04-20T08:49:21Z,Drug|Drug,Chloroquine Diphosphate|Placebo oral tablet,150mg tablets|150mg placebo tablets,2,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
NCT04341116,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-04,NA,NA,2020-04-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,144,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:14Z,2020-04-20T08:50:14Z,Drug|Drug,TJ003234|Placebo,patients receive a single infusion|patients receive a single infusion,2,Recruiting|Recruiting|Recruiting|Recruiting,"OSF Healthcare Saint Francis Medical Center|Indiana University Health|Medpharmics, LLC|Oschner Medical Center",Peoria|Indianapolis|Metairie|New Orleans,Illinois|Indiana|Louisiana|Louisiana,61637|46202|70006|70121,United States|United States|United States|United States,4
NCT04338698,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-04,NA,NA,2020-04-08,2020-04-04,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 7, 2020",Anticipated,2020-04-07,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,PROTECT,,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment,Not yet recruiting,NA,Phase 3,500,Anticipated,University of Health Sciences Lahore,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals",2020-04-20T08:50:50Z,2020-04-20T08:50:50Z,Drug|Drug|Drug,Hydroxychloroquine|Oseltamivir|Azithromycin,"Hydroxychloroquine Phosphate/Sulfate (200 mg orally thrice a day for 5 days)|Oseltamivir (75 mg orally twice a day for 5 days)|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)",3,NA,NA,NA,NA,NA,NA,NA
NCT04338568,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-04,NA,NA,2020-04-14,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,SCOUT,,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia,Recruiting,NA,N/A,50,Anticipated,Hasselt University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,no plan,2020-04-20T08:50:51Z,2020-04-20T08:50:51Z,Diagnostic Test,Lung ultrasound,The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.,1,Recruiting,Ziekenhuis Oost Limburg,Genk,Limburg,3600,Belgium,1
NCT04338828,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-05,NA,NA,2020-04-05,2020-04-05,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NO COV-ED,,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department,Not yet recruiting,NA,Phase 2,260,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:10Z,2020-04-18T09:10:10Z,Drug|Other,Nitric Oxide Gas|Inhaled Supplemental Oxygen,Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes|2 L/min oxygen therapy,2,,Massachusetts General Hospital,Boston,Massachusetts,02114,United States,1
NCT04345861,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-05,NA,NA,2020-04-09,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"April 6, 2021",Anticipated,2021-04-06,"September 6, 2020",Anticipated,2020-09-06,NA,Interventional,COVIDOC,,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Not yet recruiting,NA,Phase 2/Phase 3,150,Anticipated,"University Hospital, Montpellier",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:27Z,2020-04-20T08:47:27Z,Drug|Drug,Hydroxychloroquine + placebo|hydroxychloroquine + azithromycin,hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5),2,,Montpellier University hospital,Montpellier,,34295,France,1
NCT04343092,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-05,NA,NA,2020-04-08,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-13,Actual,"April 8, 2020",Anticipated,2020-04-08,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients,Adjuvant Use of Ivermectin To Hydroxychloroquine in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study,Not yet recruiting,NA,Phase 1,50,Anticipated,University of Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:05Z,2020-04-20T08:49:05Z,Drug|Drug|Drug,Ivermectine|Hydroxychloroquine Sulfate|Placebos,Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly|Hydroxychloroquine Sulfate 400mg/daily|(0.2 mg /kg=12 mg ) lactose single dose at once/ weekly,3,NA,NA,NA,NA,NA,NA,NA
NCT04341675,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-05,NA,NA,2020-04-15,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,SCOPE,,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial),Recruiting,NA,Phase 2,30,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,De-identified aggregate data will be made available to other researchers on a case-by-case basis.,2020-04-20T08:49:55Z,2020-04-20T08:49:55Z,Drug|Drug,Sirolimus|Placebo,"Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.|Matching placebo",2,Recruiting,University of Cincinnati,Cincinnati,Ohio,45267,United States,1
NCT04338841,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-05,NA,NA,2020-04-09,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Recruiting,NA,N/A,4000,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:49Z,2020-04-20T08:50:49Z,Other,HOME-CoV rule implementation,"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.
Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.",1,"Not yet recruiting|Not yet recruiting|Active, not recruiting|Not yet recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting",Clinique Universitaire Saint-Luc|CHU de LiÃ¨ge|Ch Argenteuil|CHU Brest|CH Cholet|CHU Clermont Ferrand|Ch Colmar|CH Alpes Lemant|CHU Dijon|CH Le Mans|CH Libourne|CH Limoges|Ch Longjumeau|Hospices Civils de Lyon (University Hospital of Lyon)|Chu Montpellier|Centre Hospitalier Universitaire de Nantes|CH Niort|Hopital Paris Saint Joseph|Hopital Saint Antoine|HÃ´pital Bichat|HÃ´pital LariboisiÃ¨re|CHU de Poitiers|CH Reims|Ch Remiremont|Chu Rennes|CHU de Rouen|CHU de St Etienne|CH de Saint-Brieuc|Ch Troyes|CH VICHY|CH Princesse Grace,Bruxelles|Liege|Argenteuil|Brest|Cholet|Clermont Ferrand|Colmar|Contamine-sur-Arve|Dijon|Le Mans|Libourne|Limoges|Longjumeau|Lyon|Montpellier|Nantes|Niort|Paris|Paris|Paris|Paris|Poitiers|Reims|Remiremont|Rennes|Rouen|Saint Etienne|Saint-Brieuc|Troyes|Vichy|Monaco,||||||||||||||||||||||||||||||,|||||||||||||||||||||86000|||||42000||||,Belgium|Belgium|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Monaco,31
NCT04338126,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"December 15, 2020",Anticipated,2020-12-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,TCInpatient,,Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients,Not yet recruiting,NA,Phase 2,60,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:36Z,2020-04-18T09:10:36Z,Drug|Drug,Tranexamic acid|Placebo oral tablet,previously described|previously described,2,,University of Alabama at Birmingham,Birmingham,Alabama,35233,United States,1
NCT04338074,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,TCOutpatient,,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,Not yet recruiting,NA,Phase 2,100,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:38Z,2020-04-18T09:10:38Z,Drug|Drug,Tranexamic acid tablets|Placebo oral tablet,Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos|2 tablets p.o. three times per day x 5 days,2,,University of Alabama at Birmingham,Birmingham,Alabama,35222,United States,1
NCT04340557,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-08,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"March 27, 2020",Actual,2020-03-27,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 6, 2020",Anticipated,2020-10-06,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Recruiting,NA,Phase 4,200,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-19T09:01:34Z,2020-04-19T09:01:34Z,Drug,Losartan,Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.,1,Recruiting|Recruiting|Recruiting|Recruiting,Sharp Grossmont Hospital|Sharp Chula Vista Medical Center|Sharp Coronado Hospital|Sharp Memorial Hospital,La Mesa|San Diego|San Diego|San Diego,California|California|California|California,91942|91911|92118|92123,United States|United States|United States|United States,4
NCT04337918,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-07,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Not yet recruiting,NA,Phase 2,200,Anticipated,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-19T09:02:43Z,2020-04-19T09:02:43Z,Drug|Drug,NORS (Nitric Oxide Releasing Solution)|NORS (Nitric Oxide Releasing Solution),"NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.|Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 28-day Treatment sub-study and receive daily NORS treatment for 21 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.",2,NA,NA,NA,NA,NA,NA,NA
NCT04349631,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-15,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 16, 2020",Anticipated,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Enrolling by invitation,NA,Phase 2,56,Anticipated,Hope Biosciences,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:15Z,2020-04-20T08:45:15Z,Drug,HB-adMSCs,"Five IV infusion of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2,6,10,14,18,22,26.",1,,Hope Biosciences Stem Cell Research Foundation,Sugar Land,Texas,77478,United States,1
NCT04346797,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-10,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,May 2020,Anticipated,2020-05-31,NA,Interventional,CORIMUNO19-ECU,,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Not yet recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:46:51Z,2020-04-20T08:46:51Z,Drug,Eculizumab,"Intravenous administration as follows:
Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22",1,NA,NA,NA,NA,NA,NA,NA
NCT04344951,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,HOPE,,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:56Z,2020-04-20T08:47:56Z,Drug,UNIKINON (Chloroquine phosphate) 200mg tablets,Two and a half tablets (500mg) twice daily for seven days.,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Divine Providence Hospital ""Pammakaristos""|Athens General Hospital ""Hippokrateio""|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 1st University Pulmonary Clinic|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 3rd University Pathology Clinic|General Hospital of Athens ""Sismanoglio""",Athens|Athens|Athens|Athens|MaroÃºsi,||||,11144|11527|11527|11527|151 26,Greece|Greece|Greece|Greece|Greece,5
NCT04341935,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Effects of DPP4 Inhibition on COVID-19,Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes,Not yet recruiting,NA,Phase 4,20,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:45Z,2020-04-20T08:49:45Z,Drug|Drug,Linagliptin|Insulin regimen,5 mg Linagliptin administered by mouth once daily|Standard of care insulin regimen as per hospital protocol,2,,University of Miami,Miami,Florida,33136,United States,1
NCT04341870,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-12,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,May 2020,Anticipated,2020-05-31,NA,Interventional,CORIMUNO-VIRO,,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:49:47Z,2020-04-20T08:49:47Z,Drug|Drug|Drug,Sarilumab|Azithromycin|Hydroxychloroquine,"Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)",3,Not yet recruiting|Not yet recruiting|Recruiting|Recruiting,AP-HP HÃ´pital EuropÃ©en George Pompidou|AP-HP HÃ´pital LariboisiÃ¨re|AP-HP HÃ´pital PitiÃ© SalpÃ©triÃ¨re|AP-HP HÃ´pital Saint Antoine,Paris|Paris|Paris|Paris,|||,|||,France|France|France|France,4
NCT04341688,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-15,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"July 1, 2020",Anticipated,2020-07-01,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,GARGLES,,A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients,"A Double Blind, Randomized Controlled Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed Coronavirus (COVID-19) Patients: GARGLES STUDY",Not yet recruiting,NA,N/A,40,Anticipated,Aga Khan University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:54Z,2020-04-20T08:49:54Z,Drug,Gargle/Mouthwash,"There will be four groups. Group A (n=5) patients on 10 ml gargle of 0.2% Povidone-Iodine for 20-30 seconds, twice daily for 5 days. Group B (n=5) patients will be subjected to 10 ml gargle of 1% Hydrogen peroxide for 20-30 seconds, twice daily for 5 days. Group C will comprise of (n=5) subjects on 10ml gargle of Neem extract based solution for 20-30 seconds, twice daily for 5 days. Group D (n=5) patient will use normal saline gargle for a similar time period.",1,NA,NA,NA,NA,NA,NA,NA
NCT04339816,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-09,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,AZIQUINE-ICU,,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial,Not yet recruiting,NA,Phase 3,240,Anticipated,"Charles University, Czech Republic",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,within 6 months of study completion,NA,http://mendeley.com,Yes,Deidentified record-level data will be shared in a public database,2020-04-20T08:50:40Z,2020-04-20T08:50:40Z,Drug|Drug|Drug,Azithromycin|Hydroxychloroquine|Placebo,orally or into nasogastric tube for 5 days|orally or into nasogastric tube for 5 days|orally or into nasogastric tube for 5 days,3,NA,NA,NA,NA,NA,NA,NA
NCT04338958,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,RuxCoFlam,,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Not yet recruiting,NA,Phase 2,200,Anticipated,University of Jena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:06Z,2020-04-18T09:10:06Z,Drug,Ruxolitinib 10 MG,2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment,1,,University Hospital Jena,Jena,,07747,Germany,1
NCT04347031,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19",Enrolling by invitation,NA,Phase 2,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:43Z,2020-04-20T08:46:43Z,Drug|Drug|Combination Product|Combination Product,Mefloquine|Hydroxychloroquine|Mefloquine + azithromycin + / - tocilizumab|Hydroxychloroquine + azithromycin + / - tocilizumab,"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.
3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.|st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;
nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.|1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.
3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.|st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;
nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.",4,,Burnasyan Federal Medical Biophysical Center FMBA of Russia,Moscow,,123098,Russian Federation,1
NCT04346082,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-15,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak,Feasibility and Acceptability of Online Based Mindfulness Interventions to Relieve Distress During COVID-19 Outbreak in a Chinese Population: a Proof-of-concept Trial,Not yet recruiting,NA,N/A,30,Anticipated,Chinese University of Hong Kong,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,may share data on request of investigators,2020-04-20T08:47:20Z,2020-04-20T08:47:20Z,Behavioral,online mindfulness group,"Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.",1,,School of public health and primary care,Hong Kong,,,Hong Kong,1
NCT04345848,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-09,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-15,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVID-HEP,,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,"Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Randomized, Open-label Clinical Trial",Not yet recruiting,NA,Phase 3,200,Anticipated,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:27Z,2020-04-20T08:47:27Z,Drug,Enoxaparin,Two different doses of anticoagulation,1,,Geneva University Hospitals,Geneva,,,Switzerland,1
NCT04345614,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-15,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia,A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients With Severe COVID-19 Pneumonia,Recruiting,NA,Phase 2,120,Anticipated,"CalciMedica, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:35Z,2020-04-20T08:47:35Z,Drug,CM4620-Injectable Emulsion,CM4620-IE 2.0 mg/kg on Day 1 and then 1.6 mg/kg on Days 2 and 3. All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.,1,Recruiting|Recruiting,Henry Ford Hospital|Regions Hospital,Detroit|Saint Paul,Michigan|Minnesota,48202|55101,United States|United States,2
NCT04344210,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 20, 2020",Anticipated,2020-08-20,NA,Interventional,NA,,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Enrolling by invitation,NA,N/A,149,Anticipated,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-20T08:48:25Z,2020-04-20T08:48:25Z,Behavioral,Tele-interventions related to diabetes management and mental well-being,Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period,1,,Hospital de ClÃ­nicas de Porto Alegre,Porto Alegre,Rio Grande Do Sul,90620-170,Brazil,1
NCT04343183,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Not yet recruiting,NA,N/A,48,Anticipated,Ochsner Health System,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,Participants will be given a unique unidentifiable study ID number and all data will be recorded accorded to unidentifiable number to protect the patients personal health information.,2020-04-20T08:49:02Z,2020-04-20T08:49:02Z,Device,Hyperbaric Oxygen Therapy,Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.,1,,Ochsner Medical Center,New Orleans,Louisiana,70121,United States,1
NCT04342169,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,Recruiting,NA,Phase 2,400,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:37Z,2020-04-20T08:49:37Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days|Placebo to be taken on the same schedule as HCQ.",2,Recruiting,University of Utah,Salt Lake City,Utah,84108,United States,1
NCT04341922,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"June 10, 2021",Anticipated,2021-06-10,"June 10, 2021",Anticipated,2021-06-10,NA,Interventional,NA,,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial,Not yet recruiting,NA,N/A,670,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:45Z,2020-04-20T08:49:45Z,Behavioral,Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic,"A three week intervention including a structured self-guided program without therapist support, administered via a secure web platform, focusing on 1) teaching participants how to discriminate between functional- and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes [e.g. becoming unemployed]), 3) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them, refrain from excessive use of media coverage about Covid-19), and 4) increase the behavioral repertoire (take walks, engage in activities that promote health without putting yourself at risk to become infected) and provide advice how to properly assess and digest new information about Covid-19 and its consequences.",1,,Karolinska Institutet,Stockholm,,17177,Sweden,1
NCT04341610,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,ASC COVID-19,,ASC Therapy for Patients With Severe Respiratory COVID-19,"Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study",Not yet recruiting,NA,Phase 1/Phase 2,40,Anticipated,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:49:57Z,2020-04-20T08:49:57Z,Drug,Stem Cell Product,100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline,1,,"2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet",Copenhagen,,2100,Denmark,1
NCT04341584,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,May 2020,Anticipated,2020-05-31,NA,Interventional,CORIMUNO-ANA,,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Not yet recruiting,NA,Phase 2,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:49:58Z,2020-04-20T08:49:58Z,Drug,Anakinra,"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERETÂ® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERETÂ® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERETÂ® 100mg (Total 100 mg) at day 5 (D5).
In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter",1,NA,NA,NA,NA,NA,NA,NA
NCT04341493,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome,Recruiting,NA,Phase 4,86,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After finishing the study.,Requested by the journal or after publication if any researcher in the world express interest if the information of this survey.,NA,Yes,"If the final selected medical journal to send the paper of our research request it, we will add the full database of the studied population.",2020-04-20T08:50:02Z,2020-04-20T08:50:02Z,Drug|Drug,Nitazoxanide 500 MG|Hydroxychloroquine,Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug,2,Recruiting,"Materno-Perinatal Hospital ""MÃ³nica Pretelini""",Toluca,,50130,Mexico,1
NCT04341441,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-13,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,WHIP COVID-19,,Will Hydroxychloroquine Impede or Prevent COVID-19,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study,Recruiting,NA,Phase 3,3000,Anticipated,Henry Ford Health System,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:04Z,2020-04-20T08:50:04Z,Drug|Drug|Other|Diagnostic Test|Diagnostic Test|Diagnostic Test|Other,Hydroxychloroquine - Daily Dosing|Hydroxychloroquine - Weekly Dosing|Placebo oral tablet|Monitoring Visit - Baseline|Monitoring Visit - Week 4|Monitoring Visit - Week 8|Weekly Assessment,"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
All treatment groups will receive placebo pills to have the patients take 2 pills a day.|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria
All treatment groups will receive placebo pills to have the patients take 2 pills a day.|Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..
Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.
Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.",7,Recruiting|Recruiting|Recruiting|Recruiting,Henry Ford Hospital|Detroit Department of Transportation (DDOT)|Detroit Fire Department & Detroit EMS|Detroit Police Department,Detroit|Detroit|Detroit|Detroit,Michigan|Michigan|Michigan|Michigan,48202|48226|48226|48226,United States|United States|United States|United States,4
NCT04341415,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,SOS-COVID19,,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.,Not yet recruiting,NA,N/A,60,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:50:05Z,2020-04-20T08:50:05Z,Procedure|Procedure,Auricular neuromodulation|Control,"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.
Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELECÂ®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.
Compress soaked with Oxygenated water on the concha (to stop potential bleeding).
Placing an opaque dressing on the ear and a non-occlusive Band-Aid|The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.
Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).
Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid.",2,,Fondation Adolphe de Rothschild,Paris,,75019,France,1
NCT04341389,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-13,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years",Recruiting,NA,Phase 2,500,Anticipated,"Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:05Z,2020-04-20T08:50:05Z,Biological|Other,Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Placebo,Intramuscular injection|Intramuscular injection,2,Recruiting,Hubei Provincial Center for Disease Control and Prevention,Wuhan,Hubei,,China,1
NCT04341038,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,TACROVID,,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19,Recruiting,NA,Phase 3,84,Anticipated,Hospital Universitari de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:19Z,2020-04-20T08:50:19Z,Drug|Drug,Tacrolimus|Methylprednisolone,the necessary dose to obtain blood levels of 8-10 ng / ml|120mg of methylprednisolone daily for 3 consecutive days,2,Recruiting,Hospital Universitari de Bellvitge,L'Hospitalet de Llobregat,Barcelona,08907,Spain,1
NCT04340050,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-12,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Recruiting,NA,Early Phase 1,10,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2020-04-20T08:50:39Z,2020-04-20T08:50:39Z,Biological,anti-SARS-CoV-2 convalescent plasma,Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours,1,Recruiting,University of Chicago Medicine,Chicago,Illinois,60637,United States,1
NCT04339426,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-09,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection",Not yet recruiting,NA,N/A,25,Anticipated,HonorHealth Research Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:45Z,2020-04-20T08:50:45Z,Drug,Atovaquone/Azithromycin,Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10),1,NA,NA,NA,NA,NA,NA,NA
NCT04350580,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,ICAR,,IgIV in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulins in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Not yet recruiting,NA,Phase 3,138,Anticipated,Centre Hospitalier St Anne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:44:42Z,2020-04-20T08:44:42Z,Drug|Drug,Human immunoglobulin|Placebo,Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin,2,NA,NA,NA,NA,NA,NA,NA
NCT04349618,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"April 14, 2022",Anticipated,2022-04-14,"July 14, 2021",Anticipated,2021-07-14,NA,Interventional,VT4COVID,,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS,Not yet recruiting,NA,N/A,200,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:15Z,2020-04-20T08:45:15Z,Other|Other,PROTECTIVE VENTILATION|ULTRAPROTECTIVE VENTILATION,"Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial",2,||||||||||,Service de MÃ©decine Intensive RÃ©animation CHU Gabriel Montpied|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Michallon - CHU Grenoble Alpes|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Edouard Herriot Hospices Civils de Lyon|Service de RÃ©animation Chirurgicale HÃ´pital Edouard Herriot Hospices Civils de Lyon|Service de MÃ©decine Intensive RÃ©animation HÃ´pital de la Croix Rousse Hospices Civils de Lyon|Service de RÃ©animation Chirurgicale HÃ´pital de la Croix Rousse Hospices Civils de Lyon|Service de rÃ©animation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc|Service de RÃ©animation Clinique de la Sauvegarde|Service de RÃ©animation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon|Service de RÃ©animation Centre hospitalier Annecy Genevois|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Nord - CHU Saint-Etienne,Clermont-Ferrand|La Tronche|Lyon|Lyon|Lyon|Lyon|Lyon|Lyon|Pierre-BÃ©nite|Pringy|Saint-Priest-en-Jarez,||||||||||,63003|38700|69003|69003|69004|69004|69007|69009|69310|74374|42055,France|France|France|France|France|France|France|France|France|France|France,11
NCT04348383,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 8, 2020",Anticipated,2020-08-08,"July 8, 2020",Anticipated,2020-07-08,NA,Interventional,DEFACOVID,,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome",Recruiting,NA,Phase 2,120,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:56Z,2020-04-20T08:45:56Z,Drug|Drug,Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Placebo 250 cc 24 hours continuous infusion for 15 days,Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Placebo 250 cc 24 hours continuous infusion for 15 days,2,Recruiting,Virgen de la Arrixaca University Clinical Hospital,Murcia,,30120,Spain,1
NCT04347941,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 11, 2020",Anticipated,2020-04-11,April 2020,2020-04-30,"May 11, 2021",Anticipated,2021-05-11,"March 11, 2021",Anticipated,2021-03-11,NA,Interventional,APPROVE-CARE,,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Not yet recruiting,NA,N/A,200,Anticipated,University College Hospital Galway,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,up to 15 years post study,NA,NA,Yes,"Electronic Case report form following informed consent, all patient identification removed, and individual patient response to intervention will be shared.",2020-04-20T08:46:11Z,2020-04-20T08:46:11Z,Procedure|Procedure,Prone Positioning|Standard of care.,"Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 <94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 >94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula|Standard of care. Prone positioning may be administered as a rescue therapy",2,,Galway University Hospital,Galway,,,Ireland,1
NCT04347681,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-12,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-15,Actual,"April 12, 2020",Anticipated,2020-04-12,April 2020,2020-04-30,"April 11, 2021",Anticipated,2021-04-11,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Not yet recruiting,NA,Phase 2,40,Anticipated,King Fahad Specialist Hospital Dammam,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:21Z,2020-04-20T08:46:21Z,Other,convalescent plasma from recovered COVID 19 donor,"After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once & if possible, daily, for up to 5 sessions.",1,|||||||||,John Hopkins Aramco Healthcare|Imam Abdulrahman Bin Faisal University|king Fahad specialist hospital|DHahran Military Medical Complex|Taibah University|Qatif Central Hospital|King Abdulaziz Medical City|King Fahad Medical City|King Faisal Specialist Hospital & Research Center|King Khalid University Hospital,Dhahran|Dammam|Dammam|Dhahran|Madinah|Qatif|Riyadh|Riyadh|Riyadh|Riyadh,Eastern Provence|||||||||,|||||||||,Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia|Saudi Arabia,10
NCT04346693,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-15,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),Enrolling by invitation,NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:54Z,2020-04-20T08:46:54Z,Procedure|Procedure|Procedure|Procedure,Standard therapy recommended by the Ministry of Health of the Russian Federation.|Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.
For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.
For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days|Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.
For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.
For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.
Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days|Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.
For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.
For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.
Additional inhalation of the drug Dalargin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.|Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.
For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.
For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.
Additional inhalation of the drug Dalargin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.
Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days",4,,Burnasyan Federal Medical Biophysical Center FMBA of Russia,Moscow,,123098,Russian Federation,1
NCT04346420,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Recruiting,NA,N/A,15,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:08Z,2020-04-20T08:47:08Z,Other|Device,Standard interface|Double-Trunk Mask,The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.,2,Recruiting,Cliniques universitaires Saint-Luc,Brussels,Brussels Capital,1200,Belgium,1
NCT04345653,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 8, 2022",Anticipated,2022-04-08,"April 8, 2021",Anticipated,2021-04-08,NA,Interventional,NA,,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Enrolling by invitation,NA,Phase 2,45,Anticipated,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:33Z,2020-04-20T08:47:33Z,Drug,Hydroxychloroquine Sulfate (HCQ),"Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.",1,,Hackensack Meridian Health - JFK Medical Center,Edison,New Jersey,08820,United States,1
NCT04345445,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-11,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,"An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression",Not yet recruiting,NA,Phase 3,310,Anticipated,University of Malaya,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:41Z,2020-04-20T08:47:41Z,Drug|Drug,Tocilizumab|Methylprednisolone,IV infusion|IV infusion,2,,University Malaya Medical Centre,Kuala Lumpur,,59100,Malaysia,1
NCT04344587,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CATNAP,,COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning,COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning,Not yet recruiting,NA,N/A,380,Anticipated,Boston University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:12Z,2020-04-20T08:48:12Z,Other|Other,Self-prone position recommendation|Usual care,"The Qualtrics self-prone position recommendation intervention website will include the following sections:
Welcome message
Educational review of the potential benefits of prone positioning
How-To guide to safely ""prone"" in a hospital bed
A recommendation to ""prone"" while lying in bed (up to 3 times daily for 1 hour each time and at night for up to 9 hours) for a total of 12 hours per day
A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking|The Qualtrics usual care website will include the following sections:
Welcome message
A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking",2,NA,NA,NA,NA,NA,NA,NA
NCT04344457,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 16, 2020",Anticipated,2020-04-16,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,COVID-19,,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms in Maricopa County",Recruiting,NA,Phase 1/Phase 2,80,Anticipated,"Perseverance Research Center, LLC",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:17Z,2020-04-20T08:48:17Z,Drug|Drug|Drug,Hydroxychloroquine|Indomethacin|Zithromax Oral Product,200 mg PO BID 5 days|50 mg PO TID 14 Days|500 mg PO QD 3 Days,3,Recruiting,Perseverance Research Center,Scottsdale,Arizona,85254,United States,1
NCT04344236,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"May 9, 2020",Anticipated,2020-05-09,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,"A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19",Recruiting,NA,Phase 2,48,Anticipated,NYU Langone Health,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests should be directed to scott.rickert@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-04-20T08:48:24Z,2020-04-20T08:48:24Z,Drug|Drug|Drug,Saline oral/nasal rinse|0.5% Povidone/Iodine oral/nasal rinse|0.12% Chlorhexidine oral/nasal rinse,"5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.",3,Recruiting,NYU Langone Health,New York,New York,10016,United States,1
NCT04344106,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,N/A,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:31Z,2020-04-20T08:48:31Z,Procedure,Prone positioning,"The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.",1,Recruiting,CHI Aix-Pertuis,Aix-en-Provence,,13100,France,1
NCT04343768,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,DIC,,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Enrolling by invitation,NA,Phase 4,60,Anticipated,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,There is no further information.,2020-04-20T08:48:44Z,2020-04-20T08:48:44Z,Drug|Drug|Drug|Drug,Hydroxychloroquine|Lopinavir / Ritonavir|Interferon Beta-1A|Interferon Beta-1B,This Drug will be used in all arms.|This Drug will be used in all arms.|This drug will be only used in Arm 1.|This drug will be only used in Arm 2.,4,,"Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services",Tehran,,,"Iran, Islamic Republic of",1
NCT04343755,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection,Recruiting,NA,Phase 2,55,Anticipated,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:44Z,2020-04-20T08:48:44Z,Biological,Convalescent Plasma,Fresh plasma will be infused one time to hospitalized patients with COVID-19 infection,1,Recruiting,Hackensack University Medical Center,Hackensack,New Jersey,07601,United States,1
NCT04343261,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Not yet recruiting,NA,Phase 2,15,Anticipated,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:00Z,2020-04-20T08:49:00Z,Biological,Convalescent Plasma,treatment with 2 Units of convalescent plasma,1,,Trinity Health Of New England,Hartford,Connecticut,06105,United States,1
NCT04343248,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",Not yet recruiting,NA,Phase 3,600,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:00Z,2020-04-20T08:49:00Z,Drug|Drug,Nitazoxanide|Placebo,Nitazoxanide 600 mg administered orally twice daily for six weeks|Placebo administered orally twice daily for six weeks,2,NA,NA,NA,NA,NA,NA,NA
NCT04343001,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2021,Anticipated,2021-08-31,April 2021,Anticipated,2021-04-30,NA,Interventional,CRASH-19,,Coronavirus Response - Active Support for Hospitalised Covid-19 Patients,"Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial",Not yet recruiting,NA,Phase 3,10000,Anticipated,London School of Hygiene and Tropical Medicine,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Within 6 months or sooner of publication,Log-in required for the sole purpose to monitor data download.,http://freebird.lshtm.ac.uk,Yes,"As many sites will contribute to this trial, individual sites cannot restrict the publication of the manuscript relating to the outcomes of this trial. All anonymised data from this trial will be made freely available on our data sharing site: http://freebird.lshtm.ac.uk.",2020-04-20T08:49:08Z,2020-04-20T08:49:08Z,Drug|Drug|Drug,Aspirin|Losartan|Simvastatin,Aspirin 75mg|Losartan 100mg|Simvastatin 80mg,3,|,University College Hospital|Shifa Tameer-e-Millat University,Ibadan|Rawalpindi,Oyo|,|,Nigeria|Pakistan,2
NCT04342728,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Enrolling by invitation,NA,N/A,520,Anticipated,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:17Z,2020-04-20T08:49:17Z,Dietary Supplement|Dietary Supplement|Dietary Supplement|Other,Ascorbic Acid|Zinc Gluconate|Ascorbic Acid and Zinc Gluconate|Standard of Care,Readily available marketed open label ascorbic acid|Readily available marketed open label zinc gluconate|Readily available marketed open label ascorbic acid and zinc gluconate|Readily available prescribed medications/ supplements- None study supplements,4,,Cleveland Clinic,Cleveland,Ohio,44195,United States,1
NCT04342689,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,The Role of Resistant Potato Starch in COVID-19 Infection,The Role of Resistant Potato Starch in COVID-19 Infection,Not yet recruiting,NA,N/A,1300,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"After publication, indefinitely",NA,NA,Yes,Deidentified data underlying results for publication are planned to be made available after publication.,2020-04-20T08:49:20Z,2020-04-20T08:49:20Z,Dietary Supplement|Dietary Supplement,Bob's Red Mill|Control - Corn Starch,"Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14 to minimize GI symptoms)|Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)",2,NA,NA,NA,NA,NA,NA,NA
NCT04342663,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-13,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Recruiting,NA,Phase 2,152,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:21Z,2020-04-20T08:49:21Z,Drug|Drug,Fluvoxamine|Placebo,Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.,2,Recruiting|Recruiting,BJC|Washington University School of Medicine,Belleville|Saint Louis,Illinois|Missouri,62220|63110,United States|United States,2
NCT04342221,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"March 29, 2020",Actual,2020-03-29,March 2020,2020-03-31,February 2022,Anticipated,2022-02-28,March 2021,Anticipated,2021-03-31,NA,Interventional,COV-HCQ,,Hydroxychloroquine for COVID-19,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19,Recruiting,NA,Phase 3,220,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:36Z,2020-04-20T08:49:36Z,Drug|Drug,Hydroxychloroquine Sulfate|Placebo,"Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.|Placebo capsules",2,Recruiting,Institute for Tropical Medicine,TÃ¼bingen,,72074,Germany,1
NCT04342156,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,NA,Interventional,SHARP COVID-19,,Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial,Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial,Not yet recruiting,NA,Phase 3,3000,Anticipated,Tan Tock Seng Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:38Z,2020-04-20T08:49:38Z,Drug,Hydroxychloroquine Sulfate 200 milligram (mg) Tab,Oral tablet of Hydroxychloroquine sulfate,1,NA,NA,NA,NA,NA,NA,NA
NCT04341207,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,ONCOVID,,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients,Recruiting,NA,Phase 2,1000,Anticipated,"Gustave Roussy, Cancer Campus, Grand Paris",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:50:11Z,2020-04-20T08:50:11Z,Drug|Drug,Hydroxychloroquine|Azithromycin,Hydroxychloroquine 200 mg 3 times a day for 10 days|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days,2,Recruiting,Gustave Roussy,Villejuif,Val De Marne,94800,France,1
NCT04341142,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-08,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 9, 2020",Anticipated,2020-04-09,April 2020,2020-04-30,"September 9, 2020",Anticipated,2020-09-09,"September 9, 2020",Anticipated,2020-09-09,NA,Interventional,COVID-SER,,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Not yet recruiting,NA,N/A,400,Anticipated,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:50:14Z,2020-04-20T08:50:14Z,Diagnostic Test,Serological tests will be applied on patients blood sampling,Application of tests on patients' serum,1,NA,NA,NA,NA,NA,NA,NA
NCT04351906,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome,Not yet recruiting,NA,N/A,20,Anticipated,University of Giessen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:43:58Z,2020-04-20T08:43:58Z,Device,ECCO2R,ECCO2R integrated into the multiFiltrate device,1,,"University Hospital Giessen and Marburg, Giessen",Giessen,Hessen,35382,Germany,1
NCT04348513,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"May 2, 2020",Anticipated,2020-05-02,April 2020,2020-04-30,"May 31, 2021",Anticipated,2021-05-31,"May 2, 2021",Anticipated,2021-05-02,NA,Interventional,Thy-Support,,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support),Not yet recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:52Z,2020-04-20T08:45:52Z,Drug|Drug,T3 solution for injection|Placebo,"For example, for a patient of 77Kg of weight, a dose of 6ml (60 Î¼g) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 Î¼g of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 Î¼g of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.|Same as with T3 solution for injection.",2,,Attikon University General Hospital,Haidari/Athens,,12462,Greece,1
NCT04347980,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-16,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DHYSCO,,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,"Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial",Recruiting,NA,Phase 3,122,Anticipated,Centre Chirurgical Marie Lannelongue,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months and ending 24 months following article publication,Researchers who provide a methodologically sound and proposal. Data are available for 24 months and request should be addressed by email,NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2020-04-20T08:46:10Z,2020-04-20T08:46:10Z,Drug|Drug,Dexamethasone and Hydroxychloroquine|Hydroxychloroquine,"Patients included in the ""Hydroxychloroquine / Dexamethasone"" group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before.|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.",2,Recruiting,Reanimation adulte. Hopital Marie Lannelongue,Le Plessis-Robinson,,92350,France,1
NCT04346615,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-14,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,"BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",Not yet recruiting,NA,Phase 2/Phase 3,120,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:01Z,2020-04-20T08:47:01Z,Drug|Drug,Vazegepant (BHV-3500)|Placebo,10 mg intranasal (IN) for 14 days|Placebo Q8h for 14 days,2,NA,NA,NA,NA,NA,NA,NA
NCT04346589,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:02Z,2020-04-20T08:47:02Z,Biological,Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,"Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.",1,||||,IRFMN - Clinical Research Center for Rare Diseases|ASST HPG23 - Unit of Nephrology|ASST Papa Giovanni XXIII - Microbiology and Virology Unit|Asst Pg23 - S.I.M.T|ASST-PG23 - Intensive Care Unit,Ranica|Bergamo|Bergamo|Bergamo|Bergamo,BG||||,24020|24100|24100|24100|24100,Italy|Italy|Italy|Italy|Italy,5
NCT04346199,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 24, 2020",Anticipated,2020-04-24,April 2020,2020-04-30,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,ACE-ID-201,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus),A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19,Not yet recruiting,NA,Phase 2,428,Anticipated,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Study start to completion date,"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2020-04-20T08:47:16Z,2020-04-20T08:47:16Z,Drug,Acalabrutinib,Acalabrutinib- administered orally or receive delivery of emptied capsule via a nasogastric (NG) or an enteral feeding tube,1,,Research Site,Barcelona,,08035,Spain,1
NCT04345692,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"March 26, 2020",Actual,2020-03-26,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,OAHU-COVID19,,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,350,Anticipated,Queen's Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:32Z,2020-04-20T08:47:32Z,Drug,Hydroxychloroquine,oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet,1,Recruiting,Queen's Medical Center,Honolulu,Hawaii,96813,United States,1
NCT04344782,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-16,2020-04-12,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,CORIMMUNO-BEVA,,"Trial Evaluating Efficacy and Safety of Bevacizumab (AvastinÂ®/ZeribevÂ®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial,Not yet recruiting,NA,Phase 2,130,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:48:05Z,2020-04-20T08:48:05Z,Drug,Bevacizumab Injection,"Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.",1,NA,NA,NA,NA,NA,NA,NA
NCT04344756,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-14,2020-04-12,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,CORIMMUNO-COAG,,"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial,Not yet recruiting,NA,Phase 2,808,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:48:06Z,2020-04-20T08:48:06Z,Drug,Tinzaparin or unfractionated heparin,"Tinzaparin INNOHEP Â® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft â‰¥ 20mL/min, Otherwise unfractionated heparin (CalciparineÂ®, HÃ©parine Sodique ChoayÂ®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days",1,||,"RÃ©animation hÃ´pital Louis Mourier|rÃ©animation hÃ´pital Cochin|MÃ©decine vasculaire, HÃ´pital EuropÃ©en Georges Pompidou",Colombes|Paris|Paris,Hauts De Seine||,92701|75014|75015,France|France|France,3
NCT04344730,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVIDICUS,,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS,Recruiting,NA,N/A,550,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:48:07Z,2020-04-20T08:48:07Z,Drug|Drug|Procedure|Procedure|Procedure|Procedure,Dexamethasone injection|placebo|conventional oxygen|CPAP|HFNO|mechanical ventilation,"Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)",6,Recruiting,Hopital Bichat - Aphp,Paris,,75018,France,1
NCT04344431,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-11,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,OHB10cov,,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Not yet recruiting,NA,Phase 2/Phase 3,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:18Z,2020-04-20T08:48:18Z,Combination Product,Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device),One session per day of HBOT in addition to the standard treatment with normobaric oxygen,1,,Sainte Anne Military Teaching Hospital,Toulon,,83130,France,1
NCT04344184,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"April 22, 2020",Anticipated,2020-04-22,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI),Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI),Not yet recruiting,NA,Phase 2,200,Anticipated,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is no default plan to share individual participant data. May be considered upon reaching the VCU IRB,2020-04-20T08:48:26Z,2020-04-20T08:48:26Z,Drug,L-ascorbic acid,100 mg/kg intravenous vitamin C infusion every 8 hours for up to 72 hours,1,|,Hunter Holmes McGuire VA Medical Center|Virginia Commonwealth University,Richmond|Richmond,Virginia|Virginia,23249|23298,United States|United States,2
NCT04344080,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,CYTOCOV-19,,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,NA,N/A,24,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:32Z,2020-04-20T08:48:32Z,Device,CytoSorb-Therapy,Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation),1,Recruiting,University Medical Center Hamburg-Eppendorf,Hamburg,,,Germany,1
NCT04344041,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Not yet recruiting,NA,Phase 3,260,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:48:33Z,2020-04-20T08:48:33Z,Drug|Drug,"cholecalciferol 200,000 IU|cholecalciferol 50,000 IU","Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose",2,||||||||,CHU Bordeaux|CH Le Mans|CHU Lille|CHU Limoges|CHU Nantes|CHU Nice|CHU Saint Etienne|CH Saumur|CHU Tours,Bordeaux|Le Mans|Lille|Limoges|Nantes|Nice|Saint Etienne|Saumur|Tours,||||||||,||||||||,France|France|France|France|France|France|France|France|France,9
NCT04344015,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-14,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"April 12, 2021",Anticipated,2021-04-12,"April 12, 2021",Anticipated,2021-04-12,NA,Interventional,NA,,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Recruiting,NA,N/A,2000,Anticipated,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:48:34Z,2020-04-20T08:48:34Z,Other,Plasma Donation,Previously infected COVID-19 patients will be recruited to donate convalescent plasma.,1,Recruiting,Thomas Jefferson University Hospital,Philadelphia,Pennsylvania,19107,United States,1
NCT04343989,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-04-20T08:48:35Z,2020-04-20T08:48:35Z,Drug|Drug|Other,Clazakizumab 12.5 mg|Clazakizumab 25 mg|Placebo,"The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.",3,Recruiting,New York University School of Medicine,New York,New York,10016,United States,1
NCT04343976,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Pegylated Interferon Lambda Treatment for COVID-19,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Standard Supportive Care in Subjects Infected With COVID-19,Not yet recruiting,NA,Phase 2,40,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"Data is anticiapted to be made available within 3 months of study completion. Safety data, specifically treatment related adverse events, will be shared in real time",researchers accessing IPD must be an approved and have a data use agreement in place with Partners Healthcare to access the data,NA,Yes,Coded data is anticipated to be shared with outside institutions. Safety data will be shared with the drug manufacturer,2020-04-20T08:48:35Z,2020-04-20T08:48:35Z,Drug,Pegylated interferon lambda,180 mcg subcutaneous injection of pegylated interferon lambda,1,,Massachusetts General Hospital,Boston,Massachusetts,02114,United States,1
NCT04343963,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,PISCO,,Pyridostigmine in Severe SARS-CoV-2 Infection,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:36Z,2020-04-20T08:48:36Z,Drug|Drug,Pyridostigmine Bromide|Placebo,One 60mg tablet P.O. once per day for 14 days|One tablet P.O. once per day for 14 days,2,Recruiting,Instituto Nacional de Ciencias MÃ©dicas y NutriciÃ³n Salvador ZubirÃ¡n,Ciudad de MÃ©xico,Tlalpan,14080,Mexico,1
NCT04343729,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-10,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,MetCOVID,,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Not yet recruiting,NA,Phase 2,420,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2020-04-20T08:48:45Z,2020-04-20T08:48:45Z,Drug|Drug,Methylprednisolone Sodium Succinate|Placebo solution,injectable solution at a dose of 0.5mg/kg|injectable saline solution,2,,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
NCT04343690,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-10,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,COPING With COVID-19( CWC-19),Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis,Not yet recruiting,NA,N/A,100,Anticipated,Duke University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:46Z,2020-04-20T08:48:46Z,Behavioral,Crisis management coaching,"Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic",1,,Duke University,Durham,North Carolina,27710,United States,1
NCT04343677,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study,Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study,Not yet recruiting,NA,Phase 2,1450,Anticipated,United States Department of Defense,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No patient data to be shared outside of the Pentagon.,2020-04-20T08:48:46Z,2020-04-20T08:48:46Z,Drug|Dietary Supplement,Hydroxychloroquine|Placebo,Daily dosing of hydroxychloroquine as PrEP or PEP|A vitamin supplement of no known activity against COVID-19,2,,Pentagon,Arlington,Virginia,20301,United States,1
NCT04343144,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-09,NA,NA,2020-04-12,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,CORIMUNO-NIVO,,"Trial Evaluating Efficacy and Safety of Nivolumab (OptivoÂ®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial,Not yet recruiting,NA,Phase 2,92,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:03Z,2020-04-20T08:49:03Z,Drug,Nivolumab Injection,Treatment consists of an infusion of OPDIVOÂ® 3mg/kg on day 1 (D1).,1,,Pneumologie hÃ´pital Tenon,Paris,,75019,France,1
NCT04351724,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-16,2020-04-16,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ACOVACT,,Austrian CoronaVirus Adaptive Clinical Trial,"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2020-04-20T08:44:03Z,2020-04-20T08:44:03Z,Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug,Chloroquine or Hydroxychloroquine|Lopinavir/Ritonavir|Best standard of care|Rivaroxaban|Thromboprophylaxis|Candesartan|non-RAS blocking antihypertensives|Clazakizumab|placebo for clazakizumab,"Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available|Lopinavir/Ritonavir 200mg/50mg 2-0-2|best standard of care|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable|as local standard, most likely to be low molecular weight heparin|starting dose 4mg once daily, titrated to normotension|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others|25mg i.v. single dose, possibly a repeated dose|sodium chloride bolus infusions as placebo for clazakizumab",9,Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Medical University of Innsbruck|Medical University of Vienna|Wilhelminenspital|SMZ SÃ¼d Kaiser Franz Josef Spital|KH Hietzing|SMZ Baumgartner HÃ¶he Otto Wagner Spital|SMZ Ost Donauspital,Innsbruck|Vienna|Vienna|Vienna|Vienna|Vienna|Vienna,Tirol||||||,6020|1090|1090|1100|1130|1140|1220,Austria|Austria|Austria|Austria|Austria|Austria|Austria,7
NCT04348929,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 16, 2020",Anticipated,2020-04-16,April 2020,2020-04-30,"November 1, 2021",Anticipated,2021-11-01,"August 16, 2021",Anticipated,2021-08-16,NA,Interventional,CONFINE,,Birth Experience During COVID-19 Confinement,Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care),Not yet recruiting,NA,N/A,600,Anticipated,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:45:39Z,2020-04-20T08:45:39Z,Other,Self-administered questionnaires,Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home),1,,Centre Hospitalier RÃ©gional Universitaire de Nancy,Nancy,,54000,France,1
NCT04348461,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,NA,,BAttLe Against COVID-19 Using MesenchYmal Stromal Cells,"Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19",Not yet recruiting,NA,Phase 2,100,Anticipated,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:45:54Z,2020-04-20T08:45:54Z,Drug,Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg,1,NA,NA,NA,NA,NA,NA,NA
NCT04346628,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19,"A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19",Not yet recruiting,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2020-04-20T08:47:01Z,2020-04-20T08:47:01Z,Drug|Other,Favipiravir|Standard of care treatment,"Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).|Standard of care treatment for COVID-19 infection",2,,Stanford University,Stanford,California,94305,United States,1
NCT04346329,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"October 1, 2020",Anticipated,2020-10-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,Chloroquine UN,,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2,Not yet recruiting,NA,Phase 3,86,Anticipated,Universidad Nacional de Colombia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:11Z,2020-04-20T08:47:11Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,Treated group|Placebo Group,2,|,Facultad de Medicina - Universidad Nacional de Colombia|Universidad Nacional de Colombia,Bogota|Bogota,Cundinamarca|Cundinamarca,111321|111321,Colombia|Colombia,2
NCT04345991,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"May 15, 2020",Anticipated,2020-05-15,NA,Interventional,CORIPLASM,,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Not yet recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:23Z,2020-04-20T08:47:23Z,Drug,Transfusion of COVID-19 convalescent plasma,"Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient",1,,"SMIT, Saint Antoine hospital",Paris,,75012,France,1
NCT04345887,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-15,Actual,"April 21, 2020",Anticipated,2020-04-21,April 2020,2020-04-30,"October 21, 2020",Anticipated,2020-10-21,"July 21, 2020",Anticipated,2020-07-21,NA,Interventional,NA,,Spironolactone in Covid-19 Induced ARDS,The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients,Not yet recruiting,NA,Phase 4,60,Anticipated,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:26Z,2020-04-20T08:47:26Z,Drug|Drug,Spironolactone 100mg|Placebo oral tablet,2x100 mg spironolactone for 5 consecutive days|2 x1 placebo tablet,2,,Istanbul University-CerrahpaÅŸa,Istanbul,,,Turkey,1
NCT04345601,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-15,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study,Not yet recruiting,NA,Early Phase 1,30,Anticipated,Baylor College of Medicine,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:35Z,2020-04-20T08:47:35Z,Genetic,Mesenchymal Stromal Cells,Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.,1,,Houston Methodist Hospital,Houston,Texas,77030,United States,1
NCT04345549,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:37Z,2020-04-20T08:47:37Z,Other,Individualised Ayurveda,"Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing",1,,Aarogyam,Leicester,,,United Kingdom,1
NCT04345289,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multi-stage, 6-armed Placebo-controlled Trial in the Framework of an Adaptive Trial Platform",Not yet recruiting,NA,Phase 3,1500,Anticipated,Hvidovre University Hospital,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:46Z,2020-04-20T08:47:46Z,Biological|Drug|Drug|Drug|Other|Other,Convalescent anti-SARS-CoV-2 plasma|Sarilumab|Baricitinib|Hydroxychloroquine|Injective placebo|Oral placebo,Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)|Pre-filled syringe 200 mg (1.14 mL) as a single dose|Tablets 4 mg/day for 7 days|Tablets 600 mg/day for 7 days|Saline 0.9% (600 ml) as an iv single dose infusion + placebo treatment with saline 0.9% (1.14 mL) as a single sc injection|Three glucose monohydrate placebo capsules daily for 7 days,6,|||||||||||,Aalborg University Hospital|Aarhus University Hospital|Bispebjerg Hospital|Rigshospitalet|Herlev Gentofte Hospital|Herning Hospital|NordsjÃ¦llands Hospital|Hvidovre Hospital|Kolding Hospital|Odense University Hospital|Roskilde Hospital|Vejle Hospital,Aalborg|Arhus|Copenhagen|Copenhagen|Herlev|Herning|HillerÃ¸d|Hvidovre|Kolding|Odense|Roskilde|Vejle,|||||||||||,|||||||||||,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,12
NCT04345276,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Recruiting,NA,Phase 4,40,Anticipated,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:46Z,2020-04-20T08:47:46Z,Drug,Danoprevir+Ritonavir,"Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.",1,Recruiting,Huoshenshan Hostipal,Wuhan,Hubei,430104,China,1
NCT04344600,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,PROTECT,,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 2,164,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:11Z,2020-04-20T08:48:11Z,Drug|Other,Peginterferon lambda alfa-1a subcutaneous injection|Saline,Peginterferon lambda-1a 180 micrograms by subcutaneous injection|Saline subcutaneous injection,2,,Johns Hopkins Hospital,Baltimore,Maryland,21287,United States,1
NCT04344561,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,UPSAT,,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT),Not yet recruiting,NA,N/A,70,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Access to IPD on reasonable request,2020-04-20T08:48:12Z,2020-04-20T08:48:12Z,Other,Postural Positioning,Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.,1,NA,NA,NA,NA,NA,NA,NA
NCT04344548,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"November 10, 2020",Anticipated,2020-11-10,"June 10, 2020",Anticipated,2020-06-10,NA,Interventional,NA,,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,Not yet recruiting,NA,Phase 1/Phase 2,10,Anticipated,Universidad Nacional de Colombia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:13Z,2020-04-20T08:48:13Z,Biological,Allogeneic NK transfer,Three doses of allogeneic NK cell transfer,1,|,Fundacion Salud De Los Andes|Universidad Nacional de Colombia,BogotÃ¡|Bogota,BogotÃ¡ Distrito Capital|Cundinamarca,111321|111321,Colombia|Colombia,2
NCT04344535,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-15,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma vs. Standard Plasma for COVID-19,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection,Enrolling by invitation,NA,Phase 1/Phase 2,500,Anticipated,Stony Brook University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:48:14Z,2020-04-20T08:48:14Z,Biological|Biological,Convalescent Plasma|Standard Donor Plasma,"450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally > 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies",2,,Stony Brook University Hospital,Stony Brook,New York,11794,United States,1
NCT04344444,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"December 10, 2021",Anticipated,2021-12-10,"April 10, 2021",Anticipated,2021-04-10,NA,Interventional,RCT,,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial,Recruiting,NA,Phase 3,600,Anticipated,LCMC Health,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:48:18Z,2020-04-20T08:48:18Z,Drug|Drug,Hydroxychloroquine|Azithromycin,tablets provided as described in Arm B|tablets provided as described in Arm C,2,Recruiting,University Medical Center New Orleans,New Orleans,Louisiana,70112,United States,1
NCT04344288,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,CORTI-Covid,,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Not yet recruiting,NA,Phase 2,304,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:48:23Z,2020-04-20T08:48:23Z,Drug|Other,Prednisone|Control group,The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.,2,,HÃ´pital Pneumologique et Cardiovasculaire Louis Pradel,Bron,,,France,1
NCT04342897,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-10,NA,NA,2020-04-14,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 18, 2020",Anticipated,2020-04-18,April 2020,2020-04-30,"July 10, 2020",Anticipated,2020-07-10,"July 10, 2020",Anticipated,2020-07-10,NA,Interventional,NA,,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Not yet recruiting,NA,Phase 2,200,Anticipated,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2020-04-20T08:49:11Z,2020-04-20T08:49:11Z,Drug|Drug,LY3127804|Placebo,Administered IV|Administered IV,2,NA,NA,NA,NA,NA,NA,NA
NCT04351789,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,PISCA,,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial,Not yet recruiting,NA,N/A,66,Anticipated,"Copenhagen University Hospital, Hvidovre",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will not be shared with other researchers due to regulatory restrictions.,2020-04-20T08:44:01Z,2020-04-20T08:44:01Z,Other,Psychoeducational intervention,"The written and verbal information provided at discharge to patients in the intervention arm will consist of:
An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.
These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital.",1,NA,NA,NA,NA,NA,NA,NA
NCT04349410,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-16,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"November 11, 2020",Anticipated,2020-11-11,"October 11, 2020",Anticipated,2020-10-11,NA,Interventional,FMTVDM,,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Enrolling by invitation,NA,Phase 2/Phase 3,500,Anticipated,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2020-04-20T08:45:22Z,2020-04-20T08:45:22Z,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,"Hydroxychloroquine, Azithromycin|Hydroxychloroquine, Doxycycline|Hydroxychloroquine, Clindamycin|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Remdesivir|Tocilizumab|Methylprednisolone|Interferon-Alpha2B|Losartan|Convalescent Serum","FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET|FMTVDM Planar, SPECT, PET",11,,FHHI-OI-Camelot; QME,Los Angeles,California,90245,United States,1
NCT04348305,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"December 30, 2021",Anticipated,2021-12-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,COVID STEROID,,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Not yet recruiting,NA,Phase 3,1000,Anticipated,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2020-04-20T08:45:59Z,2020-04-20T08:45:59Z,Drug|Drug,Hydrocortisone|Sodium Chloride 9mg/mL,"Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days",2,NA,NA,NA,NA,NA,NA,NA
NCT04347538,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-11,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-15,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Not yet recruiting,NA,N/A,90,Anticipated,Vanderbilt University Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:26Z,2020-04-20T08:46:26Z,Other|Other,Saline Nasal Irrigation|Saline with Baby Shampoo Nasal Irrigation,Saline nasal irrigation BID|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.,2,,Vanderblt University Medical Center,Nashville,Tennessee,37232,United States,1
NCT04347512,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-11,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-15,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"August 1, 2021",Anticipated,2021-08-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,TEACHCOVID,,Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study,Evaluation of Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia,Not yet recruiting,NA,Phase 3,405,Anticipated,"University Hospital, Strasbourg, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:26Z,2020-04-20T08:46:26Z,Drug|Drug|Drug,Hydroxychloroquine and azithromycin treatment arm.|Hydroxychloroquine|Control arm,"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.
For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.
For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.
Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).|Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.
Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).",3,NA,NA,NA,NA,NA,NA,NA
NCT04347382,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-11,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-15,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 25, 2020",Anticipated,2020-05-25,NA,Interventional,WUHAN Trail,,Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT,"With Uncontroversial Honey And Nigella Sativa (WUHAN) Treatment for Noval Coronavirus Infection; Randomized, Controlled, Double Blind, Investigator Initiated Trial",Recruiting,NA,Phase 3,30,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:32Z,2020-04-20T08:46:32Z,Drug|Drug|Drug,Honey|Nigella Sativa / Black Cumin|Placebos,30ml Natural Honey orally BD|Capsule 2gm seed powder orally BD|Empty capsule with 250ml of distilled water,3,Recruiting,"Mayo Hospital, Kingedward Medical University",Lahore,Punjab,54600,Pakistan,1
NCT04345679,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Anti COVID-19 Convalescent Plasma Therapy,Anti COVID-19 Convalescent Plasma Therapy,Not yet recruiting,NA,Early Phase 1,20,Anticipated,Orthosera Kft.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:33Z,2020-04-20T08:47:33Z,Biological,anti-SARS-CoV-2 convalescent plasma,Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~200 mL over 4 hours,1,NA,NA,NA,NA,NA,NA,NA
NCT04345419,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,December 2029,Anticipated,2029-12-31,December 2029,Anticipated,2029-12-31,NA,Interventional,NA,,A Real-life Experience on Treatment of Patients With COVID 19,The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19,Not yet recruiting,NA,Phase 2/Phase 3,100,Anticipated,Tanta University,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:42Z,2020-04-20T08:47:42Z,Drug|Drug|Drug|Drug|Drug,Chloroquine|Favipiravir|Nitazoxanide|Ivermectin|Niclosamide,Chloroquine pills|Favipiravir as antiviral drug|Nitazoxanide|Ivermectin drug|Yomesan or niclosamide tablets,5,,Tanta university hospital,Tanta,,,Egypt,1
NCT04345406,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-11,NA,NA,2020-04-11,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"December 1, 2029",Anticipated,2029-12-01,"December 1, 2029",Anticipated,2029-12-01,NA,Interventional,NA,,Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19,Randomized Trial of ACEIs in Treatment of COVID-19,Not yet recruiting,NA,Phase 3,60,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:42Z,2020-04-20T08:47:42Z,Drug|Drug,ACEIs|Conventional treatment,Captopril or enalapril|alexoquine,2,,Tanta University,Tanta,,35111,Egypt,1
NCT04349592,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-12,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,Q-PROTECT,,Qatar Prospective RCT Of Therapy Eliminating Covid Transmission,Qatar Prospective RCT Of Therapy Eliminating Covid Transmission,Not yet recruiting,NA,N/A,456,Anticipated,Hamad Medical Corporation,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:16Z,2020-04-20T08:45:16Z,Drug|Drug|Other,Hydroxychloroquine + Azithromycin|Hydroxychloroquine + Placebo|Placebo + Placebo,Hydroxychloroquine 200 mg oral tablet three times daily for 7 days + Azithromycin 500 mg ( 2 caps) oral capsules on day one then 250 mg ( 1 cap) daily from day 2-5.|Hydroxychloroquine 200 mg oral tablet three times daily for 7 days + Placebo oral capsules 2 capsules day one then 1 cap day 2-5.|Placebo oral 1 tablet three times daily for 7days + Placebo oral capsules 2 capsules day one then 1cap day 2-5.,3,NA,NA,NA,NA,NA,NA,NA
NCT04349371,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-12,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Saved From COVID-19,Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID,Recruiting,NA,Phase 2,350,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:45:23Z,2020-04-20T08:45:23Z,Drug|Drug,Chloroquine|Placebo oral tablet,Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).,2,Recruiting,Columbia University Irving Medical Center/NYP,New York,New York,10032,United States,1
NCT04346355,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-12,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,398,Anticipated,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:47:10Z,2020-04-20T08:47:10Z,Drug,Tocilizumab,"In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours",1,Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting,"Ospedale di Guastalla|Azienda UnitÃ  Sanitaria Locale-IRCCS di Reggio Emilia|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo|ASST Cremona|Azienda Ospedaliera S. Croce e Carle|Azienda Ospedaliero Universitaria Ferrara|Azienda Ospedaliero Universitaria Careggi|Ospedale Evangelico Internazionale di Genova|Azienda Sociosanitaria ASL 1 ,Imperia|Azienda Sociosanitaria ASL 5 La Spezia|ASST Mantova - Ospedale Carlo Poma|IRCCS Istituto Auxologico Italiano Milano|Azienda Ospedaliero-Universitaria ""Maggiore della CaritÃ "" di Novara|Ospedali Riuniti Padova Sud - ULSS 6 Euganea|Azienda Ospedaliero-Universitaria Parma|Azienda UnitÃ  Sanitaria Locale di Piacenza|Azienda Ospedaliera Universitaria Pisana|AO Ordine Mauriziano di Torino|ASST Bergamo Ovest -Treviglio|AULSS 2 Marca Trevigiana|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto|AULSS 3 Serenissima Ospedale ""Dell'Angelo""|Azienda Ospedaliera Universitaria Integrata di Verona|IRCCS Sacro Cuore Don Calabria",Guastalla|Reggio Emilia|Alessandria|Cremona|Cuneo|Ferrara|Firenze|Genova|Imperia|La Spezia|Mantova|Milano|Novara|Padova|Parma|Piacenza|Pisa|Torino|Treviglio|Treviso|Treviso|Venezia|Verona|Verona,RE|RE||||||||||||||||||||||,|42122||||||||||||||||||||||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,24
NCT04350931,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Not yet recruiting,NA,Phase 3,900,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:30Z,2020-04-20T08:44:30Z,Biological|Other,intradermal injection of BCG Vaccine|placebo,0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus,2,NA,NA,NA,NA,NA,NA,NA
NCT04350281,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-17,Estimate,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"July 31, 2022",Anticipated,2022-07-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Recruiting,NA,Phase 2,80,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:51Z,2020-04-20T08:44:51Z,Drug|Drug,Interferon Beta-1B|Hydroxychloroquine,"Daily subcutaneous injection of interferon Î²-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days",2,Recruiting,"The University of Hong Kong, Queen Mary Hospital",Hong Kong,,852,Hong Kong,1
NCT04350086,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"November 20, 2020",Anticipated,2020-11-20,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,PRODEX,,Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,Not yet recruiting,NA,Phase 4,10,Anticipated,"University Hospital, Limoges",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:57Z,2020-04-20T08:44:57Z,Drug,Treatment with Dexmedetomidine,"Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 Âµg / kg / h, with dose adjustment according to the sedation score and tolerance.",1,,University Hospital,Limoges,,87200,France,1
NCT04349241,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,FAV-001,,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Not yet recruiting,NA,Phase 3,100,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:27Z,2020-04-20T08:45:27Z,Drug|Drug,favipiravir|Standard of care therapy,"pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10",2,NA,NA,NA,NA,NA,NA,NA
NCT04348877,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,PRA-001,,Plasma Rich Antibodies From Recovered Patients From COVID19,Plasma Rich Antibodies From Recovered Patients From COVID19,Not yet recruiting,NA,N/A,20,Anticipated,Ain Shams University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:41Z,2020-04-20T08:45:41Z,Other,Antibody-Rich Plasma from COVID-19 recovered patients,400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19,1,NA,NA,NA,NA,NA,NA,NA
NCT04348864,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Antibody Self-testing Using Virtual Point-of-care,Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care,Recruiting,NA,N/A,100,Anticipated,Neuroganics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:41Z,2020-04-20T08:45:41Z,Diagnostic Test|Other,"COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support|Telemedicine","An immunodiagnostic rapid (10-20 minute) test detects circulating antibodies (IgM and IgG) in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 in the past.|Imaging of the test and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).",2,Recruiting,Neuroganics,Northglenn,Colorado,80260,United States,1
NCT04348695,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:45:46Z,2020-04-20T08:45:46Z,Drug|Other,Ruxolitinib plus simvastatin|Standard of Care,"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.
Simvastatin 40 mg orally every 24 hours for 14 days|Patients will receive treatment according to usual clinical practice in the participant site.",2,Recruiting,Hospital Universitario Madrid Sanchinarro,Madrid,,28050,Spain,1
NCT04348656,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,CONCOR-1,,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1),Not yet recruiting,NA,Phase 3,1200,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:48Z,2020-04-20T08:45:48Z,Other,Convalescent plasma,"Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.",1,||||||||||||||||||||||||||,University of Alberta|Vancouver General Hospital|Royal Jubilee Hospital|Victoria General Hospital|Health Sciences Centre|Hamilton General Hospital|St. Jospeh's Healthcare Hamtilon|Juravinski Hospital|London Health Sciences Centre - University Hospital|Ottawa Hospital - General Campus|Ottawa Hospital - Civic Campus|Thunder Bay Regional Health Sciences Centre - Cancer Centre|Sunnybrook Health Sciences Centre|Unity Health Toronto|Sinai Health System|Toronto General Hospital|Toronto Western Hospital|HÃ´pital de la CitÃ©-de-la-SantÃ©|HÃ´pital Maisonneuve-Rosemont|Centre hospitalier de l'UniversitÃ© de MontrÃ©al|Centre hospitalier universitaire Sainte-Justine|Jewish General Hospital|McGill University Health Centre|HÃ´pital du SacrÃ©-Coeur de Montreal|Centre hospitalier universitaire de QuÃ©bec|Centre hospitalier universitaire de Sherbrooke|Centre hospitalier affiliÃ© universitaire rÃ©gional de Trois-RiviÃ¨res,Edmonton|Vancouver|Victoria|Victoria|Winnipeg|Hamilton|Hamilton|Hamilton|London|Ottawa|Ottawa|Thunder Bay|Toronto|Toronto|Toronto|Toronto|Toronto|Laval|MontrÃ©al|MontrÃ©al|MontrÃ©al|MontrÃ©al|MontrÃ©al|MontrÃ©al|Quebec City|Sherbrooke|Trois-RiviÃ¨res,Alberta|British Columbia|British Columbia|British Columbia|Manitoba|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Ontario|Quebec|Quebec|Quebec|Quebec|Quebec|Quebec|Quebec|Quebec|Quebec|Quebec,T6G 2R3|V5Z 1M9|V8R 1J8|V8Z 6R5|R3A 1R9|L8L 2X2|L8N 4A6|L8V 1C3|N6A 5A5|K1H 8L6|K1Y 4E9|P7B 6V4|M4N 3M5|M5B 1W8|M5G 1X5|M5G 2C4|M5T 2S8|H7M 3L9|H1T 2M4|H2X 3E4|H3T 1C5|H3T 1E2|H4A 3J1|H4J 1C5||J1H 5N4|G8Z 3R9,Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada|Canada,27
NCT04348500,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,"April 21, 2020",Anticipated,2020-04-21,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,Not yet recruiting,NA,Phase 2,60,Anticipated,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:45:53Z,2020-04-20T08:45:53Z,Drug,Clazakizumab,Infusion,1,NA,NA,NA,NA,NA,NA,NA
NCT04348474,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,"Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus",Not yet recruiting,NA,Early Phase 1,200,Anticipated,Azidus Brasil,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-20T08:45:54Z,2020-04-20T08:45:54Z,Drug|Drug,Hydroxychloroquine Sulfate|Azithromycin Tablets,All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.|All patients included in the study will receive AZT 500 mg per day for 5 days.,2,,Prevent Senior Private Operadora de SaÃºde LTDA.,SÃ£o Paulo,,,Brazil,1
NCT04348071,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-16,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Safety and Efficacy of Ruxolitinib for COVID-19,Safety and Efficacy of Ruxolitinib for COVID-19,Not yet recruiting,NA,Phase 2/Phase 3,80,Anticipated,"University of Colorado, Denver",,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,Data will be made available upon publication in a peer-reviewed journal.,Data access requests will be reviewed by the sponsor-investigator and collaborators.,NA,Yes,De-identified individual participant data will be made available for all primary outcome measures.,2020-04-20T08:46:07Z,2020-04-20T08:46:07Z,Drug,Ruxolitinib,Participants will receive 10 mg ruxolitinib twice daily.,1,NA,NA,NA,NA,NA,NA,NA
NCT04347954,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Not yet recruiting,NA,Phase 1/Phase 2,45,Anticipated,Stanford University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:11Z,2020-04-20T08:46:11Z,Drug|Drug|Drug,Povidone-Iodine 2%|Povidone-Iodine 0.5%|Isotonic saline 0.9%,"Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day",3,,Stanford Health Care,Stanford,California,94305,United States,1
NCT04347889,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Preventing COVID-19 in Healthcare Workers With HCQ: A RCT,Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT,Not yet recruiting,NA,Phase 2,1212,Anticipated,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:13Z,2020-04-20T08:46:13Z,Drug|Other,Hydroxychloroquine|Vitamin C,Oral loading dose followed by once weekly dosing|Once daily vitamin C 1 gm,2,NA,NA,NA,NA,NA,NA,NA
NCT04347239,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,390,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:46:37Z,2020-04-20T08:46:37Z,Drug|Drug,Placebos|Leronlimab (700mg),"Placebos|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)",2,Recruiting,Montefiore Medical Center,Bronx,New York,10467,United States,1
NCT04346966,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"October 20, 2020",Anticipated,2020-10-20,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,NA,,The Effectiveness of Video-Based Exercises in Young Adults,The Effectiveness of Video-Based Exercises in Young Adults Under Social Isolation Process Due to Coronavirus,Not yet recruiting,NA,N/A,128,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:45Z,2020-04-20T08:46:45Z,Other,Study Group,"Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.",1,NA,NA,NA,NA,NA,NA,NA
NCT04346953,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic,Not yet recruiting,NA,N/A,128,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:46Z,2020-04-20T08:46:46Z,Behavioral,Video based exercise,"Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.",1,NA,NA,NA,NA,NA,NA,NA
NCT04346940,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 10, 2020",Anticipated,2020-06-10,NA,Interventional,NA,,The Effectiveness of Telerehabilitation-Based Exercises in Elderly People,The Effectiveness of Telerehabilitation-Based Exercises in Elderly People Under Social Isolation Process Due to Coronavirus,Not yet recruiting,NA,N/A,30,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:46Z,2020-04-20T08:46:46Z,Other|Other,Telerehabilitation|Exercise brochure,"15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.",2,NA,NA,NA,NA,NA,NA,NA
NCT04346927,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 10, 2020",Anticipated,2020-06-10,NA,Interventional,COVID-19,,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Not yet recruiting,NA,N/A,30,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:47Z,2020-04-20T08:46:47Z,Other|Other,Telerehabilitation|exercise brochure,"15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.",2,NA,NA,NA,NA,NA,NA,NA
NCT04346667,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"May 28, 2021",Anticipated,2021-05-28,"April 28, 2020",Anticipated,2020-04-28,NA,Interventional,PEACE,,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Not yet recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:46:55Z,2020-04-20T08:46:55Z,Drug|Drug|Drug|Drug,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Hydroxychloroquine administered as a loading dose only|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Standard of Care plus placebo,4,NA,NA,NA,NA,NA,NA,NA
NCT04346017,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Recruiting,NA,N/A,200,Anticipated,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:47:22Z,2020-04-20T08:47:22Z,Diagnostic Test|Diagnostic Test,Cytokines dosage|Complement dosage,"Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.",2,Recruiting,CHU Brugmann,Brussels,,1020,Belgium,1
NCT04351763,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-16,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 10, 2021",Anticipated,2021-04-10,"March 2, 2021",Anticipated,2021-03-02,NA,Interventional,ReCOVery-SIRIO,,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,NA,Phase 2/Phase 3,804,Anticipated,Nicolaus Copernicus University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:44:02Z,2020-04-20T08:44:02Z,Drug|Drug,Amiodarone|Verapamil,Ion channel blocker|Ion channel blocker,2,Recruiting,Nicolaus Copernicus University,Bydgoszcz,,,Poland,1
NCT04351620,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:44:07Z,2020-04-20T08:44:07Z,Drug,Hydroxychloroquine,Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days,1,Recruiting,University of Chicago,Chicago,Illinois,60637,United States,1
NCT04351581,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,RASCOVID-19,,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Not yet recruiting,NA,N/A,215,Anticipated,"University Hospital, Gentofte, Copenhagen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:08Z,2020-04-20T08:44:08Z,Other|Other,Discontinuation of ACEi/ARB|Continuation of ACEi/ARB,Discontinuation of ACEi/ARB|Continuation of ACEi/ARB,2,,"Center for Clinical Metabolic Research, Gentofte Hospital",Hellerup,Capital Region,2900,Denmark,1
NCT04351542,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,N/A,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:44:09Z,2020-04-20T08:44:09Z,Dietary Supplement|Other,Ayurveda|Usual Care,"Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.",2,,Aarogyam,Leicester,,,United Kingdom,1
NCT04351191,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,PRECISE,,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Not yet recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:21Z,2020-04-20T08:44:21Z,Drug|Drug|Drug|Drug,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Hydroxychloroquine administered as a loading dose only|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Standard of Care plus placebo,4,NA,NA,NA,NA,NA,NA,NA
NCT04350736,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,"First in Human Study SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","Ph1, Dbl-blind, Rndmzd, Plcbo-controlled, Sponsor-open, Sgl Asc Dose(SAD) and Mltpl Asc Dose(MAD) Stdy in Healthy Subjs to Eval the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Trtmnt for Acute Lung Injury Assoc w COVID-19",Not yet recruiting,NA,Phase 1,54,Anticipated,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2020-04-20T08:44:36Z,2020-04-20T08:44:36Z,Drug|Drug,TD-0903|Placebo,Study drug to be administered by inhalation|Placebo to be administered by inhalation,2,,Theravance Biopharma Investigational Site,Manchester,,M23 9QZ,United Kingdom,1
NCT04350723,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,COVI-PRONE,,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Not yet recruiting,NA,N/A,350,Anticipated,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:37Z,2020-04-20T08:44:37Z,Procedure,Awake Proning,The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.,1,,St. Joseph's Healthcare Hamilton,Hamilton,Ontario,L8N 4A6,Canada,1
NCT04350684,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 22, 2020",Anticipated,2020-04-22,NA,Interventional,UAIIC,,"Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,There is no further information.,2020-04-20T08:44:38Z,2020-04-20T08:44:38Z,Drug|Drug|Drug|Drug|Drug,Umifenovir|Interferon-Î² 1a|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine|Standards of Care,"This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.|This Drug will be used in all arms as mandated by our governmental guidelines.|This Drug will be used in all arms as mandated by our governmental guidelines.|This Drug will be used in all arms as mandated by our governmental guidelines.",5,,"Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services",Tehran,,,"Iran, Islamic Republic of",1
NCT04350671,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,IB1aIC,,"Interferon Beta 1a in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,There is no further information.,2020-04-20T08:44:38Z,2020-04-20T08:44:38Z,Drug|Drug|Drug,Interferon Beta-1A|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine,"This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-Î² 1a in COVID-19 patients.|This Drug will be used in all arms as mandated by our governmental guidelines.|This Drug will be used in all arms as mandated by our governmental guidelines.",3,,"Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services",Tehran,,,"Iran, Islamic Republic of",1
NCT04350593,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,DARE-19,,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Recruiting,NA,Phase 3,900,Anticipated,Saint Luke's Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:41Z,2020-04-20T08:44:41Z,Drug|Drug,Dapagliflozin 10 MG|Placebo,Active Comparator: Dapagliflozin 10mg|Placebo Comparator,2,Recruiting,Saint Luke's Mid America Heart Institute,Kansas City,Missouri,64111,United States,1
NCT04350476,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Remote Monitoring,Remote Monitoring in Patients With Coronavirus Disease (COVID-19),Not yet recruiting,NA,N/A,1000,Anticipated,Icahn School of Medicine at Mount Sinai,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:45Z,2020-04-20T08:44:45Z,Diagnostic Test,VitalConnect Vital Sign Patch,"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.
This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).",1,,Icahn School of Medicine at Mount Sinai,New York,New York,10029,United States,1
NCT04350450,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,"Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes",Not yet recruiting,NA,Phase 2,100,Anticipated,Montefiore Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:45Z,2020-04-20T08:44:45Z,Drug,Hydroxychloroquine,400 mg tablet,1,,Montefiore Medical Center,Bronx,New York,10467,United States,1
NCT04350320,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-16,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"November 20, 2020",Anticipated,2020-11-20,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,COL-COVID,,Randomized Open-blind Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Phase III, Prospective, Randomized, Controlled, Open-label and Pragmatic Trial, Comparing the Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria",Not yet recruiting,NA,Phase 3,102,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:50Z,2020-04-20T08:44:50Z,Drug|Drug,Colchicine Tablets|Standard therapy for COVID-19 according to the stablished hospital protocols.,standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.,2,NA,NA,NA,NA,NA,NA,NA
NCT04350073,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Not yet recruiting,NA,N/A,120,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:58Z,2020-04-20T08:44:58Z,Device|Device|Device,Q-NRG Metobolic Cart Device|MuscleSound Ultrasound|Multifrequency Bioimpedance Spectroscopy,"COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.",3,,Duke University Medial Center,Durham,North Carolina,27710,United States,1
NCT04349228,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"July 15, 2020",Anticipated,2020-07-15,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,COVID_2Pro,,Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals,"Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study",Not yet recruiting,NA,Phase 3,530,Anticipated,Abderrahmane Mami Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:28Z,2020-04-20T08:45:28Z,Drug|Drug,Hydroxychloroquine (HCQ)|Placebo oral tablet,Hydroxychloroquine (HCQ) 200mg/day|Placebo of Hydroxychloroquine (HCQ) without any active substance,2,,Eshmoun Clinical Research Centre,Tunis,,,Tunisia,1
NCT04349098,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Not yet recruiting,NA,Phase 2,230,Anticipated,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:45:33Z,2020-04-20T08:45:33Z,Drug|Other,Selinexor|Placebo,Participants will receive 20 mg of selinexor.|Participants will receive 20 mg of placebo matched to selinexor.,2,NA,NA,NA,NA,NA,NA,NA
NCT04348435,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 23, 2020",Anticipated,2020-04-23,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19,"A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Enrolling by invitation,NA,Phase 2,100,Anticipated,Hope Biosciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:45:55Z,2020-04-20T08:45:55Z,Drug|Drug,HB-adMSCs|Placebos,Hope Biosciences allogeneic adipose-derived mesenchymal stem cells|Saline,2,,Hope Biosciences Stem Cell Research Foundation,Sugar Land,Texas,77478,United States,1
NCT04347915,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 24, 2020",Anticipated,2020-04-24,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,"The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19",Not yet recruiting,NA,Phase 2,60,Anticipated,Bukwang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:46:12Z,2020-04-20T08:46:12Z,Drug|Drug,Clevudine|Hydroxychloroquine,Clevudine 120mg once a day for 14 days (up to 21 days)|Hydroxychloroquine for 200 mg twice a day for 14 days (up to 21 days),2,NA,NA,NA,NA,NA,NA,NA
NCT04346446,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Recruiting,NA,Phase 2,20,Anticipated,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:47:07Z,2020-04-20T08:47:07Z,Biological|Other,Convalescent Plasma Transfusion|Supportive Care,Convalescent Plasma Transfusion|Supportive Care,2,Recruiting|Recruiting,Maulana Azad medical College|Institute of Liver and Biliary Sciences,New Delhi|New Delhi,Delhi|Delhi,110002|110070,India|India,2
NCT04351919,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-16,2020-04-16,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"July 15, 2020",Anticipated,2020-07-15,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,COVID+PA,,Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),"Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia",Not yet recruiting,NA,Phase 4,400,Anticipated,Abderrahmane Mami Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:43:57Z,2020-04-20T08:43:57Z,Drug|Drug,Hydroxychloroquine|Azithromycin,400mg per day during 10 days|500 mg per day during 5 days,2,,Eshmoun Clinical Research Centre,Tunis,,,Tunisia,1
NCT04351516,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-16,2020-04-16,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Estimate,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID65plus,,Test and Treat COVID 65plus+,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients,Not yet recruiting,NA,Phase 2/Phase 3,350,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:44:10Z,2020-04-20T08:44:10Z,Drug|Other,Hydroxychloroquine|Placebo,dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days|Placebo: Film Coated Tablette,2,NA,NA,NA,NA,NA,NA,NA
NCT04351347,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Not yet recruiting,NA,Phase 2/Phase 3,60,Anticipated,Tanta University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:16Z,2020-04-20T08:44:16Z,Drug|Drug|Drug,Chloroquine|Nitazoxanide|Ivermectin,chloroquine|Nitazoxanide with chloroquine|Ivermectin with chloroquine,3,,Tanta University,Tanta,,35111,Egypt,1
NCT04351295,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Not yet recruiting,NA,Phase 2/Phase 3,40,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:18Z,2020-04-20T08:44:18Z,Drug|Drug,Favipiravir|Placebos,Favipiravir|Placebo oral tablet,2,,Tanta University,Tanta,,35111,Egypt,1
NCT04351243,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019,"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019",Recruiting,NA,Phase 2,270,Anticipated,Kinevant Sciences GmbH,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-20T08:44:20Z,2020-04-20T08:44:20Z,Drug|Drug,Gimsilumab|Placebo,Gimsilumab is a fully human monoclonal antibody (mAb).|Normal saline,2,Recruiting|Recruiting,Mount Sinai|Temple,New York|Philadelphia,New York|Pennsylvania,10029|19140,United States|United States,2
NCT04351152,"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-17,Estimate,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Estimate,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia",Not yet recruiting,NA,Phase 3,238,Anticipated,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-20T08:44:22Z,2020-04-20T08:44:22Z,Biological|Drug,Lenzilumab|Standard of Care,Administered as an intravenous (IV) infusion|Standard of care therapy per local written policies or guidelines,2,NA,NA,NA,NA,NA,NA,NA
